Review of Health Examination Surveys in Europe by Tolonen, Hanna et al.
R
eview
 of H
ealth Exam
ination Surveys in Europe
B
18/2008
ISBN 978-951-740-842-4 (print)
ISBN 978-951-740-843-1 (pdf)
ISSN 0359-3576
http://www.ktl.fi/portal/2920
Yliopistopaino, Helsinki 2008
Universitetstryckeriet, Helsingfors 2008
Helsinki University Print, Helsinki 2008
ISBN 978-951-740-842-4
9 7 8 9 5 1 7 4 0 8 4 2 4
Kansanterveyslaitoksen julkaisuja                          B  18/2008
Publications of the National Public Health Institute   
Review of Health Examination 
Surveys in Europe 
Edited by
Hanna Tolonen  •  Päivikki Koponen  •  Arpo Aromaa
Susanna Conti  •  Sidsel Graff-Iversen  •  Liv Grøtvedt
Mark Kanieff  •  Jennifer Mindell  •  Sanna Natunen
Paola Primatesta  •  Monique Verschuren  •  Lucie Viet
Kari Kuulasmaa for the Feasibility of a European Health  
Examination Survey (FEHES) Project
  
Kansanterveyslaitoksen julkaisuja B18 / 2008 
Publications of the National Public Health Institute 
 
 
Edited by 
 
Hanna Tolonen, Päivikki Koponen, Arpo Aromaa, Susanna Conti, Sidsel Graff-Iversen, 
Liv Grøtvedt, Mark Kanieff, Jennifer Mindell, Sanna Natunen, Paola Primatesta, 
Monique Verschuren, Lucie Viet, Kari Kuulasmaa for the Feasibility of a European 
Health Examination Survey (FEHES) Project 
 
 
REVIEW OF HEALTH EXAMINATION SURVEYS IN EUROPE 
 
 
 
 
 
 
 
 
 
 
 
Helsinki 2008 
              
  
 
 
 
 
 
 
 
 
 
Kansanterveyslaitoksen julkaisuja B18 / 2008 
Copyright National Public Health Institute 
Julkaisija-Utgivare-Publisher 
Kansanterveyslaitos (KTL) 
Mannerheimintie 166 
00300 Helsinki 
Puh. vaihde (09) 474 41, telefax (09) 4744 8408 
Folkhälsoinstitutet 
Mannerheimvägen 166 
00300 Helsingfors 
Tel. växel (09) 474 41, telefax (09) 4744 8408 
National Public Health Institute 
Mannerheimintie 166 
FIN-00300 Helsinki, Finland 
Telephone +358 9 474 41, telefax +358 9 4744 
8408 
http://www.ktl.fi 
ISBN (print)  978-951-740-848-2 
ISBN (pdf) 978-951-740-843-1 
ISSN 0359-3576 
http://www.ktl.fi/portal/2920 
Kannen kuva - cover graphic: Hanna 
Tolonen 
Yliopistopaino 
Helsinki 2008 
Discloser 
The Feasibility of a European Health 
Examination Survey (FEHES) Project received 
funding from the European Commission. The 
Review reflects the authors’ views and the 
European Commission is not liable for any use 
that may be made of the information contained 
in the Review.  
 
 
 
  
 
  
CONTENTS 
1. INTRODUCTION ............................................................................................................... 1 
References ........................................................................................................................... 3 
2. HISTORY OF HEALTH EXAMINATION SURVEYS .................................................... 5 
References ........................................................................................................................... 7 
3. SOURCES OF HEALTH DATA AND USES OF INFORMATION FROM HEALTH 
EXAMINATION SURVEYS.............................................................................................. 9 
3.1 Sources of health data ................................................................................................. 9 
3.2 Aims of previous HESs............................................................................................. 10 
3.3 Comparison of different data sources ....................................................................... 11 
3.3.1 Health interview surveys vs. administrative registers ................................... 11 
3.3.2 HIS vs. HES data ........................................................................................... 11 
3.4 Uses of health examination data ............................................................................... 12 
3.5 Conclusions ............................................................................................................... 13 
References ......................................................................................................................... 13 
4. EXPERIENCES, POTENTIALS AND PLANS FOR ORGANIZING AND 
CONDUCTING NATIONAL HEALTH EXAMINATION SURVEYS ......................... 15 
4.1 Introduction ............................................................................................................... 15 
4.2 Recent HESs.............................................................................................................. 16 
4.3 Future plans for national HESs in Europe................................................................. 17 
4.4 Different models of organizing HESs ....................................................................... 18 
4.4.1 Data collection by personal interviews, self-administered questionnaires 
and examinations ........................................................................................... 18 
4.4.2 Duration and place of examinations, and type of personnel.......................... 19 
4.4.3 Frequency and timing of the survey .............................................................. 20 
4.5 Potentials for organizing HESs in European countries ............................................. 21 
4.6 Summary and conclusions......................................................................................... 23 
References ......................................................................................................................... 24 
5. GUIDELINES AND RECOMMENDATIONS FOR HEALTH EXAMINATION 
SURVEYS ......................................................................................................................... 35 
5.1 Introduction ............................................................................................................... 35 
5.2 International projects................................................................................................. 36 
5.2.1 Projects on chronic disease risk factors and cardiovascular diseases............ 36 
5.2.2 Projects on respiratory health ........................................................................ 38 
5.2.3 Projects on diabetes ....................................................................................... 39 
5.2.4 Projects on nutrition....................................................................................... 40 
5.2.5 Projects on mental health............................................................................... 40 
5.2.6 Projects on cognitive and physical capacity .................................................. 41 
5.2.7 Projects on oral health.................................................................................... 42 
5.2.8 Projects on musculoskeletal health and physical activity.............................. 42 
5.2.9 Projects on environmental health and human biomonitoring ........................ 43 
5.2.10 Use of pooled data ......................................................................................... 43 
5.3 International aspects of national HESs ..................................................................... 44 
  
5.4 Conclusions ............................................................................................................... 45 
References ......................................................................................................................... 46 
6. LEGISLATION AFFECTING HEALTH SURVEYS...................................................... 57 
6.1 Introduction ............................................................................................................... 57 
6.2 Ethics in medical research......................................................................................... 57 
6.3 Safeguarding Privacy: Data protection and subjects’ rights ..................................... 59 
6.4 Obtaining Informed Consent (Informed consent form and Information Notice)...... 61 
6.4.1 General or specific consent............................................................................ 64 
6.4.2 Future uses of data ......................................................................................... 64 
6.4.3 Future use of blood samples .......................................................................... 64 
6.4.4 Name of person receiving consent................................................................. 64 
6.4.5 How results are communicated to the study participants .............................. 65 
6.4.6 Involvement of general practitioners (GP) .................................................... 65 
6.4.7 The possibility of withdrawing from the study at any time........................... 65 
6.4.8 Risks/benefits related to participation in the study........................................ 65 
6.4.9 Consent forms specific for children, adolescents, and persons not legally 
competent to provide consent ........................................................................ 66 
6.5 Relationship between informed consent and legislation for safeguarding privacy... 66 
6.6 Conclusions ............................................................................................................... 66 
References ......................................................................................................................... 67 
7. SAMPLING AND RECRUITMENT................................................................................ 82 
7.1 Introduction ............................................................................................................... 82 
7.2 Sampling ................................................................................................................... 83 
7.2.1 The target population ..................................................................................... 83 
7.2.1.1 Target population in European countries............................................ 84 
7.2.2 Sampling frames ............................................................................................ 84 
7.2.2.1 Sampling frames in European countries............................................. 86 
7.2.3 Sample size .................................................................................................... 88 
7.2.3.1 Sample sizes in European countries ................................................... 89 
7.2.4 Some basic sampling techniques ................................................................... 89 
7.2.4.1 Sampling techniques used in recent European surveys ...................... 91 
7.2.5 Contact rates and participation rates.............................................................. 91 
7.2.5.1 Participation rates in European countries ........................................... 93 
7.3 Recruitment to participation in health surveys.......................................................... 93 
7.3.1 Invitation strategies in recent health surveys................................................. 93 
7.3.2 Efforts to increase participation..................................................................... 94 
7.3.3 Studies of non-participants ............................................................................ 95 
7.3.4 Other experiences with participation in health surveys ................................. 95 
7.3.5 Studies of potential bias due to selective participation.................................. 98 
7.4 Conclusion............................................................................................................... 100 
References ....................................................................................................................... 101 
8. ELEMENTS FOR A CORE MODULE AND ADDITIONAL TOPICS FOR HES ...... 127 
8.1 Importance of HES as data source .......................................................................... 127 
8.2 Most common measurements.................................................................................. 128 
8.2.1 Examinations ............................................................................................... 128 
  
8.2.2 Questions ..................................................................................................... 128 
8.3 Additional measurements........................................................................................ 129 
8.3.1 Examinations ............................................................................................... 129 
8.3.2 Questions ..................................................................................................... 129 
8.4 Conclusions ............................................................................................................. 130 
9. MEASUREMENT PROCEDURES................................................................................ 154 
9.1 Height measurement................................................................................................ 154 
9.1.1 Critical issues of the measurement procedure ............................................. 154 
9.1.2 Earlier recommendations ............................................................................. 155 
9.1.3 Procedures used in previous HESs .............................................................. 155 
9.1.4 Conclusion ................................................................................................... 155 
9.2 Weight measurement............................................................................................... 155 
9.2.1 Critical issues of the measurement procedure ............................................. 155 
9.2.2 Earlier recommendations ............................................................................. 156 
9.2.3 Procedures used in previous HESs .............................................................. 156 
9.2.4 Conclusions.................................................................................................. 156 
9.3 Waist and hip circumferences ................................................................................. 156 
9.3.1 Critical issues of the measurement procedure ............................................. 157 
9.3.2 Earlier recommendations ............................................................................. 157 
9.3.3 Procedures used in previous HESs .............................................................. 157 
9.3.4 Conclusions.................................................................................................. 158 
9.4 Blood pressure......................................................................................................... 158 
9.4.1 Critical procedure issues.............................................................................. 158 
9.4.2 Earlier recommendations ............................................................................. 161 
9.4.3 Procedures used in previous HESs .............................................................. 162 
9.4.3.1 Devices ............................................................................................. 162 
9.4.3.2 Procedures ........................................................................................ 162 
9.4.4 Conclusions.................................................................................................. 163 
9.5 Blood collection ...................................................................................................... 164 
9.5.1 Critical issues of the blood collection and storage ...................................... 165 
9.5.2 Earlier recommendations ............................................................................. 168 
9.5.3 Procedures used in previous HESs .............................................................. 168 
9.5.4 Conclusions.................................................................................................. 169 
9.6 Laboratory procedures ............................................................................................ 169 
9.6.1 Critical issues of the measurement procedure ............................................. 169 
9.6.2 Earlier recommendations ............................................................................. 170 
9.6.3 Procedures used in previous HESs .............................................................. 170 
9.6.4 Conclusions.................................................................................................. 170 
9.7 Measurement of physical functioning..................................................................... 170 
9.7.1 Tests of upper body functioning .................................................................. 171 
9.7.1.1 Critical issues of the measurement procedures................................. 172 
9.7.1.2 Earlier recommendations.................................................................. 173 
9.7.1.3 Procedures used in previous HESs ................................................... 173 
9.7.1.4 Conclusions ...................................................................................... 174 
9.7.2 Tests of lower extremity .............................................................................. 174 
9.7.2.1 Critical issues of the measurement procedures................................. 175 
  
9.7.2.2 Earlier recommendations.................................................................. 177 
9.7.2.3 Procedures used in previous HESs ................................................... 178 
9.7.2.4 Conclusion ........................................................................................ 179 
9.7.3 Physical performance batteries .................................................................... 179 
9.7.3.1 Critical issues of the measurement procedures................................. 181 
9.7.3.2 Earlier recommendations.................................................................. 182 
9.7.3.3 Procedures used in previous HESs ................................................... 182 
9.7.3.4 Conclusions ...................................................................................... 182 
9.7.4 General conclusion on measuring physical functioning in HES ................. 183 
9.8 Physical fitness........................................................................................................ 183 
9.8.1 Critical issues of the measurement procedure ............................................. 184 
9.8.2 Earlier recommendations ............................................................................. 184 
9.8.3 Procedures used in previous HESs .............................................................. 184 
9.8.4 Conclusions.................................................................................................. 184 
9.9 Ankle brachial index ............................................................................................... 185 
9.9.1 Critical issues of the measurement procedure ............................................. 185 
9.9.2 Earlier recommendations ............................................................................. 185 
9.9.3 Procedures used in previous HESs .............................................................. 185 
9.9.4 Conclusion ................................................................................................... 185 
9.10 Vision test................................................................................................................ 186 
9.10.1 Critical issues of the measurement procedure ............................................. 186 
9.10.2 Earlier recommendations ............................................................................. 186 
9.10.3 Procedures used in previous HESs .............................................................. 186 
9.10.4 Conclusion ................................................................................................... 186 
9.11 Hearing test ............................................................................................................. 187 
9.11.1 Critical issues of the measurement procedures............................................ 187 
9.11.2 Earlier recommendations ............................................................................. 187 
9.11.3 Procedures in previous HESs....................................................................... 187 
9.11.4 Conclusion ................................................................................................... 187 
9.12 Bone density............................................................................................................ 187 
9.12.1 Critical issues of the measurement procedure ............................................. 188 
9.12.2 Earlier recommendations ............................................................................. 188 
9.12.3 Procedures used in previous HESs .............................................................. 188 
9.12.4 Conclusion ................................................................................................... 188 
9.13 Lung function .......................................................................................................... 188 
9.13.1 Critical issues of the measurement procedure ............................................. 189 
9.13.2 Earlier recommendations ............................................................................. 189 
9.13.3 Procedures used in previous HESs .............................................................. 189 
9.13.4 Conclusion ................................................................................................... 190 
Reference ......................................................................................................................... 190 
10. QUALITY ASSURANCE PROCEDURES.................................................................... 247 
10.1 Protocols and manuals............................................................................................. 247 
10.1.1 Critical issues............................................................................................... 247 
10.1.2 Previous HESs ............................................................................................. 248 
10.1.3 Conclusions.................................................................................................. 248 
10.2 Training ................................................................................................................... 248 
  
10.2.1 Critical issues............................................................................................... 248 
10.2.2 Previous HESs ............................................................................................. 248 
10.2.3 Conclusions.................................................................................................. 248 
10.3 Quality assurance of height measurement............................................................... 249 
10.3.1 Critical issues............................................................................................... 249 
10.3.2 Previous HESs ............................................................................................. 249 
10.3.3 Conclusions.................................................................................................. 249 
10.4 Quality assurance of weight measurement.............................................................. 250 
10.4.1 Critical issues............................................................................................... 250 
10.4.2 Previous HESs ............................................................................................. 250 
10.4.3 Conclusions.................................................................................................. 250 
10.5 Quality assurance measuring waist and hip circumferences................................... 251 
10.5.1 Critical issues............................................................................................... 251 
10.5.2 Previous HESs ............................................................................................. 251 
10.5.3 Conclusions.................................................................................................. 251 
10.6 Quality assurance of blood pressure measurement ................................................. 251 
10.6.1 Critical issues............................................................................................... 251 
10.6.2 Previous HESs ............................................................................................. 252 
10.6.3 Conclusions.................................................................................................. 253 
10.7 Quality assurance of the blood samples – collecton and analysis........................... 253 
10.7.1 Critical issues............................................................................................... 253 
10.7.1.1 Internal Quality Control (IQC) ....................................................... 253 
10.7.1.2 External Quality Control (EQC)..................................................... 253 
10.7.2 Previous HESs ............................................................................................. 254 
10.7.3 Conclusions.................................................................................................. 254 
10.8 Quality assurance of physical performance and fitness tests .................................. 254 
10.8.1 Critical issues............................................................................................... 254 
10.8.2 Previous HESs ............................................................................................. 255 
10.8.2.1 Physical Performance ..................................................................... 255 
10.8.2.2 Physical fitness ............................................................................... 255 
10.8.3 Conclusions.................................................................................................. 255 
10.9 Quality assurance of vision and hearing tests ......................................................... 255 
10.9.1 Critical issues............................................................................................... 255 
10.9.2 Previous surveys .......................................................................................... 255 
10.9.3 Conclusions.................................................................................................. 256 
10.10 Quality assurance of bone density and lung function measurements.................... 256 
10.10.1 Critical issues ........................................................................................ 256 
10.10.2 Previous surveys.................................................................................... 256 
10.10.2.1 Bone density ................................................................................. 256 
10.10.2.2 Lung function ............................................................................... 256 
10.10.3 Conclusions ........................................................................................... 257 
References ....................................................................................................................... 257 
11. RESOURCES USED IN AND COST OF PREVIOUS HEALTH EXAMINATION 
SURVEYS ....................................................................................................................... 283 
11.1 Introduction ............................................................................................................. 283 
11.2 Planning of the survey............................................................................................. 284 
  
11.3 Sampling ................................................................................................................. 285 
11.4 Preparation of the materials and infrastructure needed for the survey.................... 285 
11.5 Training of the fieldwork personnel........................................................................ 285 
11.6 Health examination fieldwork................................................................................. 286 
11.7 Reporting the survey results.................................................................................... 286 
11.8 Average cost of the surveys .................................................................................... 287 
11.9 Main sources of funding.......................................................................................... 287 
11.10 Conclusions ........................................................................................................... 287 
References ....................................................................................................................... 288 
12. SUMMARY AND DISCUSSION: FEASIBILITY OF A EUROPEAN HEALTH 
EXAMINATION SURVEY............................................................................................ 301 
12.1 What to measure in a HES ...................................................................................... 301 
12.2 Technical implementation of a HES ....................................................................... 302 
12.3 Expertise and experience in the countries............................................................... 304 
12.4 International coordination ....................................................................................... 304 
12.5 Ethical and legal issues ........................................................................................... 305 
12.6 Cost of a HES.......................................................................................................... 305 
12.7 Conclusions ............................................................................................................. 305 
ANNEX 1. MEMBERS OF THE FEHES NETWORK WHO HAVE CONTRIBUTED TO 
THIS REPORT ................................................................................................................ 307 
ANNEX 2. QUESTIONNAIRE ON HES IN EUROPE........................................................ 312 
ANNEX 3. SOME QUESTIONS ON RECRUITMENT AND PARTICIPATION ............. 324 
ANNEX 4. QUESTIONNAIRE OF SURVEY QUALITY ASSURANCE.......................... 328 
ANNEX 5. EVALUATION OF THE COST OF THE PREVIOUS HESS IN THE EU 
MEMBER STATES ........................................................................................................ 349 
ANNEX 6. PREVIOUS AND PLANNED HESS IN EUROPEAN COUNTRIES .............. 358 
References ....................................................................................................................... 377 
 
 
  
1 
 
1. INTRODUCTION 
 
Kari Kuulasmaa1 
1National Public Health Institute, Helsinki, Finland 
 
 
Information on the health, health risks and use of health services and medicines of the 
population are needed for planning and evaluating health policies and health care. Typical 
data sources for health information are various registers, such as mortality registers for total 
and cause-specific mortality and population surveys, which provide a cross-section of health 
and its determinants in the population. Different data sources provide information on different 
aspects of health, and therefore they are largely complementary. 
Health surveys based on representative probability samples of the population are 
particularly suited for providing information on health behaviours; health determinants, such 
as obesity, blood pressure, and various blood parameters; prevalence of various diseases; met 
and unmet need for health services; functional capacity; and nutritional status. Surveys are 
often classified into health interview surveys (HISs) and health examination surveys (HESs). 
HISs are based on interviews or self-administered questionnaires, and can be used for 
measuring health, use of health services, lifestyle and health behaviour. HESs always include 
an interview or a self-administered questionnaire, and also include some or all of 
anthropometric, physiological, clinical and/or performance measurements and tests, and blood 
samples. Therefore, HESs can measure aspects that cannot be addressed through a HIS. Also, 
for many of the measurements a HES provides much more valid information than a HIS. An 
example of this is the prevalence of various diseases, where self-reported information is 
known to be quite inaccurate, although its validity varies with disease [1-5]. Sometimes the 
inaccuracy is due to the fact that the disease has not been diagnosed. 
The longest series of national HESs with a wide range of measurements is in the United 
States, where the first National Health Examination Survey was carried out in the 1950s. 
European examples are the Finnish surveys since the 1970s, German surveys since the 1980s, 
Norwegian surveys since the 1980s, and English and Scottish surveys since the 1990s (see 
Chapter 2). The main international activity was the WHO MONICA Project, which carried 
out standardized cardiovascular risk factor surveys in 31 centres in 21 countries in the 1980s 
and 1990s [6]. More recently there have been occasional HESs in many other countries, 
comprising a varying set of measurements. However, the measurements have not been 
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standardized between the countries, and there are no comprehensive HES data available from 
most European countries. 
In the 1990s, the European Union found that it was essential to consider public health in 
its agenda. The first effort was an extensive review by the Danish Ministry of Health 
published in 1994. The need for comparable health information from the Member States also 
becomes obvious. The Health Monitoring Programme was launched, with the aim of 
producing comparable information on health and health-related behaviour of the population, 
on diseases and health systems. The Health Monitoring Programme was followed in 2003-
2008 by the Community Public Health Programme. One of its objectives was establishing and 
operating a sustainable health monitoring system. As a part of the implementation of the 
Programme, EUROSTAT, the European statistical agency, and DG Sanco, Directorate 
General for Health and Consumer Protection of the Commission, outlined the European 
Health Survey System, comprising a European HIS, coordinated by EUROSTAT, and a 
European HES, coordinated by DG Sanco [7]. 
Feasibility of a European Health Examination Survey (FEHES) is a project of the Public 
Health Programme 2003-2008, with its aim to assess the feasibility of carrying out a 
standardized HES in each European Country [8]. To meet its objectives, FEHES has created a 
network of experts and institutes in 32 countries (Annex 1). With their help, FEHES has 
collected information on relevant legal, data confidentiality and ethical issues, availability of 
sampling frames, previous HESs, experience and expertise, and perceived importance and 
interest in HESs at the national or regional level. FEHES has also conducted a review of the 
development of methods that has taken place to facilitate international standardization of 
HESs. Based on this information, FEHES has analyzed the feasibility of models of HES with 
different numbers of measurements and cost and makes proposals and recommendations for 
future standardized HESs. An important objective is to prepare a proposal for a European 
HES pilot. 
FEHES is focusing on HESs in the adult population, although the need for health 
information about children and adolescents is also recognized. Many of the most relevant 
measurements are different in children and adults. The potential approaches to the surveys are 
also different, and there is much less experience of HESs in children than in adults. Therefore, 
we felt that the assessment of the feasibility of surveys in children and adolescents deserves 
more attention than can be devoted to it in this Project.  
The work of FEHES is complementary to the recent work for the development of a 
European Health Interview Survey as well as to the work of various lifestyle and disease 
oriented projects of the EU's Public Health Programme [7, 9].  
The purpose of this report is to document and assess the existing experience and 
knowledge of HESs, and hence to provide the evidence base for the proposals and 
recommendations for future standardized HESs. The proposals and recommendations will be 
reported separately. 
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Chapter 2 of this report elaborates the history and Chapter 3 the role and importance of 
HESs. Chapter 4 gives an overview of HESs that have been carried out or are being planned 
in European countries and outside Europe, also specifying the models of organizing the 
surveys. Chapter 5 reviews international activities for developing methods for HES and the 
need for international collaboration in HESs. Chapters 6-11 address different aspects relevant 
to conducting a HES, including: 
• Legislation, data protection and ethical issues (Chapter 6); 
• Sampling issues (Chapter 7); 
• Topics and measurements covered in HESs (Chapter 8); 
• Measurement procedures (Chapter 9); 
• Quality assurance (Chapter 10); and 
• Resources used in and cost of previous HESs (Chapter 11). 
Finally, conclusions about the feasibility of a European Health Examination Survey are 
summarized and discussed in Chapter 12. 
An important source of information for many of the chapters was direct communication 
with the experts of the FEHES network. They were sent a questionnaire, hereafter called "the 
FEHES questionnaire" (Annex 2). It included questions on HESs in the country in the past 10 
years, expertise in the country for conducting a national HES, plans for HES in the future, 
availability of sampling frames, aspects affecting the feasibility of conducting a HES in the 
country, ethical and legal aspects of HESs, practical aspects of HESs and international aspects 
of HESs. Response was received from all 32 countries, and was often followed by additional 
communication. Additional questionnaires were used to get in depth information on the 
recruitment of survey participants (Annex 3), quality assurance (Annex 4) and costs of HESs 
(Annex 5). 
REFERENCES 
[1] Karen Jenum A, Lorentzen C, Anderssen SA, Birkeland KI, Holme I, Lund-Larsen PG, et al. Promoting 
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[2] Klungel OH, de Boer A, Paes AH, Seidell JC, Bakker A. Cardiovascular diseases and risk factors in a 
population-based study in The Netherlands: agreement between questionnaire information and medical records. 
The Netherlands journal of medicine. 1999 Oct;55(4):177-83. 
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2. HISTORY OF HEALTH EXAMINATION SURVEYS 
 
Arpo Aromaa1, Hanna Tolonen1  
1National Public Health Institute, Helsinki, Finland 
 
 
The first health examination surveys in the 19th and 20th century were those carried out 
by responsible general practitioners to increase knowledge of health, illness and their 
determinants in the population. Next, directed screening examinations were used in the 1920s 
to 1940s to find patients suffering from tuberculosis for treatment and sanitary purposes, and 
some types of cancer (cervical cancer) for early treatment. Although not comprehensive, these 
surveys were used to develop many principles and practices of screening examinations [1].   
In the 1950s and 1960s, the fast development of laboratory automation led to a hope that 
a number of conditions and their early precursors could be detected cheaply by multiphase 
screening. Simultaneously, topics such as screening for lung cancer and breast cancer were 
under investigation. Unfortunately, only some of the hopes for improving prognosis by early 
detection of disease as a results of screening were proven to be correct. This reduced the 
perceived importance of screening in early diagnostics.   
In Europe, the main tradition since the 1960s has been to carry out health interview 
surveys in household samples. Many of those studies such as the Finnish ones [2] followed 
US examples. From the point of view of describing the health of the whole population, these 
had two drawbacks: First, institutionalized persons were not included in the household 
samples, meaning that a large proportion of those with severe disability did not belong to the 
study population. Second, relying solely on interviews meant that conditions easily defined 
medically were not captured and the same was true of determinants of health such as 
hypertension or high serum cholesterol. Because of the relative ease with which HISs could 
be carried out, many countries did not consider the more expensive HESs – in fact the 
expense was considered prohibitive and the added value limited.  
In the 1960s, the National Center for Health Statistics in the United States initiated 
examination surveys of random sample of the whole US population using multistage 
sampling. The first National Health Examination Survey (NHES I) was conducted 1960-1962 
on adults aged 18-79. In the second NHES, children aged 6-11 were also included and the 
third NHES focused only on children aged 12-17. In the beginning of the 1970s, the nutrition 
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component became an important part of these health examination surveys, resulting in a 
National Health and Nutrition Examination Survey (NHANES). Since that survey, a series of 
NHANES and Hispanic Health and Nutrition Examination Surveys have been conducted 
including both children and adults. From the beginning, these surveys have been conducted in 
mobile clinics.  [3] 
In the Nordic countries, comparable efforts were initiated in the early 1960s in Finland 
and in Sweden. In Finland, the Mobile Clinic of Social Insurance Institution, examined a 
random sample of people aged 15 years and older around the country in 1966-1972 [4]. In 
Sweden, the Värmlandsundersökningen, tested the feasibility of large-scale laboratory 
screening [5]. These examination surveys still catered for the idea of early detection and 
treatment of diseases. Already since  the early 1950s there were population based studies on 
cardiovascular diseases in several countries, but these were limited to a few regions in each 
country (Framingham [6], the Seven Country Study [7] including population groups from the 
USA, Croatia, Japan, Finland, Italy, the Netherlands, Greece and Serbia).  
Since the 1970s, health examinations have been applied in major international studies in 
limited populations, on cardiovascular diseases and their determinants as well as their 
development (WHO MONICA Project [8]), cancer (EPIC [9]) and functional limitations [10]. 
Comparative studies of the efficacy of cancer screening have also been carried out.  
In the United Kingdom, health examination surveys have been conducted annually since 
1991 in England and in 1995, 1998 and 2003 in Scotland. These surveys have been household 
surveys, where the examinations have been conducted in the home of chosen participants. In 
England, surveys between 1991-1994 included only adults but from 1995 onwards children 
were also included. In Scotland, only adults were examined during the 1995 survey but in 
1998 and 2003 children were also included.   
In the Netherlands, health examination surveys have been carried out since 1987, first by 
the Monitoring Project on Cardiovascular Disease Risk Factors until 1991 [11], followed by 
the Monitoring Project on Risk Factors for Chronic Diseases (MORGEN) in 1993-1997 [12] 
and Risk Factors and Health in the Netherlands, a Survey by Municipal Public Services from 
1999 to 2001 [13].  
Germany carried out a national health examination survey of adults in 1998 [14]. Before 
the unification of West and East Germany, a series of health examination surveys was 
conducted in West Germany between 1984-1991 as part of the German Cardiovascular 
Prevention Study [15]. In 2003-2006, a comprehensive health examination survey was 
conducted among children and adolescents (KiGGS) [16].  
In Norway, a series of regional HESs were conducted by the National Health Screening 
Service (SHUS) from 1974 until 2003, primarily to monitor risk factors for cardiovascular 
diseases. The HESs were conducted by county, and all inhabitants in the chosen age groups 
were invited. In 1974-1988, cardiovascular HESs were performed three times in three 
counties, inviting inhabitants aged 35-49 years in the first round. In 1985-1999, the Age 40-
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programme was run, and by 1993, these regional HESs covered the entire country. [17] Since 
then, there has not been any nationally representative health examination survey. However, 
surveys have been carried out in Oslo [18] and the counties of Hedmark, Oppland, Troms and 
Finmark [19]. The data from these HESs and other large regional HES constitute the Cohort 
Norway which is used for research purposes. [20] 
In addition to the massive health interview (80 000 persons) by the Statistical Office of 
Italy, the Italian Public Health Institute (ISS) organized a regional pilot HES 1998-2001 in 51 
centres, each inviting 200 persons aged 35-74. This has not been continued by a national 
HES. [21] 
Probably the most extensive experience of carrying out HESs in Europe is found in 
Finland. In addition to national health interview surveys since 1964, a range of health 
examination surveys has been carried out since the 1960s: the Social Insurance Institution’s 
Mobile Clinic Surveys (1964-1978) [4, 22], the comprehensive Mini-Finland HES (1978-
1980) [23], the FINRISK (and FinMONICA) surveys every five years since 1972 and finally 
the comprehensive Health 2000 survey of 2000 – 2001 [24]. The Finnish comprehensive 
surveys comprise interviews and examinations for health determinants, physiological 
measurements, a clinical examination by a doctor, a dental examination by a dentist, and 
symptom interviews including psychiatric symptoms and syndromes such as the CIDI.  
In European countries with a long tradition of national health examination surveys, the 
demand for HES-based information has been very strong. The examination based assessments 
have been considered more trustworthy than those from interviews alone. In particular, there 
are many health determinants not well known to the average person. For example, most 
people do not know their actual value of serum cholesterol and blood pressure, body weight is 
often reported as lower than the actual, and the presence/absence of diseases may not be 
correctly reported. In addition, many measurements may provide information about individual 
disease risk. Furthermore, the ability to provide real measured data on health determinants 
and on many aspects of health and functioning is clearly appreciated by the media, politicians 
and professionals.  
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3.1 SOURCES OF HEALTH DATA 
Information about the health of the population and health determinants can be obtained 
from different data sources such as administrative registers, specific disease registers, 
screenings, health interview surveys and health examinations surveys. All these data sources 
have their strengths and limitations but they also supplement each others. 
Administrative registers, like hospital discharge registers and disease specific registers 
provide information about the incidence of diagnosed and treated diseases in the population. 
These are valuable data sources when most of the people getting the disease get treated in 
hospital. Good examples are cancers, which require treatment in hospital. Administrative and 
disease specific registers generally have limited information about the background of the 
persons, like their socio-economic status, which could provide valuable additional 
information about the socio-economic differences in the incidence of diseases.  
Screenings are usually targeted at some population group and are focused on detection of 
a specific disease, for example pap-smear screening of women to detect cervical cancer. 
Screenings are good data sources when we want to know the incidence of a specific disease in 
the population and they are especially good for early diagnoses of diseases, which usually are 
unsymptomatic in the early stages.  
Health interview surveys, where information about person’s health and health 
determinants is collected by questionnaires, can provide representative information about 
perceived health, health attitudes, health behaviours and diagnosed diseases. Self reported 
data on health determinants and diseases depends on persons’ recall of the diagnoses as well 
as the knowledge of the health determinants in question. Health interview surveys generally 
have information about the socio-economic status, health determinants and behaviours, and 
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diagnosed diseases in same person, which allows reporting of the results by different 
population groups and estimation of the associations between health determinants and 
behaviours and diagnosed diseases. 
Health examination surveys, where information is collected with questionnaires and also 
through examinations and laboratory tests, can provide same information than health 
interview surveys and additional information about the disease diagnoses and health 
conditions of the same persons from whom the questionnaires information is obtained.  
3.2 AIMS OF PREVIOUS HESS 
Information collected through health examination surveys provides extensive information 
about the health and health determinants of the population and differences in health between 
population groups. The Chief Executive of the Information Centre for health and social care 
of England has stated that the Health Survey for England is vital for the understanding of 
health situation and behaviours of the population and it is a great help to ensure that policies 
are informed [1]. 
For several other health examination surveys similar aims have been stated. The aim of 
the Norwegian Age 40-programme was to monitor cardiovascular disease risk, to facilitate 
epidemiological research, to provide education for health professionals, to prevent 
cardiovascular disease risk in the total population through population strategies as well as 
through high risk strategies, and to do secondary prevention through early diagnoses of 
diseases. [2] 
In Germany, the German Health Survey for Children and Adolescents (KiGGS) aims to 
identify health risks and health care demands among children and adolescents in Germany as 
a whole and in specific population subgroups, to serve as a reference base for biomedical 
parameters and various laboratory measures, to delineate subgroup-specific approaches to 
prevention, to serve as a basis for decision making and prioritization to health care providers, 
health authorities and politicians, to set the stage for future health monitoring programs and to 
generate new hypotheses for epidemiological and etiological research. [3] 
The NHANES aims to determine rates of major diseases and health conditions (e.g., 
cardiovascular disease, diabetes, obesity, infectious diseases) as well as identify and monitor 
trends in medical conditions, risk factors, and emerging public health issues, so that the 
appropriate public health policies and prevention interventions can be developed. The surveys 
have been widely utilised in epidemiological research. Data derived from the surveys have 
been widely used in the development and implementation of a number of health-related 
guidelines and reforms and public-policy initiatives. [4] 
 The aim of the Canadian Health Measures Survey is that this information will help 
evaluate the extent of health problems associated with such major health concerns as diabetes, 
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obesity, hypertension, cardiovascular disease, exposure to infectious diseases, and the extent 
of exposure to environmental contaminants. It will serve to ascertain relationships among 
disease risk factors, health protection practices, and health status based on direct measures. 
The survey will also provide a platform to explore emerging public health issues and new 
measurement technologies. [5]  
3.3 COMPARISON OF DIFFERENT DATA SOURCES 
3.3.1 HEALTH INTERVIEW SURVEYS VS. ADMINISTRATIVE REGISTERS 
Previous studies have shown that the validity of self-reported health varies between 
indicators. It has been found that for example self-reported hypertension can be confirmed by 
medical record in 86-94% of cases [6, 7] and diabetes in almost 100% of cases [6]. For 
myocardial infarction, the proportion of positive self-reports confirmed by medical records 
varies from 10% to 79% between studies [6].  
3.3.2 HIS VS. HES DATA 
Previous studies about the accuracy of self-reported health in comparison to the health 
examination survey results, where the measurements have been done to diagnose the 
conditions have shown that for many health outcomes, self-reported results are inaccurate.  
For example, self-reported hypertension tends to be underestimated [8-10] so that results 
from health examination surveys may give up-to over two-fold higher prevalence than self-
reported results [10]. Also the prevalence of hypercholesterolaemia [8], diabetes [8-10], 
osteoarthritis [9] and coronary heart disease [9] often get underestimated by self-reported 
data. 
For weight and height data, which are used to calculate BMI and obesity prevalence, self-
reported results for weight tend to be under-reported while height tends to be over-reported 
[8, 11]. Under-reporting of weight varies from 0.1 kg to 3.5 kg and over-estimation of height 
varies from 0.2 cm to 7.5 cm between studies [11]. As a consequence, BMI calculated from 
self-reported results tends to be under-estimated, from 0.2 kg/m2 to 1.8 kg/m2 [11]. 
It should also be noted that inaccuracy of self-reported data on health outcomes is not 
uniform throughout population groups. Women tend to over-report chronic diseases more 
frequently than men as well as 55-64 years old in comparison to younger persons. Also less 
educated over-report chronic diseases more frequently than persons with higher educational 
level. [9] For self-reported height and weight, there is tendency for young men to over-report 
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their height more than women in same age while women tend to under-report their weight 
more than men. [8]  
3.4 USES OF HEALTH EXAMINATION DATA 
Actual examples about the uses of data collected by health examination surveys can be 
found from every country which has conducted HESs. Here we will present few examples to 
illustrate the potentials of the health examination survey data 
One example, how data from HES can be used to present the differences between 
population groups in given time point but also used to predict possible future trends is from 
England. Data from Health Survey for England have been used to forecast the obesity 
prevalence in the country in year 2010. This report first illustrates the situation in 2003 giving 
the prevalence and number of obese adults by different population groups (sex, social class 
and regions) and then provides the forecast for these population groups in year 2010. [12]  
Examples from NHANES data show how HES data can be used to evaluate the efforts to 
lower risk factors like high total cholesterol [13], to monitor differences and trends in the 
obesity [14] and hypertension awareness, treatment and control [15] between population 
groups. 
When cross-sectional health examination data can be linked to different kinds of register 
data for follow-up of individual’s morbidity and mortality, new aspects of data use arise. This 
allows the estimation of the number of cases of a specific disease due to given risk factors in 
the country. An example of this is a SCORE project and risk score charts by ESC [16], for the 
use of clinical practitioners which are tailored to different countries using national HES data 
and mortality follow-up of the subjects.  
In Norway, the HES data has been used in health reports as background for policy on 
nutrition and physical activity, policy for counteracting social inequity in health (such as 
giving extra resources to districts with less good health) and planning of health care (such as 
surgery for high-grade obesity). [17] 
Examples can be found also from Finland, where population level, cross-sectional 
FINRISK, Mini-Finland and Health 2000 health examination survey data has been linked to 
the hospital discharge and causes of death registers. From FINRISK data a risk assessment 
calculator for CVD risk has been developed and this calculator is available on the web for 
practitioners and individuals to use and see how the changes in smoking status, blood pressure 
levels and total cholesterol levels could affect the CVD risk [18]. An other example is the 
Elämä pelissä (Life on stake) where person can estimate his/her expected years of life based 
on their health behaviours and determinants [19]. 
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3.5 CONCLUSIONS 
Different aspects of the health of the population can be obtained from number of data 
sources, such as administrative registers, screenings, health interview surveys and health 
examination surveys. Each of the data sources has their advantages and limitations, but 
generally they do not rule out each others, more so they supplement each others. For example, 
the incidence of cancers can only be obtained from the administrative or disease specific 
registers and in some cases from screenings, since for most cancers there is no test that could 
be conducted on the health examination survey to diagnose the cancer. On the other hand, 
administrative registers and health interview surveys can provide information about the 
prevalence of hypertension only among those who have been diagnosed and in health 
interview surveys, who can recall their diagnoses. In health examination surveys, where the 
blood pressure is measured from the participants, also undiagnosed cases of elevated blood 
pressure (often indicating hypertension) can be detected. 
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4.1 INTRODUCTION 
This chapter provides an overview of recent and planned health examination surveys 
(HES) in Europe, i.e. European Union Member States and Candidate Countries, as well as 
EFTA/EEA Member States. In addition some major HESs in other industrialized countries 
outside Europe (e.g. USA, Canada, and Australia) are reviewed.  In this respect, the text 
updates information from earlier reviews [1, 2]. This chapter presents an overview of the level 
of experience and expertise in HES in the European countries, and the views of FEHES 
network members on the interest and importance of HES in their countries. This chapter will 
focus on different models of organizing the HES and conducting the fieldwork. The 
availability of sampling frames, the level of response rates, and ethical and legal issues, which 
are also relevant for the feasibility of HES, are considered in other chapters.   
The five main sources of information for this chapter are:  
1. The European Health Surveys Information Database (HIS/HES database) [3],  
2. The PubMed Database (Search term; "name of the country + health + survey") 
[4] 
3. WHO information sources: the WHOLIS database [5], and the WHO Global 
InfoBase Online [6](covering surveys including risk factor measurements, 
search term; "health survey"), and  
4. The International Health Data Reference Guide [7] prepared by the National 
Center for Health Statistics in USA.  
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5. The FEHES Questionnaire on Health Examination Surveys in Europe (FEHES 
questionnaire; Annex 2), and personal communication with FEHES network 
members in 32 countries. 
The main focus of this chapter is on health surveys carried out in the adult population 
(aged 18 and over) at national or regional level using probability sampling. Surveys targeted 
at specific age groups to study major public health problems and their risk factors were 
considered. Excluded were small scale local surveys, surveys focusing on certain rare 
diseases, and surveys based on samples of hospital patients or disease registers.  
4.2 RECENT HESS  
Within the last ten years, national HESs have been carried out in ten European countries 
(Croatia, Czech Republic, Finland, France, Germany, Ireland, Netherlands, Poland, Romania, 
and UK), in most of them with quite irregular and long intervals (Table 4.1 and 4.4). There is 
a new ongoing national survey in three countries without previous national HESs (Denmark, 
Luxembourg, and Spain). Countries with the longest traditions of organizing national HESs in 
Europe are Finland (since 1960s), Germany and the Netherlands (since 1980s), and UK (since 
the beginning of 1990s) (see Chapter 2 and Annex 6). In England the HES is carried out 
annually, and the survey field work operates continuously. Scotland started similar continuous 
annual HES in 2008. In most countries, HESs have been carried out with quite irregular or 
long intervals. In contrast to the few national HESs, several national HISs have been carried 
out within the last 5-10 years and with regular intervals in most European countries. 
There have been major regional surveys repeated at regular intervals and/or covering 
several regions in different parts of the country in nine countries which did not have any 
nationally representative surveys (Cyprus, Denmark, Iceland, Italy, Lithuania, Norway, 
Slovakia, Slovenia, and Sweden). Most of these were cardiovascular risk factor surveys that 
were initiated in the WHO MONICA Project [8] and/or carried out in CINDI [9] 
demonstration areas. Local, regional or topic-specific surveys have been carried out in almost 
all countries. Only large population-based surveys that might form a basis for organizing a 
national HES have been considered in this review and are listed in Annex 6. Therefore some 
regional or local topic-specific surveys may be missing.  
Experiences in USA, Canada and Australia also give major examples of success and 
difficulties in organizing national HESs. The National Health and Nutrition Examination 
Survey (NHANES) in USA is the largest and longest-running national HES in the world [10]. 
The fieldwork for a new Canadian Health Measures Survey (CHMS) started in 2007 to 
address previous limitations within Canada’s health surveillance system [11]. In Australia, 
large specific surveys, such as the 1999-2000 Australian Diabetes and Lifestyle Study, the 
AusDiab [12], have been carried out, as well as several major regional risk factor surveys. In 
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2003, a pilot test of a proposed new national Australian Health Measurement Survey (AHMS) 
was carried out [13, 14].  
Pilot studies have been conducted in several countries to assess the feasibility of a full-
scale national HES. They have not always led directly to full-scale national surveys, due to 
many challenges involved in creating the necessary survey organization involving several 
institutes, setting up the fieldwork capacity and obtaining the needed resources. For example 
in France two pilots carried out in 2002-2003 for a national HES suggested poor feasibility 
due to low response rates. However, a few years later in 2006 a new nutrition oriented HES 
was launched, and was well accepted by the population as the response rate was about 80%. 
Similarly, although the conduct of the Australian AHMS pilot was considered to be otherwise 
successful, the response rates were not satisfactory to justify the full AHMS. In 2007, a new 
pilot health measurement survey was started in Australia, which may become a nation wide 
survey in the future. In Italy, the pilot for national HES carried out in the city of Florence in 
2000-2001 by Istituto Superiore di Sanità (ISS) in collaboration with other organizations did 
not proceed to a full scale nationwide survey, mainly due to difficulties in finding sufficient 
funding [15]. However, there are active plans in Italy that a previous cardiovascular risk 
factor survey [16] will be expanded to cover other health topics. Changes in the national 
healthcare system have also affected the possibility of organising HESs in some countries. In 
Romania, where a series of national HES have been conducted in the past, the FEHES contact 
persons judge that new HESs are no longer feasible due to the high cost following  
privatization of the family physicians in 1998.   
4.3 FUTURE PLANS FOR NATIONAL HESS IN EUROPE 
According to information we received from the FEHES contact persons, there are active 
plans for national HESs in a sample of the adult population within the next five years in 17 
countries (Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, 
Italy, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, and UK). 
Preliminary plans have been prepared in three countries (Cyprus, Romania, and Turkey). In 
addition, plans for specific HESs in the elderly population and/or among children and 
adolescents were reported in four countries (Ireland, Finland, Luxembourg, Poland), as well 
as plans for regional surveys in most countries. Only in six countries no plans at all for future 
HESs were reported (Austria, Estonia, Hungary, Iceland, Latvia, Macedonia).  
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4.4 DIFFERENT MODELS OF ORGANIZING HESS 
4.4.1 DATA COLLECTION BY PERSONAL INTERVIEWS, SELF-ADMINISTERED 
QUESTIONNAIRES AND EXAMINATIONS 
The model of organizing the HES varies from the simple model of interview data 
supplemented by basic anthropometric and blood pressure measurements to a survey with an 
extensive clinical examination carried out by a team of different professionals and with 
several phases of fieldwork (Table 4.2).  HESs usually include an interview phase before the 
examinations or the HES is directly linked with the national HIS. As an exception, no prior 
interview phase has been used in the German surveys. There are also models that select a sub-
sample of the total HIS sample for the HES (e.g. Ireland). In the Netherlands, the participants 
of the HIS were later invited to the HES at the local health centre, which resulted in a high 
non-response rate for the examinations. In the Finnish Health 2000 survey, the prior health 
interview was used to motivate everybody to participate in the health examination and to 
make an appointment for the examination, resulting in high response rates (80 to 85 % of the 
whole sample). The NHANES in the USA and the Canadian CHMS also have two parts: the 
home interview followed by the invitation to the health examination in the mobile clinic.  
Nevertheless, there are several examples that demonstrate that if a survey has several 
phases and only the participants in the previous phase are invited to the next, the participation 
rates calculated from the original sample are bound to become low. In the Australian AHMS 
pilot, participants were recruited at the end of the National Health Survey interview [14]. 
Only 48% of eligible individuals aged 2-74 years living in private dwellings consented to 
being contacted about participating in the AHMS component (a nurse visit). It was concluded 
that future development of a national HES in Australia should consider a stand-alone survey 
to reduce respondent burden and thus the number of potential drop-out points. Similar 
experiences have been reported from New Zealand, where the linkage of the national health 
survey to the national nutrition survey was said to reduce the response rate in the second 
survey due to the multiple drop-out opportunities [14].  
In most European surveys, there has been a personal interview at home prior to the health 
examination in a clinic (Table 4.2). In England and Scotland there is first an interview and 
another appointment is made for the health examination, both conducted at the home of the 
participant. Starting from 2008, the Scottish Health Survey includes the biological module 
(nurse visit) for around one-sixth of the sample whereas it was previously offered to the 
whole sample. In some surveys, a questionnaire is mailed together with the invitation to the 
examination. In the five-yearly FINRISK surveys in Finland, the self-administered 
questionnaire is mailed to the selected persons together with the invitation to the examination. 
All examinees are asked to complete the questionnaire and bring it with them to the 
examination, where it is checked and missing data are completed with the help of the survey 
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personnel. In Finland, there are positive experiences of such an approach used since the 
Mobile Clinic Health Examination Surveys in the 1960s and later used in the FINRISK 
surveys.  
Some surveys, such as the Finnish Health 2000 survey, have used several questionnaires, 
both self-administered and computer-assisted personal interviews, at different phases of the 
survey. The last questionnaire was given at the end of the examinations to be filled in at home 
and returned by post (pre-paid mail). Such additional self-administered questionnaires given 
at the end of the examination have also been used in all the regional surveys in Norway. In the 
UK, self-administered questionnaires are filled in during or near the end of the interview 
phase, with different versions for specific age-groups. Telephone interviews are rare as a part 
of HESs. However, for example the Finnish Health 2000 survey employed telephone 
interviews to obtain basic health data from persons otherwise unable or unwilling to 
participate.  
4.4.2 DURATION AND PLACE OF EXAMINATIONS, AND TYPE OF PERSONNEL 
The average duration of the health examination has varied from ten minutes to four hours 
30 minutes per participant. In most surveys, the examinations were carried out at specific 
(temporary) clinics, often located in local health centers, while the examinations in Croatia, 
UK and Ireland were conducted during home visits (Table 4.3). Home and/or institutional 
visits have also been used to complement the HES clinic visits when the respondent would 
otherwise have been unable to attend (e.g. in Finland). Mobile health examination units (buses 
and trailers) have been widely used in USA from the first national HES survey in 1959-1962 
until the ongoing continuous NHANES survey. The mobile examination center (MEC) of 
NHANES is made up of trailers containing high-tech medical equipment. Partly the same and 
partly similar mobile units are also used in the Canadian CHMS.  
Mobile units are rare in Europe. In the early surveys in Finland, buses were used in the 
1960s and 1970s. Most recently, mobile survey units have been used in Europe only in 
Switzerland (the Bus Santé survey) and in Norway (Cohort Norway). In Norway, the buses 
are owned by the health care organization and they are used both for surveys and for clinical 
screening purposes in a mostly rural region, the county of Nord Trøndelag.   
In some countries (e.g. Finland), the planning, coordination and fieldwork of the HES 
has been the responsibility of one organization in collaboration with several other 
organizations. In other countries, the fieldwork has been carried out by an organization 
selected through an open call for tender by the Ministry of Health (e.g. UK, Ireland). The 
fieldwork of recent HESs in Europe has been carried out either by  personnel specially 
employed for the survey (e.g. surveys in Finland and in the UK), or by using the regular staff 
in the health care organizations, such as hospitals (as in the Italian Observatory study) or 
primary health care centres (in the Netherlands). The type and number of personnel depends 
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on the measurements included and the number of participants in the survey. The HESs have 
comprised variable topics from a few simple measurements (core topics) to extensive physical 
measurements, tests of functioning and clinical examinations. In the simplest cases, one nurse 
can carry out all measurements on one participant. In the extensive surveys, the examinations 
are carried out by a team of fieldwork personnel with different professional qualifications, 
such as physicians, dentists, nutritionists, laboratory technicians and trained interviewers. The 
number of personnel used in HESs varied from a few nurses to a large number of health 
measure specialist with different qualifications (Table 4.3). 
The complexity of the examinations has also been affected by differences in whether the 
country organizes one comprehensive HES (e.g. in Germany and Finland), also organizes 
other topic-specific HESs, such as separate national dental health and also psychiatric/mental 
health surveys (e,g, in the UK and the Netherlands), or uses additional modules. In Germany, 
there were additional modules to the national core survey, such as an additional regional 
sample, and an additional environmental health module. Additional booster samples have 
been selected in the UK, to cover specific groups in the population, such as the largest ethnic 
minorities and the elderly. In Scotland, the Health Boards are given the option to boost their 
samples beyond the level which is being funded centrally, but these boosted interviews will 
only comprise core questions (no additional module questions). In Finland, the Health 2000 
survey included an additional separate sample of the participants of the previous Mini Finland 
Survey. Other additional modules and phases of fieldwork were included to address selected 
scientific purposes. Persons selected with specific criteria were invited after the examination 
to attend for additional clinic visits. For example, a sub-sample was selected for the in-depth 
clinical examinations for cardiovascular diseases and diabetes in the Finnish Health 2000 
survey; these persons were invited to the hospital clinics after the original fieldwork for the 
survey was completed. The data collection for the surveys has also been extended from the 
original cross-sectional survey to follow-up, most often based on register linkages (e.g. causes 
of death, cancer registers). 
4.4.3 FREQUENCY AND TIMING OF THE SURVEY 
Most surveys have been carried out at irregular or about five year intervals (Table 4.4). 
The timing of the surveys has also varied. Some of the surveys have been carried out 
throughout the year from January to December (France, the Netherlands, Norway, UK, 
Canada and USA). In most countries, the surveys have taken place within a few months 
during the autumn or winter season. The summer holiday months (July-August) have been 
quite rarely used. Both the seasonal variation and differences in the time of the day used for 
examinations are known to affect symptoms and many physiological and biochemical 
measurements. The time of the day used for the examinations has also affected the feasibility 
of including measurements requiring fasting, and the availability of opportunities for the 
participants to choose a time that is easy from the point of view of their personal schedule, 
thus affecting their willingness to participate.   
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Core health topics covered in previous national HESs are reviewed in Chapter 8.  In the 
countries with extensive comprehensive surveys, there has been a set of core measurements 
targeted at all age groups and additional measurements (modules) targeted at specific age 
groups or other sub-samples of the participants comprising e.g. tests on functional capacity 
carried out only with the elderly, or a module on environmental health and another module on 
mental health targeted at a random sub-sample in Germany. In addition to the core 
measurements carried out every year, different specific topics and additional measurements 
have been selected for the survey each year in UK. 
4.5 POTENTIALS FOR ORGANIZING HESS IN EUROPEAN COUNTRIES 
In the FEHES questionnaire, we asked the national experts to assess how possible it 
would be to solve specified issues before a national HES could be conducted.  Expertise is 
available in national research and public health organizations in most European countries. 
Only in four countries were difficulties identified in raising interest among these organisations 
to carry out a HES. Difficulties mentioned most often were related to obtaining national 
funding and challenges related to the participant recruitment and raising interest in HES 
among the general population (Figure 4.1). In particular, it was felt in many countries where 
no previous national HES had been carried out that the political authorities do not recognize 
the need for this type of survey to improve health information. Difficulties were also 
identified in accepting the value of health information obtainable only by HES. These issues 
were well reflected also in the comments of the individual contact persons. One of them 
thought that it will not be possible to raise additional funds unless there are strong arguments 
concerning the "added value" of HES in comparison with HIS. Another contact person 
pointed out that in a small country, conducting a HES will be difficult if it is not planned 
jointly with a national HIS. A third contact person referred to the difficulty of estimating the 
cost, determining a sample size and choosing the age range to include if no relevant 
experience concerning this kind of surveys was available in the country.  
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0 % 20 % 40 % 60 % 80 % 100 %
Obtaining national funding
Raising interest to participate
Raising interest to carry out
Recognizing need
Accepting the value
Availability of expertice
Not difficult Somewhat difficult Very difficult
 
Figure 4.1 Potential for and difficulties in organising HES (Data source: FEHES 
questionnaire: % of countries/contact persons, total 32)  
Some of the contact persons demonstrated a poor knowledge of the public health value of 
a HES. One contact person indicated that prevalence information on most chronic diseases 
would be available through valid central registers, another thought that the "digital health 
record system" might be an alternative for future use with a linkage to HIS. One referred to 
the difficulty of raising interest among the general population to participate in a HES. A 
further contact person named the rather good access to care and free of charge health 
examinations. He also thought that in such countries there is no benefit to the participants in 
getting test results that they could receive otherwise. 
Normal health care facilities (e.g. health centres, general practitioner (GP) surgeries, 
hospital clinics) were considered to be the most feasible environment for the measurements of 
HES in most countries (Figure 4.2). Home visits and rented premises for temporary clinics 
were also considered to be feasible in several countries, while mobile clinics were prioritized 
in only four countries. This reflects the previous practices and experiences in organizing 
HESs in different countries. In Norway, mobile units were used in previous regional HESs. 
They are still available for future use in national surveys, but have to be rented. In a few 
countries with no previous experience in national HES, it was anticipated that the public 
health care facilities might be used. In one country, the use of the private sector was 
anticipated to increase response rates.  
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0 % 20 % 40 % 60 % 80 % 100 %
Rented premises
Mobile units
Home visits
Health care
Very feasible Fairly/somewhat feasible Not feasible at all
 
Figure 4.2 Feasibility of conducting HES fieldwork in different environments (Data souce: 
FEHES-questionnaire: % of countries/contact persons, total 32)  
Physicians and dentists are needed if clinical examinations will be carried out and 
diagnoses will be made. With regard to standardized measurements and structured interviews, 
the personnel of choice are nurses, physicians and the like. There are differences in the 
qualifications and role of different health professionals in the European countries. We asked 
our contact persons to assess if physicians are needed to carry out a few selected 
measurements to see whether these differences should be taken into account in the training of 
fieldwork personnel and in cost estimates for future surveys. While all measurements can be 
carried out by specially trained nurses or laboratory technicians in most countries, physicians 
have been employed in others to carry out the measurements or at least their presence at the 
fieldwork site is required (Table 4.5).    
4.6 SUMMARY AND CONCLUSIONS  
Compared with HIS, national HESs are still relatively rare but active or preliminary plans 
are being prepared in most EU countries. In almost all European countries there is both 
previous experience and current interest in organizing HESs. However in a few countries, 
national HESs are considered too expensive and major difficulties are anticipated with 
organizing them. The views of the FEHES contact persons clearly demonstrated that in 
countries where HESs had not been carried out there is lack of information concerning both 
the limitations of register-based data and the added value of a HES. The doubts were clearly 
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associated with no recognition of the fact that data available from registers and health service 
utilization are insufficient and biased. Such data can only cover users of services and do not 
describe the population at large. As an example, socioeconomic differences in health care 
utilization only reflect users’ health and are clearly biased in respect of the health of the 
population at large.  
Previous surveys have typically covered risk factors and prevalence of a few chronic 
diseases, especially cardiovascular disease and diabetes. In many EU countries these are also 
considered to be the most important topics for future surveys. However, examination surveys 
can provide data on many items from health determinants through several chronic diseases to 
measures of functioning. Before initiating new examination surveys, it is essential to design 
them on the basis of national and European information needs, not only on previous national 
experiences alone. Successful public health initiatives based on cardiovascular surveys since 
the 1970s may have led to the assumption that there is no need for such surveys in the future. 
However, the value of HESs should be evaluated in respect to current public health 
challenges, such as the ageing European populations, widening social inequality in chronic 
diseases, and the increases in obesity and diabetes. In order to develop feasible survey 
protocols, one must also take into account the existing health care systems, the role and 
qualifications of health professionals, and other practical aspects.  
Currently, the implementation of HESs in Europe varies considerably. As 17 European 
countries have active plans to conduct a HES in the next five years, there is an urgent need 
and an opportunity to standardize HES contents and practices.    
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Table 4.1 Recent and planned HESs in European countries (number of countries, FEHES 
questionnaire: number of countries/contact persons, total 32) 
 
Past (including 
surveys ongoing 
in 2007) 
Active plans for 
surveys between 
2008-2012 
Preliminary 
plans3 
National HES in the general adult population1  13 17 3 
National HES specific for children and adolescents 1 2 - 
National HES specific for the elderly 0 2 - 
Major regional surveys2  10 5 - 
 1 May include also children, adolescents and the elderly, and specific modules for them 
 2 Includes regional risk factor surveys covering a substantial part of the country or several 
regions (e.g. CINDI program areas)  
3 Not including other than national HES in the general adult population  
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Table 4.5 Measurements that might need to be carried out by physicians in various countries 
(Data source: FEHES questionnaire: number of countries/contact persons, total 32) 
  No physician needed Carried out in the 
presence of a 
physician or 
physician needs 
to be available 
Carried out by 
physician 
Blood pressure measurement 28 1 3 
Electrocardiogram 22 8 2 
Drawing blood samples 20 11 1 
Measurement of lung function by spirometry 20 8 4 
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5.1 INTRODUCTION 
Methods that can be used in health interviews and examinations have been developed in 
innumerable research studies, but the number of international guidelines that are available 
specifically for health examination surveys is quite moderate. The longest tradition of 
guidelines is for cardiovascular surveys. WHO published the first edition of their international 
guidelines on cardiovascular survey methods in 1968 [1]. These guidelines were later revised 
and updated in 1982 and 2004 [2, 3]. Several standards have been prepared by different 
organizations for specific measurements, resulting in differences between the existing 
standards, e.g. for spirometry. In 2005, the American Thoracic Society and the European 
Respiratory Society published common standards for lung function tests (Miller et al 2005). 
However, these are focused on clinical settings rather than survey environments. For many 
other health topics, several gaps still exist in the availability of methodological guidelines and 
recommendations both for clinical practice and for surveys.  
Much work has been done to promote the use of standardized Health Interview Survey 
(HIS) methods in Europe. In 1988, the WHO Regional Office for Europe initiated a series of 
international consultations to develop common methods for HIS. In 1996 some general 
recommendations for methodology and recommended instruments for perceived health, some 
aspects of disability, chronic conditions, health determinants, and socioeconomic 
classification were published [4]. As a result of the EuroHIS project, these were updated and 
supplemented in 2003 [5]. Several Eurostat initiatives have aimed at developing standardized 
instruments and survey methods, leading to the adoption of the standard European Health 
Interview Survey (EHIS) Questionnaire in 2006 [6]. The EHIS has been prepared by Eurostat 
in collaboration with several experts and organizations. The aim is that it will be implemented 
in EU Member States during the period of 2007-2009. EHIS includes modules for background 
variables, health status, health care and health determinants. Three Task Forces have 
developed the guidelines for the methods of EHIS. The results of the first task force have 
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been published on the development and criteria for the adoption of Health Survey instruments 
[7]. 
Despite these several efforts to develop international standards, also doubts have been 
expressed concerning the need and feasibility of the use of standardized methodology in 
national or local health surveys in Europe [8]. Several methodological problems, such as 
difficulties in conceptualization and translation across different cultures and societies, have 
been reported [9, 10]. 
This chapter focuses on guidelines and recommendations developed in international 
collaborative projects. The project Health Surveys in the EU: HIS and HIS/HES Evaluations 
and Models assessed the comparability of findings of previous HIS and HIS/HES, and 
summarized the previous and ongoing projects in the 1990's and before the year 2003 [11].  
Therefore this chapter comprises mainly projects carried out and/or finalized in 2003-2007. 
Major earlier activities are included only as background for the recent development. We give 
an overview of recent international projects that have developed or are currently developing 
methods for HES. Finally the FEHES contact persons' views on the need for international 
standards and collaboration for national HESs are summarized.  
5.2 INTERNATIONAL PROJECTS 
5.2.1 PROJECTS ON CHRONIC DISEASE RISK FACTORS AND CARDIOVASCULAR 
DISEASES 
The WHO MONICA Project collected valid and internationally comparable data on risk 
factors for coronary heart disease and the incidence of myocardial infarction in geographically 
defined populations in 21 countries in the 1980s and 1990s. The aim was to compare trends in 
risk factors and in the disease. The MONICA project laid the basis for international training, 
quality control and assessment of the achieved quality of the surveys [12]. A detailed manual 
of operations was prepared, including procedures for sample selection, measurement 
procedures and quality assurance [13]. The WHO Regional Lipid Reference Centre in Prague, 
Czech Republic, provided external quality control for the cholesterol determination methods 
for MONICA partners, but also for other laboratories from 1978 to 1997, when the European 
level reference laboratory activities ceased. For the American surveys, the standardization has 
been in the hands of the Centers for Disease Control (CDC) Atlanta for several decades, using 
methods which guarantee stability of the reference values over the years. The MONICA 
project made thorough assessment of the standardization [14]. The standardization was 
successful, although considerable variation in the quality of data was also observed [15]. In a 
few study areas, such as in two Swedish regions, the MONICA surveys have been repeated at 
regular intervals also after the project.  
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The MONICA methods have been used widely beyond the WHO MONICA Project, and 
were updated for future use in European HES by the European Health Risk Monitoring 
(EHRM) project, carried out in 1999-2002. The EHRM prepared a recommendation for 
indicators, international collaboration, protocol and manual of operations (listed in Table 5.1.) 
for chronic disease risk factor surveys [16]. The experience and technical developments over 
the 20 years were taken into account, and protocols for other relevant measurements, such as 
fasting blood glucose, were added. The EHRM recommendations pointed out the importance 
of establishing a replacement for the previous WHO Regional Lipid Reference Centre to 
serve European surveys. The WHO Cardiovascular Survey Methods were also updated in 
2004 [2]. These latest editions go beyond practical guidelines to different methods for data 
collection, editing, analysis and interpretation. They provide the conceptual background and 
literature base for proposed research approaches and procedures.  
The Countrywide Integrated Non-communicable Disease Intervention (CINDI) 
Programme involves demonstration areas in 26 countries of the European Region, plus 
Canada and Cyprus. The evaluation part of CINDI involves health surveys in the 
demonstration areas. The CINDI protocol published in 1994 [17] includes guidelines for 
blood pressure measurement, height and weight measurements, and questionnaires on 
smoking habits, alcohol, physical activity, diet, and disability assessment (Table 5.1). For 
measurements that were conducted in MONICA, CINDI adopted the MONICA methods. 
However, the quality assurance activities have not been as extensive as in MONICA. One of 
the conclusions of a feasibility study of surveys across CINDI countries was that although 
countries attempt to follow the agreed principles of the survey implementation, the 
methodology varied and depended on local conditions and possibilities [18]. 
The HAPIEE (Health, Alcohol and Psychosocial factors in Eastern Europe) study is a 
prospective cohort study designed to investigate the effect of several risk factors on 
cardiovascular and other non-communicable diseases in Eastern Europe and the former Soviet 
Union [19]. The baseline survey was conducted in 2002-2005 with the total planned sample 
size 36 500. Data were collected by structured questionnaires and examination in clinic 
including blood samples, anthropometric measurements, blood pressure, lung function and 
cognitive function. Re-examination of the cohorts started in spring 2006. Achieving 
satisfactory response rates was identified as the most serious challenge in the study, as the 
total response rate for the baseline study was 59%. The HAPIEE study is an ongoing multi-
country study, where the experiences in survey co-ordination, participant recruitment and 
fieldwork organization may provide valuable information needed in assessing feasibility of 
HESs in these Eastern European countries.     
The WHO has several initiatives of standardization of health surveys on an international 
level. The WHO STEPwise approach to Surveillance (STEPS) focuses on obtaining core data 
on the established risk factors that determine the major disease burden. It is sufficiently 
flexible to allow each country to expand on the core variables and risk factors, and to 
incorporate optional modules related to local or regional interests. The STEPS survey 
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protocol includes both standardized questionnaires and protocols for the physical and 
biochemical measurements [20] (see Table 5.1). The STEPS programme is targeted primarily 
at low and middle income countries outside Europe, providing an entry point to start chronic 
disease surveillance activities. WHO delivers and funds regional training workshops for 
planning and implementing STEPS as well as for analyzing, reporting and disseminating 
STEPS data. For the European HESs, the STEPS programme can be used as an example of an 
international survey organization with core and optional modules.  
The EUROCISS-project (phase I in 2000-2003) has defined cardiovascular disease 
indicators and survey items including e.g. risk factors (hypertension, hypercholesterolemia, 
overweight), health behaviours (physical inactivity, smoking) and medication use. Although 
register-based data (hospital discharges) have mainly been assessed, other sources of 
information (including surveys) by country have also been evaluated and reported. During its 
second phase (2004-2007), the project prepared a manual of operations for the 
implementation of CVD surveys for the collection of standardized indicators, in particular for 
prevalence of ischaemic heart disease, heart failure, stroke and other CVDs.  It also identified 
a minimum set of questions and examinations to be included in the HIS/HES for evaluating 
the prevalence of CVDs at European level.  [21, 22] 
5.2.2 PROJECTS ON RESPIRATORY HEALTH  
The European Community Respiratory Health Survey (ECRHS) was the first study that 
assessed the prevalence of asthma and allergic disease in a large number of countries using a 
standardized protocol [23]. The protocol was published in 1993 [24].  Men and women aged 
20-44 years were randomly selected for the study. A short screening questionnaire was posted 
and a random sample of respondents was selected for the clinical examination. The ECRHS 
included a interviewer-administered questionnaire, an indoor environment questionnaire, 
occupational modules and women's questionnaire, blood samples and the detailed protocol for 
lung function measurement [25]. The quality control programme included training seminars 
before the study and quality control visits to each centre during the study. However, a wide 
variation in participation rates (12-90%) was reported between the 25 countries and 56 study 
centres [23].  
The ECRHS II began in 1998: it was a nine-year follow-up in 14 countries and 29 study 
centres. Individuals taking part in the clinical stage of ECRHS I were sent a short screening 
questionnaire and all those who responded were invited to a local fieldwork centre, situated in 
an outpatient or lung function laboratory in a local hospital or centre. Environmental 
information was collected by home visits in a subsample of homes, and past and current 
exposure to air pollution was assessed through retrieval of air pollution records and by a 
programme of air pollution monitoring. In the fieldwork centre, the following procedures 
were performed: detailed interviewer and self-administered questionnaires on symptoms, 
exposure to known or suspected risk factors of asthma, and health service utilization; SF-36, a 
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quality of life questionnaire, and a disease-specific measure of quality of life; blood samples 
for measurement of specific IgE and total IgE; and measurement of lung function and 
bronchial challenge testing. In some centres, samples were stored for later use in DNA 
studies.  Higher response rates have been reported in ECRHS II than in the first stage. [26, 
27]  
In the first phase of the Indicators for Monitoring COPD and Asthma in the EU (IMCA) 
project (2002-2004), indicators for monitoring Chronic Obstructive Pulmonary Disease 
(COPD) and asthma were selected and defined and methods for data collection were 
recommended. The availability of data from surveys and "routine data" in EU Member States 
was evaluated. The indicators include health status (e.g. prevalence of symptoms, bronchial 
hyperresponsiveness, sensitization to allergens, total IgE, BMI), determinants of health (e.g. 
smoking), and health care (e.g. hospital admissions and primary care visits). The ongoing 
second phase of IMCA (2006-2008) aims to develop a module to be incorporated in future 
HESs and to test its feasibility. Four geographical areas in Spain, Italy, Sweden and Germany 
have been selected to explore the use of innovative technological methods to carry out 
measurements, validate and transmit the data (fieldwork online) and the use of a telemedicine 
network to provide training and support online to the fieldworkers. A new questionnaire 
module based on previously validated questionnaires to estimate the IMCA I indicators will 
be developed. The project will also explore the feasibility of taking a blood sample at home to 
measure relevant indicators on allergy (total IgE and specific IgE) and to obtain DNA samples 
to create a DNA databank in future HES. The pilot includes measurements such as 
spirometry, pulse-oximetry, exhaled NO, blood pressure, height and weight. [28, 29]  
5.2.3  PROJECTS ON DIABETES  
The European Diabetes Indicators Project (EUDIP, carried out in 1999-2002) developed 
indicators for the risk of diabetes and for the situation of diabetes patients in European 
countries. The European Core Indicators for Diabetes Mellitus (EUCID) project (2006-2007) 
continues the work of EUDIP to reach agreement on core indicators and methodology. The 
EUCID project [30] aims to demonstrate the feasibility of the data collection on 27 indicators 
of Diabetes Mellitus and it's risk factors from EU countries. It will prepare a proposal for 
collection of data in the future, using a stable paper and electronic platform for reporting. A 
codebook of indicators has been prepared and surveys (HISs and HESs) have been considered 
as potential sources of information. Only a few indicators, such as BMI and impaired fasting 
glucose, are defined for the general population, while most indicators are defined for the 
diabetic population. [30] 
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5.2.4 PROJECTS ON NUTRITION  
The European Prospective Investigation into Cancer and Nutrition (EPIC) was designed 
to investigate the relationships between diet, nutritional status, lifestyle and environmental 
factors and the incidence of cancer and other chronic diseases [31]. It is the largest study of 
diet and health ever undertaken, carried out in ten European countries in 23 study centres. The 
recruitment was principally volunteers from the adult population aged 20 years and over, and 
took place between 1993 and 1999. The subjects agreed to have their health status followed 
up for the rest of their lives. However in some countries, volunteers from selected groups of 
persons, such as blood donors or members of the local vegetarian society or members of a 
health insurance plan, were recruited. The EPIC questionnaires contained common diet and 
lifestyle questions across each centre (core questions, including standardised Food Frequency 
Questionnaires, and Health and Lifestyle Questionnaires), and some optional sections or 
questions. Anthropometric examinations were undertaken by trained observers using 
standardized methods and included measurements of weight, height and waist and hip 
circumference. The process for collecting and storing the blood was standardized throughout 
the participating countries. Additional measurements have been carried out in different study 
centres. Some validation and quality control results have been published [32]. EPIC includes 
several follow-up studies and ongoing research activities covering e.g. cardiovascular diseases 
and ageing, and particular cancer sites.  
The European Food Consumption Survey Methods (EFCOSUM) Project [33] involved 
14 EU Member States. Consensus recommendations were published in 2002 for sampling, 
recruitment, fieldwork, biomarkers, interviewer qualifications, and training and quality 
control. The 24h recall was chosen as the preferred method for assessing the diet. In the 
EFCOSUM project it was assumed that collection of biological material necessitates special 
logistical conditions, special safety needs and increases the risk of non-response. Therefore, it 
was recommended to measure biomarkers in the context of other public health monitoring 
systems. It was concluded that specific and sensitive markers for the dietary intake of iodine, 
sodium, iron, folate and vitamin D are available, which have the advantage of being more 
accurate than intake estimations derived from dietary surveys, but more basic data for the 
validity of cross-country comparisons are needed [34]. 
5.2.5 PROJECTS ON MENTAL HEALTH 
The European Study of the Epidemiology of Mental Disorders (ESEMeD) (also referred 
to as the Mental health disability: a European assessment in the year 2000, MHEDEA study) 
was a cross-sectional study investigating the prevalence of and the factors associated with 
mental disorders, as well as their effect on health-related quality of life and the use of services 
in six European countries [35]. Trained interviewers used a computer-assisted personal 
interview (CAPI) including the most recent version of the Composite International Diagnostic 
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Interview (CIDI), a well-established epidemiological survey instrument for assessing mental 
disorders. This was the first international study using the standardized up-to-date 
methodology for epidemiological assessment in mental health with representative samples 
(n=6,000 per country). With co-ordinated analyses and rigorous quality control, the study 
aimed to ensure validity and comparability of results. The European Policy Information 
Research for Mental Disorders (2005-2007) aims to maximise the realisation of the policy 
information research, scientific and community potential of the ESEMeD/MHEDEA project 
[36]. 
The MINDFUL project [37] developed a database of mental health indicators with 
metadata (descriptions, definitions and data sources) and statistics (numerical data by 
indicator/country/year). It recommended a set of survey instruments (see Table 5.1.) and 
carried out a pilot survey in five countries to test the implementation of the set of mental 
health indicators [38]. The pilot sample consisted of 2,059 participants interviewed by phone. 
The conclusions were that the set of indicators could be easily incorporated into general 
health surveys, as the average length of the interviews was less than 15 minutes and the 
interviewed persons found the survey easily acceptable. Given the importance of the burden 
of poor mental health and its high co-morbidity with many physical disorders, it was strongly 
recommended that mental health measures should be included in any health-related survey. It 
was also recommended that a mental health survey should be conducted every five to 10 
years, with a minimum sample size of 3 000 per country.  
5.2.6 PROJECTS ON COGNITIVE AND PHYSICAL CAPACITY 
The European Collaboration on Dementia (EuroCODE) -project (2006-2008) aims to 
develop guidelines and indicators for Alzheimer's disease and other forms of dementia,  
European guidelines on the diagnosis and treatment of Alzheimer's disease and other forms of 
dementia, European guidelines for psycho-social interventions in dementia, and European 
parameters for the risk factors of dementia and risk reduction and prevention strategies. It will 
develop a network bringing together the main actors in the field of dementia in Europe, such 
as Alzheimer Europe, Alzheimer's Disease International, the Cochrane Dementia and 
Cognitive Improvement Group, the European Alzheimer's Disease Consortium, the European 
Association of Geriatric Psychiatry, the Dementia Panel of the European Federation of 
Neurological Societies, the INTERDEM (Early detection and timely intervention in dementia) 
group, the International Association of Gerontology (European Region) and the North Sea 
Dementia Research Group. The various guidelines and indicators will be developed by 
specific working groups comprised of representatives of the network partners and other 
experts chosen for their expertise. The project will provide basis for the development of 
health survey instruments by gathering existing epidemiological studies and analyzing the 
respective merits and shortcomings of the individual studies [39]. 
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The baseline wave of the Survey on Health, Ageing and Retirement in Europe (SHARE) 
was carried out in 2004 in 11 European countries [40, 41]. The survey includes some 27 000 
persons aged 50 and over, with a 57 % household response rate (ranging from 38 to 69 in 
different countries). To ensure comparable data sampling, interview and measurement 
procedures were harmonized. The survey included measurements of cognitive and physical 
functioning (such as hand grip strength and walking speed).  The second wave of the data was 
collected in 2006-2007 from the original sample and additional samples from three new 
European countries. This is planned to be the beginning of a European Longitudinal Ageing 
Survey. The intensive methodological development and fieldwork protocols applied in 
SHARE are relevant for the development of HESs.   
5.2.7 PROJECTS ON ORAL HEALTH 
The European Global Oral Health Indicators Development Phase II (EGOHID II, 2006-
2008) continues the work of EGOHID I (2003-2005) to develop and promote the use of 
common oral health instruments in Europe. It aims to facilitate comparisons of indicator data 
by promoting standardization of methods. It also aims to improve the capacity of area health 
services to monitor their oral health improvement activities in a standardized manner. In the 
longer term, it aims to improve service specifications across health services with a view to 
maintaining and improving performance, and to enhance the capacity to analyze the social, 
economic, behavioural and political determinants with particular reference to poor and 
disadvantaged populations. The EGOHID II will develop recommended common instruments 
for national health interview surveys, and for national health clinical surveys. The next step is 
to promote the actual implementation of these instruments in the national oral health 
interview survey, the national oral health clinical survey and to evaluate their performance. 
[42] The project has published EGOHID software at the end of 2007 to support the data 
collection [43]. The recommendations will be published during the year 2008. 
5.2.8 PROJECTS ON MUSCULOSKELETAL HEALTH AND PHYSICAL ACTIVITY  
The Indicators for monitoring Musculoskeletal Conditions project recommended in 2003 
a set of core questions on musculoskeletal pain to be included in all HIS questionnaires. It 
also recommended questions on function and specific questions about diagnoses in HIS 
and/or HES. HES was mentioned as the recommended source of information on the 
prevalence of rheumatoid arthritis, osteoarthritis, osteoporosis fractures and low bone mineral 
density, but no guidelines for measurement were given. [44] 
The European Network for Action on Ageing and Physical Activity (EUNAAPA) project 
(2006-2008) includes a work package with objectives to collect information on current 
instruments for the assessment of physical activity and physical function in older people. The 
project is evaluating the measurement properties and appropriateness of existing instruments 
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through critical review of the literature and collaboration with other organizations and 
networks on assessing instruments for evaluating physical activity and physical functioning 
among older populations. [45] The project has published an overview of instruments currently 
used in assessing physical activity and physical functioning in elderly people. [46] 
5.2.9  PROJECTS ON ENVIRONMENTAL HEALTH AND HUMAN BIOMONITORING 
Human Biomonitoring aims to assess human exposure to and health effects from 
environmental pollutants based on sampling and analysis of human tissues and fluids (e.g. 
blood, urine) and it is seen as a powerful tool to support environmental policy as well as 
public health policy. The ESBIO project [47] aimed to prepare the European Pilot Project to 
develop a coherent approach to Human Biomonitoring in Europe in close cooperation with 
the Member States in 2004-2007. Several of the pilot aims are also relevant for FEHES as it 
aims to gain practical knowledge of access to study populations, recruitment procedures and 
response rates, to test the developed guidelines, protocols and technical procedures for field 
work, questionnaires, chemical analyses, data handling and processing, to test ethical 
guidelines and gain experience on ethical rules. The study population for the proposed 
biomonitoring pilot study will be children (aged 6-11years) and their mothers. Scenario 1 
(biomarkers: lead, cadmium, methyl-mercury and cotinine) forms the obligatory element, and 
Scenario 2 (a number of organic pollutants) the optional part of the project. Questionnaires 
will be used to assess exposure of the individual pollutants, and blood, urine and hair 
specimens will be collected.  
 A questionnaire has been prepared to be used in the EU Human Biomonitoring Pilot 
Study. It includes questions on children's potential exposure pathways, behaviours and socio-
demography [48]. Protocols for blood sampling, urine and hair samples are included. 
Guidelines have been proposed for data collection (population sampling, recruitment and 
chemical analysis) [49], and for laboratory selection (criteria for selection, invitation to tender 
and evaluation of proposals) in the framework of a EU Human Pilot Study [50]. In addition 
guidelines have been prepared for quality control, data management, data treatment and 
reporting [51].  
5.2.10  USE OF POOLED DATA  
Several previous projects, such as the EURALIM (EURope ALIMentation) and 
EURODEM (the European Community Concerted Action on the Epidemiology and 
Prevention of Dementia Group), have used pooled data from different European population-
based studies. These projects indicate the possibilities and difficulties in pooling data from 
independent studies without standardized methodology. EURALIM aimed to determine and 
describe the extent to which European data on risk factor distributions from different 
populations could be pooled and harmonized in a common database for international 
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comparisons [52]. The main result of the project was that because of the variability among 
methods used in the seven independent surveys from six European countries, direct 
comparisons of risk factor distributions and prevalence between studies were overly 
problematic. However, international comparisons of within population contrasts by sex, age-
group, and other health determinants were considered as meaningful. In the EURODEM 
project a total of 20 centres participated by sending original data from 23 population studies 
[53]. 
Primatesta et al [54] used HIS and HES data from three national surveys (England, 
Germany and Italy) to investigate the possibility of merging data, and the practices of pooling 
and analyzing the merged data. The study aimed to compare the self-assessed health status of 
people with some chosen risk factors for cardiovascular disease. The self-assessed health 
status was measured by the Short Form Health Survey instrument (SF-36/SF-12). Information 
on hypertension and obesity were collected by direct measurement and self-reporting. The 
study demonstrated that the task of merging data collected in national health surveys is 
possible, but subject to several restrictions because of differences in instruments used, 
phrasing of questions, and protocols used in the measurements. Similar methodological 
problems have been identified in other international comparisons based on national survey 
data.    
5.3 INTERNATIONAL ASPECTS OF NATIONAL HESS 
International standards and protocols have been developed to improve the comparability 
of data between different regions and countries. It is anticipated that this will also enhance 
implementation in countries with less experience of national HESs. However, a possible 
drawback in countries already having a tradition of national surveys is that the application of 
international standards and protocols could impact negatively on the assessment of national 
time trends, if the old and new procedures differ.  
In the FEHES questionnaire, we asked our contact persons to assess the importance of 
different standards, and the way they could be incorporated in national HESs in their country. 
All contact persons seemed to value the adoption of international standards, and most of them 
assessed the international collaboration for quality assurance as very important (Table 5.2). 
International expert consultation was considered most important in countries without much 
previous experience in national surveys. 
We presented two alternatives for a European HES to the FEHES contact persons. The 
first alternative would be to conduct the European HES as a part of a national survey 
incorporating some topics and modules to meet the international needs. The other alternative 
would be to conduct a separate internationally-standardized survey. Most contact persons 
considered both alternatives as very or somewhat likely in their country (Table 5.3.).  
Assuming that the international standardization would be funded by an outside source (e.g. by 
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the European Commission research funds), most contact persons considered that the needed 
additional national funding could be found. One contact person anticipated that participation 
in an international initiative, even if only a pilot study would be very useful in convincing 
national political authorities of the importance and utility of HES, thus increasing the chance 
of receiving sufficient national funds.  
5.4 CONCLUSIONS 
Most FEHES contact persons considered international standardization and quality 
assurance important. However, for countries with a long tradition of national surveys, such as 
the UK, it is important to find an optimal strategy to integrate the European standards without 
impeding time trends. There are no fully standardized and internationally comparable HES 
data in Europe after the WHO MONICA project, for which the data collection ended in the 
mid 1990s. Several recent projects have focused on specific disease groups or health topics, 
such as oral health, diabetes, musculoskeletal diseases, mental health, and cardiovascular 
diseases. Some of these projects are ongoing, and are continuing their work in indicator 
development and promotion of standardized and comparable survey methodology. The input 
of these projects is a good basis and several opportunities exist for collaboration for the future 
development of European standards for national HESs. It is important to notice that some 
aspects relevant in surveys focusing on specific diseases may not be feasible in national 
surveys targeted to a sample of the whole adult population.  
Several gaps still exist in the availability of methodological guidelines in many health 
topics, such as in the field of musculoskeletal diseases, and measurement of functional 
capacity and disability. Even though some recommendations may be available, they have not 
been properly tested and evaluated in actual field surveys, and there may be lack of agreement 
on the feasibility and quality of the methods developed and proposed by various experts. One 
major drawback in respect of biochemical determinations is the lack of a European reference 
laboratory network and other quality assurance and control schemes. A reference laboratory is 
needed for providing secondary calibrators for the survey laboratories as well as providing 
external quality control [16].  
In most recent European projects, much work has been done to standardize instruments 
and measurements. However, standardization of the sampling process has been less 
successful, and even less attention has been given to differences in survey administration and 
adaptation of the fieldwork protocols. These require much more attention due to the highly 
complex circumstances of the European context [9, 10]. 
Difficulties reported at local level, such as in achieving an acceptable response, can be 
solved with thorough implementation and addressing different aspects related to survey co-
operation throughout the study process [55]. It needs to be accepted that many sources of 
variation and bias can also be affected by several apparently random factors and culturally 
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sensitive issues. Thus international standards need to be carefully adapted into national 
circumstances, at the same time taking care to not jeopardize either international 
comparability or national time trends.     
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Table 5.2 Importance of international standards and collaboration for a national HES in 
European countries (FEHES questionnaire: number of countries/contact persons, total 32) 
  Very 
important 
Important Not 
important at 
all 
Adoption of international standards 23 9 0 
Continued use of national standards to follow national 
time trends 
14 13 5 
International collaboration for quality assurance and 
control 
21 10 1 
Receiving international expert consultation   17 12 3 
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Table 5.3 Participation in a HES with European standards (FEHES questionnaire: number of 
countries/contact persons, total 32) 
  Very 
likely 
Somewhat 
likely 
Not at all 
likely 
National survey incorporating topics/modules to meet the international 
needs 
7 21 4 
Participation in a separate internationally standardised survey 19 12 1 
Availability of national funding if international co-ordination and much 
of the international standardisation would be funded by an outside 
source 
10 16 4 
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6. LEGISLATION AFFECTING HEALTH SURVEYS 
 
Susanna Conti1, Mark Kanieff1, and Grazia Rago1 
1Italian National Institute of Public Health (ISS), Rome, Italy 
 
6.1 INTRODUCTION 
As part of the FEHES project, we have assessed the obligations in and limitations of HES 
data collection due to legal and ethical issues. In conducting research involving humans, 
fundamental concerns include the ethical conduct of the research itself, the safeguarding of 
privacy, and obtaining informed consent. We investigated how countries in Europe have 
addressed these concerns in the HESs conducted to date. We performed a survey using a 
specifically designed questionnaire, which was included as part of the more extensive 
“Questionnaire on HES in Europe” (Annex 2) sent to the national contact persons of the 
FEHES network. 
The contact persons from all 32 countries in FEHES completed our questionnaire. We 
asked these persons to send us copies of the informed consent form and information notice 
used in the HES or, if no HES had been performed, in similar studies. In this chapter, we 
provide the results of the survey.  We also discuss the issues fundamental to safeguarding 
privacy and obtaining informed consent, including a brief description of some of the most 
important reference documents in the ethical conduct of medical research in general and a 
glossary of terms used in this field. 
6.2 ETHICS IN MEDICAL RESEARCH 
To have a clearer understanding of how ethical issues in medical research are addressed 
in Europe, we start with a description of some important documents which many countries 
have used as a reference for national legislation or recommendations. These documents 
address issues regarding the ethical conduct of research, the safeguarding of privacy, and 
obtaining informed consent.  
In historical terms, the most important document (and the first to address informed 
consent in research) is the Nuremberg Code [1], a set of principles for human 
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experimentation. It was created in 1947 as a result of the Nuremberg trials, in response to the 
experimentation carried out by the Nazis during World War II. Since then, a number of 
documents have served as important references. In particular, the Declaration of Helsinki 
(“Ethical Principles for Medical Research Involving Human Subjects”) [2] is considered 
internationally to be the pillar of ethical standards for biomedical research involving humans. 
It was created by the World Medical Association (an international organization representing 
physicians from hundreds of nations) [3] in 1964 and was last updated in 2000. The 
Declaration outlines the basic principles for medical research, including in-depth coverage of 
informed consent. It was the first document to introduce the concept of an independent ethical 
review committee. Another important document is the Belmont Report (“Ethical Principles 
and Guidelines for the Protection of Human Subjects of Research”) [4], created in 1979 in an 
attempt to summarize the basic ethic principles (“Respect for Persons”, “Beneficence”, and 
“Justice”) of the U.S. National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research. 
The principles of ethics in biomedical research have also been addressed at the 
government level. Two important acts of the Council of Europe merit mention: the 
Recommendation of the Committee of Ministers No. R(90) 3 [5] concerning medical research 
on human beings (6 February 1990) and the Oviedo Convention on Human Rights and 
Biomedicine (1997) [6]. 
In our survey, we asked the national contact persons to provide information on legislation 
regarding the ethical conduct of research involving humans in their countries, specifically: 
• Acts regulating the status and/or rights of patients 
• Medical research acts 
• Other national ethical principles of research involving humans 
• International biomedical research guidelines 
• Other (contact person asked to specify) 
 
We downloaded the actual laws from the internet and reviewed them for salient points. 
Information on this legislation for the individual countries is provided in Table 6.1. With 
regard to acts regulating the status and/or rights of patients, nearly all of the countries 
surveyed have laws for protecting rights (e.g., the right to physical and mental integrity and 
security and the right to respect for private life and to dignity of treatment). The right to 
confidentiality is guaranteed by all of these laws. In some cases, for instance Hungary, 
reference is made to “professional secrecy”. In other countries, such as Cyprus, reference is 
made to a Data Protection Act. In Portugal, there is a general law on health (the Health 
Framework Law of 1990) which establishes that the protection of health is a right of citizens 
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and of the community and that protecting this right is the joint responsibility of citizens, the 
society and the State, in terms of freedom of research and provision of care, as stipulated in 
the Constitution and laws. 
With regard to medical research acts and international biomedical research guidelines, 
most of the countries make reference to the Declaration of Helsinki; some also refer to the 
Oviedo Convention. Finally, all the countries reported that the research protocol must be 
approved by a regional or national ethics committee; Portugal makes reference to an ethics 
committee at the institute that performs the survey.  
6.3 SAFEGUARDING PRIVACY: DATA PROTECTION AND SUBJECTS’ 
RIGHTS 
As stated in the Declaration of Helsinki (Paragraph 21) “…Every precaution should be 
taken to respect the privacy of the subject [and] the confidentiality of the patient's 
information…”. The need to safeguard privacy has become increasingly important, given the 
progress made in information technology and the consequent ease of access to data. The most 
important document regarding this issue in Europe, though not dealing exclusively with 
medical research, is “Directive 95/46/EC of the European Parliament and of the Council of 24 
October 1995 on the protection of individuals with regard to the processing of personal data 
and on the free movement of such data” [7]. According to this Directive, “Member States 
shall protect the fundamental rights and freedoms of natural persons, and in particular their 
right to privacy with respect to the processing of personal data”. 
To understand better the procedures applied to the use and protection of data, definitions 
of some commonly used terms are provided below. More detailed definitions are provided in 
the above-mentioned Directive. 
 
• Personal Data – information regarding an identifiable person, that is, one who can be 
directly or indirectly identified, in particular by reference to an identification number 
or to factors specific to his/her physical, physiological, mental, economic, cultural or 
social identity 
• Processing of Personal Data – any operation (automatic or not) performed on 
personal data, for example, collection, storage, adaptation or alteration, retrieval, 
destruction and dissemination 
• Controller – the person or entity that determines the purposes and means of the 
processing of personal data 
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• Processor – the person or entity that processes personal data on behalf of the 
controller 
• Personal Data Act (or Data Protection Act) – legislation for protecting the privacy of 
natural persons in the processing of personal data  
• Sensitive Data – personal data revealing racial or ethnic origin, political opinions, 
religious or philosophical beliefs, trade-union membership, criminal convictions, and 
data concerning health or sex life 
• Right of Access – the right of a human subject to consult the data collected on him/her 
• Duty of Notification – the obligation of the controller to notify the data protection 
authorities of the intention to perform data processing, including a description of the 
processing 
Given that performing a HES includes collecting a particular type of personal data (i.e., 
sensitive data regarding health), respecting the privacy and confidentiality of participants 
entails carefully controlling the processing of personal data, which may be governed by 
national-level legislation, often referred to as a “Personal Data Act”. 
To this regard, the following aspects, which are covered in the above-mentioned EC 
Directive, are particularly important: 
• the authorities responsible for data protection (e.g., Data Inspectorate, Data 
Protection Board) 
• for individual studies, the persons or institutions responsible for controlling the use of 
personal data (Controller, which could be the study’s Project Leader or Principal 
Investigator), and those who process the data (Processor, including those who analyse 
the data collected)  
• duty of notification 
• time limits on the storage of personal data 
• right of access to personal data 
• transfer of personal data to other countries 
• electronic handling/transmission of data (e.g., via Internet) 
• information to be given to the data subject 
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In our survey, we also requested information on legislation for protecting personal data. 
All countries have a data protection act, except Turkey; most made reference to the 
aforementioned EC directive (Table 6.1). 
The Network of Competent Authorities (NCA) of the Health Information Strand of DG 
SANCO has also reviewed the legislation on the protection of health data. Although the NCA 
was not able to obtain information from all Member States, their summary report [8] provides 
an in-depth analysis. Some passages from this report have been quoted below.  
“Obviously health data require a high level of protection due to their sensitive nature. 
On the other hand, the public interest of health monitoring at population level can be 
regarded as overriding the privacy interests of the individual. EU Directive 95/46/EC on 
Data Protection appears to be sensitive to both the needs and rights of the individual citizen 
and the needs and rights of society. In principle the processing of health data is prohibited. At 
the same time, exemptions are made for data collection without consent of the data subject for 
provision of health care services and for important public needs. The EU Member States, 
however, have interpreted these possibilities in different ways, resulting in extreme 
differences between Member States: while processing of personal health data is hardly 
possible in some, sophisticated national data collection systems are present in others.” 
The report goes on to state that though most data protection acts make reference to the 
same Directive, “…there is a lot of confusion. Laws are difficult to interpret and there is no 
common definition of key terminology […]. Conditions for the exchange of health data 
between Member States appear to differ. The current situation in Europe seems to be at odds 
with the situation aimed for by the Directive, whose objective is to provide adequate 
protection of the fundamental rights of individuals, and at the same time to ensure that 
Member States cannot use reasons connected with this protection for inhibiting the free flow 
of personal data between Member States.” 
6.4 OBTAINING INFORMED CONSENT (INFORMED CONSENT FORM AND 
INFORMATION NOTICE) 
Research involving humans cannot be performed without the explicit consent of the 
research subjects. This consent is provided on what is known as an “informed consent form”, 
which must be signed by the individual after he/she has received all of the necessary 
information on the study and on what participation entails. This information is either provided 
on the informed consent form itself or in a separate document known as an “information 
notice”. However, obtaining informed consent goes beyond merely getting an individual to 
sign a written form: it is a process of communication between the individual and the 
healthcare professional who is conducting the study, with the goal of ensuring that the 
individual fully understands the scopes of the study, the methods adopted, and how the data 
will be used. This communication process is both an ethical and a legal obligation. The 
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concept of consent is relevant to both the performance of the study itself and protecting the 
privacy of the individual. 
The fundamental issues regarding consent in medical research on humans are particularly 
well expressed in the Declaration of Helsinki. Selected paragraphs from this Declaration are 
provided below. 
Paragraph 20) The subjects must be volunteers and informed participants in the 
research project. 
Paragraph 22) In any research on human beings, each potential subject must be 
adequately informed of the aims, methods, sources of funding, any possible conflicts 
of interest, institutional affiliations of the researcher, the anticipated benefits and 
potential risks of the study and the discomfort it may entail. The subject should be 
informed of the right to abstain from participation in the study or to withdraw consent 
to participate at any time without reprisal. After ensuring that the subject has 
understood the information, the physician should then obtain the subject's freely-given 
informed consent, preferably in writing. If the consent cannot be obtained in writing, 
the non-written consent must be formally documented and witnessed.  
Paragraph 23) When obtaining informed consent for the research project the 
physician should be particularly cautious if the subject is in a dependent relationship 
with the physician or may consent under duress. In that case the informed consent 
should be obtained by a well-informed physician who is not engaged in the 
investigation and who is completely independent of this relationship. 
Paragraph 24) For a research subject who is legally incompetent, physically or 
mentally incapable of giving consent or is a legally incompetent minor, the 
investigator must obtain informed consent from the legally authorized representative 
in accordance with applicable law. These groups should not be included in research 
unless the research is necessary to promote the health of the population represented 
and this research cannot instead be performed on legally competent persons.  
Paragraph 25) When a subject deemed legally incompetent, such as a minor child, 
is able to give assent to decisions about participation in research, the investigator must 
obtain that assent in addition to the consent of the legally authorized representative. 
Paragraph 26) Research on individuals from whom it is not possible to obtain 
consent, including proxy or advance consent, should be done only if the 
physical/mental condition that prevents obtaining informed consent is a necessary 
characteristic of the research population. The specific reasons for involving research 
subjects with a condition that renders them unable to give informed consent should be 
stated in the experimental protocol for consideration and approval of the review 
committee. The protocol should state that consent to remain in the research should be 
obtained as soon as possible from the individual or a legally authorized surrogate. 
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As mentioned, we asked the national contact persons for copies of the informed consent 
form and information notice used for HES or for similar types of studies involving humans. 
The contact persons from four of the 32 countries informed us that they did not have a 
specific informed consent form or information notice for HES or similar studies. Specifically, 
Latvia responded that when a HES-type study was performed in 1991, the country was in the 
middle of Soviet occupation and that no consent form existed at the time. Malta responded 
that a model for a consent form does not yet exist for a HES, yet the reference person 
described those points that according to Maltese law must be covered. Macedonia and 
Romania responded that there is no specific consent form. For an additional eight countries, it 
was not possible to obtain a copy of the informed consent form or information notice (Austria, 
Belgium, Croatia, Czech Republic, Iceland, Luxembourg, Slovenia, and Spain). Thus the 
information on consent provided in this report refers to 20 countries. 
The issues covered in the informed consent forms and information notices used in the 
HES performed to date are summarized in Table 6.2 and discussed below. The specific 
studies in which these forms were used are specified in Table 6.3.  
The informed consent forms and information notices vary greatly by individual country. 
Some use a more detailed information notice and consequently a reduced informed consent 
form. For example, the United Kingdom uses a hefty information booklet. 
In some cases, the information notice was mailed to participants before the informed 
consent form, to provide potential participants with time to read and understand the 
information before deciding whether or not to participate. In many countries, the telephone 
numbers of persons or institutions available for providing clarification were provided (usually 
the project leader). In France and Ireland, a toll-free hotline was created for any questions 
regarding the information notice; in Lithuania, the telephone numbers of the national and 
regional ethics committees were provided. In some cases (e.g., France), the duration of the 
interview and the visit was specified. 
An interesting feature of the information notice sent by the contact person in Poland is 
that the study is described in the wider context of the overall health situation in the country, 
which could help to understand the importance of the study. “State of health of the Polish 
society is still not satisfactory in spite of some improvement. It is mainly connected with 
improper style of living of Poles and with not sufficient control of well known cardiovascular 
risk factors that maintain the highest threat of the modern societies”. 
Below we discuss some of the key elements of informed consent forms and information 
notices revealed in our survey (Table 6.2). 
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6.4.1 GENERAL OR SPECIFIC CONSENT 
Some informed consent forms and information notices request that the participant 
provide general consent only, whereas others require that consent be provided for individual 
aspects of the study. According to our survey, the latter is required in six of the 20 countries 
that provided this information. A related point is that some forms and notices specify which 
tests will be performed. For example, in France, it is specified that a sample of hair will be 
taken to test for traces of heavy metal and that the participant should not wash his/her hair for 
three days. Others specify which tests will NOT be performed: in some cases it is only stated 
that nothing else will be done, whereas in other cases they specify exactly what will not be 
done (for example, stating that no drug or HIV testing will be performed). 
A related issue is that for certain aspects of the studies (e.g. the future use of data or of 
biological samples, the linking or merging of data with other databases, and the providing of 
information to the subject’s general practitioner), some countries ask for consent, but others 
merely state that these activities will be performed, so that general consent is also a consent to 
perform these activities. 
6.4.2 FUTURE USES OF DATA 
Some informed consent forms and information notices request specific consent to use the 
data in the future, to contact the subject for follow up or additional research, and/or to link or 
merge the data with other registries (e.g., cancer registries). In Norway, linking or merging 
the results of the HES with information in other registries requires not only the consent of the 
subject but also the approval of the Norwegian Data Inspectorate. 
6.4.3 FUTURE USE OF BLOOD SAMPLES 
Some forms and notices include a specific request for consent to store blood samples for 
further medical research. In France, there is a separate detailed consent form entitled, 
“Biotheque” (bio-bank); on this form it is specified that the Comité Consultatif de Protection 
des Personnes participant à une Recherche Biomédicale (Consulting Committee for the 
Protection of Participants in Biomedical Research) has approved the development of the bio-
bank. 
6.4.4 NAME OF PERSON RECEIVING CONSENT 
In many countries, the name of the person who obtains the consent from the subject is 
specified on the form. In some countries, the signature of the director of the laboratory or a 
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laboratory technician in the laboratory that conducts the analyses is provided. In Turkey, the 
signature of an “interview witness” is required. 
6.4.5 HOW RESULTS ARE COMMUNICATED TO THE STUDY PARTICIPANTS 
The results of the HES are generally provided directly to the subjects. In Bulgaria, the 
subject is asked if he/she wishes to receive the results of the examinations performed. In 
Lithuania, study candidates are asked to provide general consent for the entire study, yet it is 
specified that among the future uses of blood samples stored in the bio-bank is the possibility 
of studies for the presence of genetic markers of various diseases and that the subjects will not 
be provided with the results because, as stated on the informed consent form, “It is not yet 
known what effect these genes have on disease risk”. 
6.4.6 INVOLVEMENT OF GENERAL PRACTITIONERS (GP) 
In some countries, the subject’s GP is involved. On the informed consent forms and 
information notices used in the United Kingdom, Portugal and Ireland, there is an explicit 
request for consent to provide some measures to the subject’s GP. On the consent form used 
in the United Kingdom, it is also stated that the GP could inform health insurance companies 
of test results. In France, when the results of analyses are abnormal, the HES organizers will 
prepare a letter that the subject can give to his or her GP. In Hungary, the subject’s GP is 
extracted together with the subject and it is this GP who visits the subject, although the study 
in which this was done was not a HES.  
6.4.7 THE POSSIBILITY OF WITHDRAWING FROM THE STUDY AT ANY TIME 
In most countries, the consent form explicitly stated that participants could withdraw 
from the study at any time.  
6.4.8 RISKS/BENEFITS RELATED TO PARTICIPATION IN THE STUDY 
In Bulgaria, the information notice specifically mentions that blood collection may pose 
a minimal risk. Insurance coverage is provided for the days in which blood is collected and 
the medical examinations are performed. In Turkey, it is stated that blood taking poses a risk, 
though low, of infection or prolonged bleeding. Some informed consent forms and 
information notices specifically state some of the advantages of participating in the study. For 
example, in Norway it is stated that the participant will be given a free medical check up; in 
Denmark the information notice specifies that a health screening test will be performed to 
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determine whether the individual has an increased risk of developing several common 
diseases. 
6.4.9 CONSENT FORMS SPECIFIC FOR CHILDREN, ADOLESCENTS, AND 
PERSONS NOT LEGALLY COMPETENT TO PROVIDE CONSENT 
Depending on the target population, it may be necessary to take into account the issue of 
obtaining consent from minors (the definition of which varies by country) or persons not 
capable of providing consent. According to the results of our survey, the informed consent 
form or information notice addressed the issue of consent from minors in three countries, 
though one of the studies was conducted specifically among children and adolescents. None 
of the informed consent forms or information notices mentioned obtaining consent from 
persons considered to be incapable of providing it. Although these population groups may not 
be involved in a European HES, this is nonetheless an important issue, which is covered in the 
Declaration of Helsinki (see above, Paragraphs 24, 25, and 26). 
6.5 RELATIONSHIP BETWEEN INFORMED CONSENT AND LEGISLATION 
FOR SAFEGUARDING PRIVACY 
In the information notice and informed consent form in many countries, explicit 
reference is made to data protection laws. In Cyprus, prior to gaining access to any personal 
data, the researcher must have the approval of the Cypriot Ombudsman. In France, explicit 
reference is made to the law “Informatique et Liberté” (Computing and Freedom), and it is 
specified that the survey was approved by the Commission Nationale de l’Informatique et des 
Libertés (CNIL). In Lithuania, it is stated that all personal and medical information will be 
protected according to the Personal Data Protection Act. In Slovakia, the act on the Protection 
of Personal Data is cited (Act 428/2002). In Norway, it is stated that the study had been 
approved by the Norwegian Data Inspectorate. In Malta, according to the Data Protection Act 
of 2001, it is necessary to notify the Data Protection Commissioner that personal sensitive 
data will be collected and, if a longitudinal component is envisaged, that patient details will 
be kept for follow-up. 
6.6 CONCLUSIONS 
The results of our survey revealed both similarities and differences in terms of 
safeguarding privacy and obtaining informed consent in the countries considered and that 
these issues are closely related. In performing a European-level HES, a standardized set of 
criteria to be adhered to by all participating countries will have to be developed. These criteria 
will need to be flexible enough to take into account the specific legislation in these countries, 
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as well as their specific objectives in conducting a HES, which could slightly vary from 
country to country.  
Regarding the safeguarding of privacy, as mentioned, the ease of access to data is 
progressively increasing, and in conducting a European-level HES all efforts must be made to 
protect the privacy of individuals. This will constitute quite a challenge, considering that 
multiple stakeholders will be involved in a European-level HES and that each of them will be 
required to act in accordance with national-level legislation, which varies from country to 
country. 
With respect to informed consent, it is clear that being truly “informed” signifies 
awareness not only of what participation in the study itself entails but also of how data and 
biological samples will be used in both the present and the future. In the European-level HES, 
although it remains to be decided whether or not separate consent must be obtained for each 
aspect of the study, the fundamental concern is that participants be completely aware and that 
the communication process through which information is provided is both an ethical and a 
legal obligation. 
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Table 6.3 Studies for which the described information notices and informed consent forms 
were used 
 Country Survey Institution / Organization 
Bulgaria Balkan Endemic Nephropathy (BEN): 
Environmental/Clinical Epidemiology 
(2003-2007) 
 National Institute of Health 
Cyprus Standardized Consent Form –  -- 
Denmark HELBRED 2006 (2006-2008) Research Centre for Prevention and Health – 
Glostrup University Hospital – Copenhagen 
County 
Estonia* CVD risk factors in young families of 
Tallinn 
Estonian Institute of Cardiology 
Finland Health 2000 was a health 
interview/examination survey carried 
out in Finland from fall 2000 to spring 
2001 
National Public Health Institute (KTL); Statistics 
Finland 
France Etude Nationale Nutrition Santé 
(ENNS) 
Institut de Veille Sanitaire (InVS) 
Germany KiGGS The German Health Survey for 
Children and Adolescents (2005) 
Robert Koch Institut (RKI), Berlin; Federal 
Environmental Agency (UBA). 
On behalf of the Federal Ministry of Health and 
Social Security and the Federal Ministry for the 
Environment, Nature Conservation and Nuclear 
Safety 
Greece * EPIC European Prospective 
Investigation into Cancer  
Department of Nutrition and Biochemistry of the 
Athens School of Hygiene; 
Department of Hygiene and Epidemiology of the 
University of Athens; 
Hellenic Society for Food and Nutrition 
Hungary* The incidence and clinical 
characteristics of Metabolic X 
Syndrome study  (2006) 
Medical and Health Science Centre of University 
of Debrecen; 
National Public Health and Medical Officers’ 
Service; 
Department of Internal medicine of University of 
Debrecen 
Hungarian Diabetes Association; SANOFI-
AVENTIS 
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 Country Survey Institution / Organization 
Ireland SLAN 2006: Survey of Health and 
Lifestyles 
The Royal College of Surgeons in Ireland (RCSI);-
The Economic and Social Research Institute 
(ESRI); 
University College Cork (UCC) ; 
The National University of Ireland Galway 
(NUIG) 
Italy The Italian Cardiovascular 
Epidemiological Observatory (1998) 
Association of Hospital Cardiologists; 
National Health Institute (ISS) 
Lithuania HAPIEE (Health, Alcohol and 
Psychosocial Factors in central and 
Eastern Europe) study among Kaunas 
population aged 45-72 (Lithuania) – 
2006 
Institute of cardiology of Kaunas University of 
Medicine 
Netherlands Regenboog Project 1998-2001 
(NETHERLANDS HES 2001) 
National Institute for Public Health and 
Environment (RIVM); 
Statistics Netherlands (CBS);  
Municipal Health Centres 
Norway MoRo Project 1998-2001 is part of 
COHORT NORWAY 2002 (database 
that comprises information from 
several examination surveys) 
 Norwegian Institute of Public Health (FHI) 
Poland  WOBASZ: Polish National Multicenter 
Health Survey – 2005 
National Institute of Cardiology in Warsaw, Lodz 
Medical University, Medical Academy in Gdansk 
and Poznan, Silesian Medical Academy, 
Collegium Medicum of Jagiellonian University 
Portugal* National Serological Survey – 
2001/2002 
National Institute of Health; General Directorate of 
Health 
Slovakia CINDI 2003 Regional Authority of Public Health Banska 
Bystrica 
Sweden MONICA-projektet och Medicinska 
biobanken  
Umea Universitet 
Turkey  Example of  Consent Form  -- 
United 
Kingdom 
The Health Survey for England: 2004  National Centre of Social Research (NatCen); 
University College London (UCL); 
Department of Health  
* Study cannot be defined as a “HES” 
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7.1 INTRODUCTION 
To be able to carry out nationally representative and comparable health examination 
surveys (HESs) in the European countries, it is important to have a common understanding 
and definition of the respective populations we want to obtain data on and also, to understand 
and agree on how a sample of this population can be drawn.  
One important prerequisite for a HES is the availability of an up-to-date sampling frame, 
which is a list of units (most often persons) with contact information for the target population.  
In the first section of this chapter some main explanations about and characteristics of 
target populations and sampling frames used in different countries for HES and health 
interview surveys (HISs) are given. General knowledge about sampling techniques and 
sample sizes are presented as well. Information is available through the HIS-HES-database  
and from the “Questionnaire on HES in Europe” (Annex 2).  
A trend towards decreasing participation rates has been reported in several European 
countries during the last decades [1], and recruitment methods are of increasing interest for 
this reason. The second section of this chapter describes briefly recruitment strategies and 
methods used to increase participation in different countries, based on both available recent 
literature and on information collected through the “Questionnaire on recruitment and 
participation” (Annex 3). Both questionnaires were sent to our FEHES contact persons in 32 
countries.  
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7.2 SAMPLING 
7.2.1 THE TARGET POPULATION  
The target population for a survey is a set of units (individuals, households) that we want 
to get data from. In survey sampling theory, this target population is finite, meaning that the 
units can be labelled (i.e. identified by names or numbers) and counted. This is different from 
populations in other fields of statistics where the population is a concept. For instance, if you 
carry out an experiment to test the effect of a new medicine for patients with diabetes, the 
population to which the results will be generalised is “patients with diabetes” as a concept, 
and not a finite set of individuals. 
The first step in planning a survey is to define the target population. Important 
characteristics of the target population are i) a finite size, ii) existence within a specified time 
interval, and iii) accessibility. The population within a country or within any geographical 
area is continuously changing. As people are born, aging, dying and migrating, it is crucial to 
specify the time interval together with the population characteristics. In addition, the target 
population (e.g. the individuals) in that specific area has to be accessible either directly 
through a population register or indirectly through another sampling frame (a list of units 
covering the target population, e.g. a list of households, housing addresses, maps). The 
definition of the target population determines for whom the results should be considered 
relevant. 
Some people may be physically or mentally incapable of taking part in the examinations 
or providing information on their health. Some groups of incapable people may be identifiable 
as such in the sampling frame, like people living in institutions. Institutionalised persons have 
been regarded as being ineligible for the survey, and this criterion has been used to exclude 
these groups from the target population [2]. In other cases these groups may be missing from 
the sampling frame initially. 
Unfortunately, the above a priori considerations mean that a proportion of the people we 
should examine are excluded. The institutionalised elderly have more illnesses and disabilities 
than the rest of the population and excluding them leads to underestimation of health 
problems. Since care delivery and criteria for institutional care differ between different 
countries, such exclusions will also distort comparisons.  
Exclusions in general limit generalisation of the results. In typical household health 
interview survey the results may be representative for the non-institutionalised population but 
not for all adults.  
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7.2.1.1  TARGET POPULATION IN EUROPEAN COUNTRIES 
In earlier European surveys the target population was chosen differently in different 
countries conducting the surveys (Table 7.1). All European countries with a recent national 
HES, and some of the countries with regional HES experience, have given information about 
the target population in the HIS-HES-database [3]. The age range in the surveys differed 
considerable from narrow 45-72 years to a wide age range without any age limits. In a few 
countries children were included, and some included elderly people. In previous HESs from 
the countries reporting an age range, most included persons aged 25-64 years. Recent HES 
from Czech Republic and Ireland did not include the young age groups and started their HES 
at 45 years. From six countries including the oldest citizens, only two had also included 
institutionalized elderly in the survey.  
Languages used in survey materials may in practice cause exclusion. Where a large 
proportion of the sample does not master any of the majority languages in a country, special 
facilities have sometimes been provided. In surveys in England, Germany and Norway efforts 
were made to include ethnic minorities by using several languages (see Section 7.3.1). The 
Finnish Health 2000 survey provided interpreters for persons using other languages than 
Finnish and Swedish.  
7.2.2 SAMPLING FRAMES 
A sampling frame is a list of individuals in the target population from which a sample 
can be drawn. The sample is drawn by names, by other personal identification, by households 
or by addresses.  
An ideal sampling frame includes all population units while excluding a defined “non-
population”. Moreover, it has no duplicates, assigns the units correctly to clusters (by age, 
educational level, etc.) and contains correct auxiliary information. It also has up-to-date 
contact information [4].  
The available sampling frame, as different from ideal ones, may not cover all population 
groups we wish to survey. Examples of groups not covered by a frame can be children, 
homeless persons, individuals with no legal residence, persons in institutional care, and 
persons with a temporary residence. Very often, if not always, the target population for a 
survey needs to be limited to the population covered by the frame. However, it is vitally 
important to try to overcome the weaknesses of available sampling frames.  
Available frames have what is called over-coverage and/or under-coverage. Over-
coverage consists of frame units that do not cover units in the target population, e.g. persons 
who have recently emigrated or died or are listed in duplicate. Under-coverage consists of 
units that should have been in the frame but are not there. Coverage errors occur in changing 
populations since the frames are not completely up-to-date and there is always a time lag 
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between the most recent updating of the sampling frame, the sampling, and the data 
collection. Over-coverage will often, however not always, be uncovered in the data collection 
and can be removed from the sample. An example of over-coverage being problematic is from 
two countries taking part in MONICA. Both countries had major over-coverage in the 
sampling frame, and the contact information was not up-to-date. As a result, it was never 
possible to tell, for a substantial percentage of the initial sample, if the persons belonged to 
the target population or not.  
Under-coverage will usually not be identified and may, if considerable, lead to bias in the 
estimates from the survey. This is counteracted by continual updating of the frame until the 
end of the reference period for the survey. If the survey is long-term, sampling might occur in 
several stages to be based on an as up-to-date frame as possible. 
 
Possible sampling frames 
Population register In a continually updated population register, all inhabitants 
with valid residence permit are included (however with some 
time lag).  
 
Census  A census includes the entire population at a fixed time. 
Problems increase with time since the last update. 
 
Electoral register Listing adult people eligible for voting in election. Mostly 
used when population register or an updated census are not 
available.  
 
General practitioner list or 
lists from other health care 
organisations 
Lists of patients from physicians (general practitioners, GPs) 
may cover all citizens in some countries, but in general only 
those who seek a doctor. The lists may be advantageous for 
the possibility of including non-citizens or the 
institutionalized.  
 
Telephone directory  Telephone lists may not include all, and the coverage of 
households will differ between the countries. The lists often 
name one family member only, and persons may be listed 
twice. 
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Postcode address file  The frame lists each house in the street/area or each private 
household address, but has no information about the people 
living at the address. In this way, non-citizens are included. 
 
High school/ university lists The list may be useful for supplementary contact information. 
 
Address list The list may be useful for supplementary contact information.  
 
Insurance registers The list may be useful for supplementary contact information.  
 
Maps [5, 6] Maps of administrative or statistical geographical units along 
with reasonably good statistics of their population sizes. 
 
It is essential to know how completely the sampling frames account for deaths, migration 
and change of address and to what extent temporary addresses are taken into account and how 
up-to-date they are. From the potential sampling frames listed above, the population register 
will normally have the best coverage, but the update intervals vary. In a continually updated 
population register, all inhabitants (including also those with valid residence permits) are 
included. But there are population groups without valid residence, such as refugees, the 
homeless, seasonal workers and long term tourists. In general, the delay in notifying changes 
when people move from one residence to another will contribute to error. Thus, the contact 
information will never be fully up-to-date.  
Regarding telephone lists, the increasing number of mobile phones and decreasing 
number of fixed lines in most countries, as well as an increasing proportion of unlisted 
numbers, causes further problems [2]. There may be registers covering temporary inhabitants 
like seasonal workers, students (high-schools and universities’ lists, postal register) and long-
term tourists (postal address or properties list).  
7.2.2.1  SAMPLING FRAMES IN EUROPEAN COUNTRIES 
From the Questionnaire on HES in Europe (Annex 2) we obtained information about 
existing and preferred sampling frames and their coverage and updating (Table 7.2). From 23 
countries with a population register (national or regional), 16 preferred to use them for the 
sample for HES. Census lists were preferred by seven countries as the sampling frame and 
electoral rolls by three countries.  
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The Postcode Address List was preferred by UK [7, 8]. Addresses are selected rather 
than individuals, which gives the opportunity to reach all people in the target population, 
temporary as well as permanent residents (except for homeless people). In this way it is easier 
to include students, refugees, foreign temporary workers and other population groups not 
registered in official registers. For example, the English HES uses the Small User Postcode 
Address File, to try to limit the sampling frame to domestic addresses and not businesses. 
When calculating response rates, the numerator would become relatively valid and correct, 
but a correct denominator would be difficult to assess, as the exact number of individuals in 
each of the addresses not visited will be unknown.  
The population registers were continually updated in 14 of the 16 countries preferring to 
use them. Among the seven countries wanting to use census data, three had them continually 
updated. Among three countries wanting to use data from electoral rolls, one had them 
continually updated. The population registers covered the entire population in 11 of the 16 
countries. The census data covered the entire population in five of the seven countries with a 
preference for using these (Table 7.2).  
Altogether nine countries had a continually updated population register covering the 
whole population. All nine countries also indicated in the FEHES questionnaire that they 
wanted to use the population register in a future HES. In addition, Bulgaria and the Czech 
Republic have population registers covering the whole population, and are “annually or more 
frequently updated”. Lithuania, Latvia, Poland, Slovakia and The Netherlands have 
population registers which are continually updated, but may have some problems to cover the 
entire population, as institutionalized persons or non-citizens are not in the frame (Table 7.2).  
Three countries provided no information about a preferred sampling frame for HES, but 
two of these countries reported that they had a population register (Hungary and Poland). At 
present we have no knowledge about possible sampling frames in Austria and Northern 
Ireland (UK), but we know that recent national HISs or a census have been carried out in both 
countries.   
Maps are important for dividing each country into small areas or neighbourhoods of 
suitable sizes to be handled by an examination clinic. Maps may be the basis for carrying out 
a survey in countries where no individual or postal code based frame exist. This is the case in 
the US NHANES survey. The design of NHANES is roughly described on [5] as follows: “In 
simple terms, NHANES divides the United States into communities. The communities are 
divided into neighbourhoods. The neighbourhoods are selected at random. From each 
neighbourhood, housing units are selected at random. Selected households are approached 
by our interviewers who ask residents a few short questions to determine if their household is 
eligible for the study”. The neighbourhoods described here must be small enough to make this 
approach feasible. 
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7.2.3 SAMPLE SIZE 
Sample size depends on the topics to be studied and their occurrence in the population as 
well as the size of the differences (between sexes, regions, and population groups) one needs 
to detect. It is important to note that sample size does not depend on the size of the target 
population. Relatively common public health problems can be well described in HES, 
whereas rare conditions can most often not be analysed by geographical and socioeconomic 
groups. The conclusion from the above is that sample size in national HES is a compromise 
between characteristics of the target population, study aims and survey costs.  
The following is a theoretical presentation of sample size determination.  
The sample size depends on:  
1. Measurement characteristics: the planned level of precision in estimates of 
disease prevalence, levels and distribution of risk factors and other measures. 
The precision of an estimate from a survey is measured by the standard error. 
The lower the standard error is the higher the precision. In one-stage samples, 
the standard error decreases by 1/ n  where n is the net sample size. The 
standard errors are less dependent on the finite population size. 
2. The variation of the value of the characteristic among sampling units.  For 
comparing results with other nations and earlier national results, the variation 
within each nation matters. If results are planned for subgroups in the national 
target population, the sample sizes for some of the subgroups may have to be 
increased, depending on the relative size of these groups and the variation 
within them. A very important consideration is the need to make geographical 
and socioeconomic comparisons. Estimates for these requirements must be 
made.  
National health surveys are a special case, however, since they are multipurpose and 
make statistical sample size calculations problematic. For a practical rough estimate of sample 
size it is advisable to look back at previous international experiences. Thus, the original 
NHES studies in US employed samples of 8 000 persons to represent the whole of US, the 
recent Canadian health measures survey between 7 000 and 8 000, The Netherlands 
Regenboog survey 7 000, the original Mini-Finland survey 8 000 persons and the Finnish 
Health 2000 survey 10 000 persons. To allow sufficiently large samples by region, the Finnish 
FinRisk Survey included a total sample of 13 500 adults. Large samples have been used in the 
German HESs, for adults 13 000 and for children (KiGGS) 28 000.  
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7.2.3.1  SAMPLE SIZES IN EUROPEAN COUNTRIES 
Table 7.3 shows the sample sizes in European HESs. For most European HESs the 
samples size was 7 000-13 000 persons. The purpose of most of these surveys was research in 
addition to health monitoring. The high number in some countries was either because of the 
survey’s additional use for research or because precise information for sub-groups of the 
population was desired, to monitor inequalities or to identify or monitor target groups for 
interventions.  
7.2.4 SOME BASIC SAMPLING TECHNIQUES 
The purpose of sampling is to obtain information that is representative of the full 
population of interest, without the need to examine everybody in the population. With good 
sampling, the number of people examined can be only a small fraction of the total population, 
and the required sample size is practically independent of the size of the total population (see 
section Sample size above.) Such a sample can be obtained through probability sampling, 
where the probability of each possible sample is determined by the sampling scheme. 
Probability sampling allows unbiased estimation of the population characteristics of interest 
and the estimation of the error of the population estimates. Non-probability sampling should 
be considered only in situations where everybody is selected, such as everybody in a 
household when households have first been selected through probability sampling. (Choosing 
everybody is actually a special case of probability sampling, where all are selected with 
probability one.) 
Probability sampling can be classified into one-stage sampling and multistage sampling. 
In one-stage sampling, there is probability sampling in a single stage, whereas in multistage 
sampling, there are several stages of probability sampling, and the next stage of sampling is 
carried out within the selected sampling units of the previous stage. As an example of a three-
stage sampling that may be relevant for HES, in the first stage municipalities of the country 
are sampled, in the second stage households of the selected municipalities are sampled, and in 
the third stage, one individual from each selected household is sampled. In each stage of a 
multistage sampling, one-stage samplings are carried out. 
In multistage probability sampling each stage has its sampling frame. Often, 
administrative units are drawn at random in the first stage, for instance municipalities from a 
list of all such unites. In the second stage, individuals are drawn within each of the first stage 
units (example: inhabitants are drawn within each drawn municipality). This method will 
make it less expensive to carry out measurements and face to face interviews by reducing the 
costs of travelling per participant. This may be the only feasible method, if there are regional 
but no national population register with individuals as the units. This is the only feasible 
method for HESs also in large countries and countries with complicated communications. 
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A special case of one-stage sampling is the simple probability sampling, where each 
possible sample of n units has the same probability of being selected. Such a sample is easy to 
analyze, but is not often feasible for a HES because it may require long travel of the 
participants or examination teams. Another example of one-stage sampling is cluster 
sampling, where the population is divided into subgroups (clusters). A sample of clusters is 
drawn, and all members of the selected cluster are selected to the next stage. The Health 
Survey for England is an example of cluster sampling. A sample of households (clusters) is 
selected, and everyone in the selected households is examined. The use of cluster sampling 
and two-stage sampling can be cost-effective; in particular if the survey is carried out with 
home-visits, since less travelling will be necessary to reach the same number of individuals. 
However, if there are positive intra class correlations within the clusters for some variables of 
interest, cluster and two-stage sampling will lead to increased sampling variances compared 
to sampling the same number of individuals directly. 
In ”two-phase sampling” a large sample is selected first. In this large sample information 
is collected by a short questionnaire or a non-expensive test, in order to screen for a defined 
condition, which could be symptoms suggesting a disease. An example from Norwegian 
surveys is to screen all health survey participants by means of a test for non-fasting serum 
glucose, and in this way define a subpopulation at increased risk of diabetes. In the next phase 
one can sample e.g. 10 percent within this high-risk subgroup or invite the whole high-risk 
group for extended examination.  
In stratification, the population is first divided into non-overlapping subpopulations 
called strata, and sampling is then carried out independently within each stratum. The 
sampling fraction can be the same in all strata (proportional allocation) or there can be 
different fractions in different strata. Stratification is possible only if the necessary 
information on the strata is available in the sampling frame. By use of population register or 
census as sampling frame, stratification can be applied for age, sex, marital status, region, 
urban- or rural area, socio-economic status, country of origin or living in institution. If 
proportional allocation was not used in the stratified sampling, the data have to be weighted to 
give population representative results, and the information needed for assigning the weights 
will need to be collected when planning and during the sampling. 
If a subgroup of interest of the population would otherwise have too small a number of 
representatives in the sample to obtain conclusive results about it, the sampling probabilities 
of its members can be increased. Examples are sparsely populated areas, age groups or other 
specific interest groups, such as children, adolescents or the elderly, disabled persons and 
minority groups. The sampling probabilities can be increased for example by suitable 
stratification or by over-representation, where one chooses to add extra units to the number 
otherwise invited. To obtain representative results on the entire population, the individuals of 
the over-represented subgroup need to be given smaller weights in the over-all analysis, or the 
over-represented individuals can be left out from the analysis. 
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7.2.4.1  SAMPLING TECHNIQUES USED IN RECENT EUROPEAN SURVEYS 
Table 7.4 summarizes the sampling designs and procedures of recent European HESs. 
Most of the surveys used multistage sampling. Only four of the surveys included a stage of 
selecting households. From the five surveys using a household sample, three included all 
household members within a certain age and two included only one person per household. 
Among countries where household was not used as a sampling unit, none reported selecting 
additional household members. 
All national HESs used multistage probability sampling. A household sample was used 
in England, Scotland, France and Croatia. In England an Scotland, all household members 
aged 16+ and up to two children aged 0-15 were included, whereas in the other two countries 
only one household member was selected for the sample. Among the countries with regional 
HES, Cyprus and Slovakia used multistage probability sampling, while Norway invited all 
residents within certain age groups to participate. Over-sampling and stratification was 
applied for age, sex, ethnic groups and geographical area in several surveys. 
7.2.5 CONTACT RATES AND PARTICIPATION RATES   
To be able to compare participation rates between countries it is of importance to use the 
same definition of the term “participant”. In a HIS, a participant may be defined as somebody 
for whom the survey questionnaire or a part of it was filled in. For HES, however, it is more 
relevant to define a participant as a person who both has at least one valid examination 
measurement, like measured weight and height, in addition to some questionnaire results.  
An issue remains whether the sampling frame should be corrected for people who should 
not have been in it at the time of HIS or HES. Specially, those who had died before the 
contact date or had moved permanently abroad or to another area had no chance to be 
contacted. In fact, they should not have been in the sampling frame. In many surveys these 
people are removed from the denominator before calculating the true response rate.  
In the WHO MONICA study, participants were defined as the sample members who 
answered the main study questionnaire. Non-participants were all sample members for whom 
no data were collected because they had died, moved or could not be contacted for other 
reasons, or were contacted but did not participate (e.g. refusal, temporarily away, medical 
reasons) [9].  
These over-all sample response rates can be described in more detail by two terms 
according to: Contact rate which is the proportion of selected persons (total sample) that 
received the letter of invitation, phone call, or personal visit. Non-participants are selected 
persons who 1) received a letter (or a visit or telephone call) but did not choose to participate 
plus 2) those who did not receive the letter of invitation. The latter group would also contain 
those not found, often resulting in letters returned to the survey administration. For keeping 
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this subgroup small, the population register (or other sampling frame) should be recently 
updated prior to the survey.  
Enrolment rate is the proportion of the persons contacted who actually participated in the 
survey. The response rate (participation rate) is the product of the contact rate and the 
enrolment rate.  
Participation rate = (members contacted/ total sample) x (participants/members 
contacted) = contact rate x enrolment rate 
Enrolment rate and contact rate both range from 0-1.0. 
Eurostat’s “Standard Quality Report Manual” [10] has the following definition of “non-
response” and response rates:  
Non-response is the failure of a survey to collect data on all survey variables, from all the 
population units designated for data collection in a sample or complete enumeration. The 
difference between the statistics computed from the collected data and those that would be 
computed if there were no missing values is the non-response error. 
There are two types of non response: unit non-response which occurs when no data are 
collected about a designated population unit (the person did not participate at all), and item 
non response which occurs when data only on some, but not all survey variables are collected 
about a designated population unit. 
The extent of response (and accordingly of non-response) is measured with response 
rates. They can be of two kinds: unit response rate, which is the ratio of the number of units 
which have provided data at least on some variables over the total number of units designated 
for data collection. Item response rate is the ratio of the number of units which have provided 
data for a given variable (an item) over the total number of designated units or over the 
number of units that have provided data at least for some variables.   
As shown by the two examples above, the response rate can be calculated in different 
ways, depending on definitions of the numerator and denominator. The numerator, the 
participants, may be a sample member i) who answered the main study questionnaire, ii) who 
answered at least one question or iii) who had at least one technically valid examination 
result.  
The denominator may or may not include persons who were selected for HES, but for 
obvious and known reasons (in retrospect) were unable to attend (permanently moved to 
nursing homes, died, emigrated or other reasons). In the MONICA example above, persons 
selected to the sample but who had died or moved out of the survey area between the updating 
of the sampling frame and the scheduled date of examination were included in the 
denominator. On the other hand, in MONICA’s earlier reports of response rates, such people 
were considered to be part of the over-coverage, and therefore were excluded from the 
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denominator [11]. It is a policy issue to decide when a sampling unit (usually a person) is to 
be accepted in the numerator or the denominator of the response rate. 
7.2.5.1  PARTICIPATION RATES IN EUROPEAN COUNTRIES 
The definitions of numerator and denominator vary in European HES, and an accurate 
description is probably available to a different extent in different countries. As examples, 
information was collected from Italy and Finland for this report. In Italy, the numerator was 
defined as the number of persons who participated in the survey. The denominator was 
defined as the total representative sample in the specific region and age group (all selected). 
In Finland the numerator was defined as the number of persons who participated in the health 
examinations (for HES): the denominator was all selected persons excluding those who were 
deceased before the contact. The contact rate was 94% in Italy (electoral register) and 98.6% 
in Finland (population register). See Table 7.3 for Finland and Italy.  
The variation in response rates between countries is large, varying between 21% and 
85% in European HESs (as reported in the HIS-HES-database), see Table 7.3.  
In the ongoing survey in Nord-Trondelag, Norway, the participation rate is 65-75% 
among those aged 60-79 and in women aged 50-59, after several extra recruitment efforts, 
including the establishment of survey clinics at high-schools, university campus and 
worksites. In the 20-39 age-group, the participation varied from 25% (men 20-29) to 50% 
(women 30-39): in those aged 80 years and older, 35-40% participation was were obtained 
(no home or institution visits). 
We do not know enough about how response rates have been calculated in each country; 
therefore the rates are not fully comparable. The achievement of a high response rate is 
crucial for the usefulness and the generalization of the survey results to the population in each 
country and the decline in response rates in both HIS and HES is a challenge for planning of 
future surveys.  
7.3 RECRUITMENT TO PARTICIPATION IN HEALTH SURVEYS  
7.3.1 INVITATION STRATEGIES IN RECENT HEALTH SURVEYS 
In 2007, we asked our FEHES contact persons by e-mail to reply to nine questions 
regarding recruitment and participation in a recent health survey, if possible, in their countries 
(Questionnaire on recruitment and participation, Annex 3). After three reminders, we received 
information from 27 countries. Most contact persons have given answers from their 
experience with one specific, relatively recent or even ongoing HES. Two contact persons 
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answered for HES and HIS, respectively in the 1980s, and the answers from three contact 
persons were based on HIS (Table 7.5). We present the results based on this questionnaire and 
also results from relevant studies on recruitment and participation.   
Most of the contact persons who answered the Questionnaire on recruitment and 
participation reported that a mailed invitation letter, often without the survey questionnaire, 
was the first attempt to contact the selected persons or households. In nearly all countries, at 
least one re-attempt was made in case of non-participation by the first invitation. Home visits 
or phone calls were most often used as the second recruitment attempt. In some countries only 
one attempt was made after the first invitation. However, half of the countries routinely made 
a third recruitment attempt. This could be a letter, a visit or a phone call. Five of the 27 
responders to our questionnaire made a fourth attempt, and in some countries five or even 
more attempts were made (Table 7.5). 
In some of the countries special efforts were used for recruitment of minorities. Germany 
and England used seven foreign languages for the written materials in the surveys reported. In 
England, this was done only in years when the HES focused on the health of minority ethnic 
groups [12]. Finland used English as well as Finnish and Swedish versions of the 
questionnaire, and Estonia used Estonian and Russian. In most of the countries [13], no 
special efforts were made to include minorities in the survey. Other means that could facilitate 
participation among linguistic subgroups were interpreter on site, personal assistance, user-
friendly layout, culturally adapted materials, trained fieldworkers and phone help line to assist 
with the questionnaire and other written materials.  
A study of how to improve recruitment rates among ethnic minorities in the UK found 
that audio-recorded methods of obtaining informed consent worked better than written 
consent in some study populations. Additionally, telephone contact was better than face-to-
face contact for recruiting participants to the study [14].    
One reason reported for non-participation was difficulty in contacting persons selected to 
the sample because of incorrect address or no telephone contact. 
7.3.2 EFFORTS TO INCREASE PARTICIPATION 
Table 7.6 lists the reported efforts to increase the participation in health surveys. Most 
countries have informed the public about the planned or ongoing survey. Newspapers, radio 
and television are broadly used, as well as survey websites. Four countries had no information 
to the public.  
Among incentives used for motivating the selected persons to participation, 
reimbursement of travel expenses was used by three countries and lottery tickets were given 
by four countries. Small gifts were used by five countries. In the Czech Republic, vitamins 
were given to the participants, and in Greece the measurements, tests and dietary 
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recommendations from experts were seen as incentives. No incentives were offered in 14 
countries.  
Regarding the most effective strategy to increase participation, personal contact (phone 
or home-visit) with the potential participant was emphasized by many contact persons. One 
contact person mentioned the use of mobile phone as the most effective strategy, whereas 
another one suggested a change of interviewer, both pointing at the importance of the direct 
and personal contact between the participant and the interviewer. Incentives (a small gift or 
lottery ticket) were mentioned by two countries as the most effective strategy.  
7.3.3 STUDIES OF NON-PARTICIPANTS  
Reasons for refusal given by non-participants were reported by 14 contact persons (Table 
7.7). The most common reasons given were: Not interested, no time, health problems, feeling 
healthy or too personal (confidentiality issues). “Too many surveys” or “too long 
questionnaire” were also mentioned.  
Only a few countries collected health information from non-participants in the survey 
they reported from. Finland, Germany and Sweden used short questionnaires for non-
participants, by phone or by mail. Denmark and the Netherlands used registers as a source of 
health information. In the Netherlands, health information was available for those among HES 
non-participants who had participated in a HIS that preceded and was linked with the HES. 
Similarly, those being interviewed for the HIS part of the Scottish and English HES were 
asked to be visited later by a nurse for HES, entailing available HIS-information for the HES 
non-participants. However, no such knowledge was available for those not participating in the 
interview part of the survey.  
Some basic information about the non-participants was available from the sampling 
frame in most countries. Macedonia, Latvia, Ireland and Bulgaria did not have this possibility, 
and in Cyprus the possibility was poor because the sampling frame was not updated.   
7.3.4 OTHER EXPERIENCES WITH PARTICIPATION IN HEALTH SURVEYS 
Studies of motives for and factors enhancing participation and of recruitment efforts are 
relevant sources of knowledge on ways to stimulate participation. Studies of potential non-
participation bias are important for the awareness of the size and the consequences of the 
problem. A literature search on PubMed using “Motivation and Participation and Surveys” 
yielded several studies we considered relevant also for HES [15-20].  
In preparation for a Norwegian survey 2006-8 (Nord-Trondelag), some members of the 
target population were invited to focus groups [15].  Perceived self-interest appeared to be the 
first motivational factor, and willingness to contribute to research was the next, the latter 
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mostly in elderly and highly educated persons. Among the elderly, some saw participation as 
a civil duty. Practical obstacles were seen as the most important barrier. The informants were 
rather sceptical to incentives, and felt that this could undermine public confidence in the 
survey. Another study compared the participation rate by use of alternative titles of a cancer 
research study and found that one of the titles was linked with higher participation [21].   
A review published in September 2007 discussed the decreasing participation in 
epidemiological surveys [22]. This review was not a systematic one, but rather a summary 
and discussion based on 146 references. One explanation for lower willingness to participate 
in scientific studies during the last decades is, according to this review, the increasing number 
of research studies in total together with a proliferation of political polls, marketing by 
telephone calls and marketing surveys that may look similar to scientific surveys. Information 
materials, conveyed through the mail or by phone, may well be received by intended 
participants who are routinely sorting through numerous items of unsolicited mail or phone 
messages, of which practically all end up as “junk”. If so, it means that a barrier builds up in 
the target group against even considering participation when contacted.  
Studies of recruitment to HIS are, to some degree, relevant also for HES. Table 7.8 
presents results of a review of published and unpublished controlled recruitment trials in HIS 
[23]. Most studies included in this review were health related, but some social surveys and 
marketing studies were also included. It should be noted that results from recruitment to HIS, 
and in particular marketing surveys, cannot directly be used for HES, as a HES is far more 
demanding for the participant.  
As noted in 7.3.2, nearly all the FEHES contact persons reported that one or more 
recruitment re-attempt was made in case of non-participation by the first invitation. Among 
the publications concerning repeated recruitment efforts, few studies included the aspect of 
costs. One such study investigated the interrelation of recruitment efforts and expense with 
respect to potential non-response bias based on a HES in Augsburg, Germany, 1999-2001 
[24].  
In the Augsburg study, telephone calls and home visits were used to contact people for 
re-invitation. Re-invited HES participants (examined three months or more after the first 
invitation letter) showed many similarities with a subgroup (49%) of non-participants who 
responded to a short questionnaire, as both included a higher percentage of people with 
impaired health and with higher level of behavioural health risks, compared with persons who 
participated in the HES within three months. However, for the HES non-participants who did 
not respond to the short non-participant questionnaire, there was no information other than 
age and sex. It is to be noted that persons recruited by home visits had higher disease 
prevalence and lower educational level than other participants in this study.  
The distribution of total recruitment cost per individual was highly skewed with 50% of 
the total sum spent on 17% of the sample. The authors conclude, based on their own results 
plus comparable studies:  
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1. Expenses for recruitment increased with decreasing age of the invited persons, 
as more telephone calls were needed to contact them, and, if reached, younger 
people were less willing to participate.  
2. Eliminating home visits seems to be the most cost-effective strategy in terms 
of saved costs per lost participant, but this strategy also seems to be the most 
likely to introduce bias.  
3. Stopping recruitment efforts after 10 unsuccessful contact attempts by 
telephone may be the best choice, with respect to cost-benefit and non-
participation bias as well. 
 
In summary, according to the above cited papers, the factors found to increase motivation 
and participation in HES were:  
 
Attitudes of the invited persons: 
• the participant’s personal interest (free medical examination, interest in tests or 
other content of the survey) 
• general willingness to contribute to research (altruism, volunteerism) 
• general understanding of the importance of health surveillance and research 
• confidence in “science” and the medical profession 
• social support for participation in the participant’s environment 
 
Content and presentation of the HES: 
• an alert letter in advance 
• user-friendly lay-out for all written materials 
• starting the questionnaire with the more interesting questions 
• incentives (may be motivating, but not unanimously) 
• face-to-face recruitment (and data collection) in contrast to less personal 
contact 
• not too large total participant burden (time and commitments) 
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• data collection by use of “hybrid data collection methods”, such as offering 
HES by home visit to subgroups or by second recruitment attempts, after first 
having invited people to visit a clinic.   
 
And factors that counteracted participation were: 
• practical obstacles making it difficult to participate 
• the volume of the questionnaire and of the informed consent (may represent a 
barrier, but not necessarily, see chapter 6 on legal aspects) 
• the experience of “too many surveys” being offered in total 
7.3.5 STUDIES OF POTENTIAL BIAS DUE TO SELECTIVE PARTICIPATION  
The group of non-participants consists of persons with many different reasons for not 
taking part and the health status may differ from the average of the participants. Analyses 
from different countries have consistently shown that in total the non-participants have lower 
education, less healthy life style and less good health, and elevated mortality compared to 
participants. According to calculations based on demographic factors, low participation may 
not seem to bias the results substantially, given that health and risk factors are similar for non-
participants and participants within the categories one can “control for”, like marital status, 
age and gender. However, available register information does not contain detailed information 
on current health or risk factors, so adjustment according to demographic factors does not 
compensate for low participation rates.  
Several European surveys can use the sampling frame to compare participants and non-
participants by age and sex, and some have experience with the linkage to other data.  
A HES in Oslo, Norway 2000-2001 included an evaluation of extra recruitment attempts 
(reminders) by sending a second and third invitation with the survey questionnaire enclosed 
[13]. Factors associated with non-participation were male sex, young age (study’s upper age 
was 76 years), less education, non-married status, disability pension and non-western country 
of birth. The participation rate increased from 28% to 42% in all men and from 33% to 49% 
in all women, resulting in an overall 46% attendance. In the 60 years old, participation 
increased from 39% to 55% and in the 30 years old from 22% to 36%. Prevalence estimates 
without and with the extra participants was compared. The prevalence of obesity (according 
to measurements) was higher among the extra participants, but the total prevalence estimates 
for obesity increased by 0.2-2 %-points only by the reminder efforts. Next, the list of all 
invited (aged below 70 years) was linked with data on social security benefits. The 
distribution of socio-demographic variables, including different types of benefits, differed 
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modestly between participants and all invited. Given that the disease and risk factor 
prevalence were similar in participants and non-participants within each socio-demographic 
stratum, most prevalence estimates among participants were valid for the target population 
[25].  
According to the review by Galea and Tracy 2007 [22], most systematic efforts to 
characterise who does and who does not participate in studies have focused on demographic 
characteristics, probably due to the relatively easier access to these data than to health 
registers. Moreover, the health issues that are focused in studies may influence participation 
in different ways: Studies of environmental or occupational exposure may be more likely to 
recruit persons with higher levels of exposure, while focus on domestic violence may fail to 
recruit exposed persons [22].   
As European studies are of particular relevance here, some recent European non-
responder studies should be noted. A study from Amsterdam [26] found that estimated 
prevalence figures for health care utilization were higher when based on participant than if 
based on the total target sample. This was the case for prescription of drugs and for a number 
of out-patients services, but not for hospitalisation. Of 54 background characteristics for 
which odds ratio for health care utilization were computed, 11 showed at least 10% difference 
between participants and the total sample. It may, based on these and similar surveys, be 
concluded that resources spent on extra recruitment attempts give relatively little value for 
money. But little is known of the actual health of the non-participants, even with data on use 
of health services and social security benefits linked to the file.  
In a Finnish study, differences between participants and non-participants similar to the 
Oslo Study have been described [27]. Participants recruited by extra attempts smoked more 
often and used more psycho-pharmaceutical drugs than the early participants, suggesting 
similar features as non-participants, but most self-reports on health problems were not 
significantly different. Here, it was found that elderly persons were less likely to participate. 
With respect to smoking, a similar pattern was found in an earlier Norwegian study [28]. In a 
Swedish study of non-response to HIS, smoking prevalence was compared by initial 
responders (63%) and those who responded by extra attempts (additional 19%). The estimated 
smoking prevalence increased from 36.1 to 38.7%, and extra recruitment attempts resulted in 
increased smoking prevalence among participants with higher social status. The authors 
conclude that a postal questionnaire with high non-response rate may overestimate social 
status differences and underestimate smoking prevalence [29]. 
A Dutch study compared participants and non-participants to HES in the setting of a 
survey that started with HIS and in a next phase invited the HIS participants to examinations. 
Only 29 % of the HIS attendees were recruited for HES [30]. According to the HIS data, the 
HES population contained more persons who were healthier, but more likely to be worried 
about their health (“worried well”). Otherwise no major difference in the HIS data was found 
by attendance to HES. But this study gives no data at all for nearly half of the total sample, as 
only 56% participated in the HIS.  
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Among elderly people invited to the Health 2000 Survey in Finland, it was found that a 
higher proportion of non-participants suffer from functional limitations [31]. 
A study of 32 354 participants and 4 890 non-participants in FINRISK 1972, 1977, 1982, 
1987 and 1992 found that lower socio-economic groups were under-represented in the 
surveys [32]. Further, a mortality follow-up for 9.5 years showed that the absolute mortality 
risk was underestimated when based on participants only, while the relative risk of death 
associated with socio-economic position was not distorted. In the same HES in Finland a 
higher mortality (2-2,5-fold) was found among non-participants at eight year follow up by an 
average participation rate above 80% [33]. 
The non-participant information collected in the MONICA populations (age 35-64 years 
by 1985, participation by 43-89 %, in all 32 populations) made it possible to estimate the 
effect of non-participation on cross-sectional estimates in 27 populations and trend estimates 
in 17 populations. Cross-sectional estimates from participants were compared with adjusted 
estimates that took into account the result in non-participants, and in men, the ratios ranged 
from 1.0 to 1.08 for self-reported BMI, from 0.5 to 1.26 for daily smokers, and from 0.56 to 
1.67 for use of antihypertensive medication. In women the ranges of the ratios were rather 
similar. The effect of non-response on the trend estimates was by far more pronounced, 
particularly for smoking in men because of decreasing smoking prevalence in participants and 
in some populations increasing rates in non-participants [34]. The trend estimated changed in 
each of the 17 populations when information from non-participants was taken into account.   
A hypothetical analysis demonstrates the effect of non-participation: the bigger the 
difference in participation rate between a first and a second survey, the bigger the difference 
in trend estimate between participants and adjusted population estimates and the lower 
precision of the estimator [34].    
There seem to be agreement among studies that female sex and being married, employed, 
in higher socioeconomic stratum and highly educated are positively associated with 
participation. On the other hand, risk behaviour (like smoking) and major health problems are 
associated with non-participation. In adult age groups, both the young (20-39 years) and the 
old seem to be difficult to recruit. Interestingly, some of the HESs conducted relatively 
recently have been limited to the age 45 as the lowest age (Czech Republic 2004, Kaunas 
2006-7, and Ireland 2006), Table 7.1.  
7.4 CONCLUSION 
Earlier European HESs differed regarding the defined target population, but most 
countries had included the age range 25-64. The sampling frames in 16 of 32 countries in the 
FEHES project cover the whole population. The sampling frames were continually updated in 
19 countries and updated at least annually in six countries. This means that many countries 
have the possibility to carry out surveys with similar target population and that the quality of 
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the sampling frames would make it possible to have a well defined sample of households or 
individuals who can be reached by the survey teams.  
Most European HESs had applied multistage probability sampling and most of them had 
a sample size of 7 000-13 000 persons. The response rates, however, varied between 21% and 
85% and there is a trend towards lower response rates over time. This means that the 
recruitment issue is increasingly important when planning future surveys.    
The questionnaire to contact persons on participation and recruitment in European 
surveys gave answers in line with other knowledge on strategies aiming at high participation 
rates. The strategies used until now include promotion of the participants’ interest and 
understanding of the value of the survey. In the future, rather personal recruitment attempts 
seem to be needed, and it seems increasingly important to visualise the difference between a 
public health survey and other surveys and marketing efforts that people are contacted for. 
This holds for the first invitation and by the extra attempts. No less important, the total survey 
content as well as the details need to be considered, aiming at reducing the participant burden, 
including practical barriers.  
European survey experiences as well as other epidemiological research tell a convincing 
story. Participants in a survey are healthier and socially better off than non-participants, and 
their behaviour is more health promoting.   
It is, at best, uncertain if studies of non-participants and calculations from such can 
compensate for low participation rates. This means that the participation rate should be at 
least 70 % and preferably higher.  
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Table 7.2 Sampling frames available in European countries (Data source: FEHES 
questionnaire on Annex 2.) 
Country  Available sampling frames  Preferred 
sampling frame  
Coverage of 
population 
groups in 
preferred 
sampling 
frame 
Updating of 
preferred 
sampling 
frame 
Austria No information available No information 
available 
No information 
available 
No 
information 
available 
Belgium National population register  Population register Covers all Continually  
Bulgari Population register 
(national./regional) 
Census 
Population register Covers all Annually (or 
more frequent) 
Croatia 
 
Health /social insurance register 
Electoral rolls  
Census 
Census 
 
Covers all No 
information 
Cyprus 
 
National population register 
Census 
Health /social insurance register 
Electoral rolls 
Census Covers all 
except 
institutional 
Annually (or 
more frequent) 
Czech Republic National population register 
Health /social insurance register 
Population register Covers all Annually (or 
more frequent) 
Denmark National population register Population register Covers all  Continually  
Estonia 
 
National population register 
Census 
Health /social insurance register 
Census Covers all   Annually (or 
less frequent) 
updated .New 
law may allow 
yearly (or for 
survey 
purpose)  
Finland 
  
National population register 
Health /social insurance register 
Electoral rolls 
Population register Covers all Continually  
France National population register 
Health /social insurance register 
Telephone lists 
Census Covers all Continually  
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Country  Available sampling frames  Preferred 
sampling frame  
Coverage of 
population 
groups in 
preferred 
sampling 
frame 
Updating of 
preferred 
sampling 
frame 
Germany Regional population register 
List of postal addresses 
Population register Covers all Continually  
Greece   
 
Census 
Electoral rolls 
(national./regional)  
Electoral rolls (if 
made available) 
Covers all 18+ 
except non-
citizens 
Less frequent 
than annually 
(prob. every 4 
years) 
Hungary 
 
Population register 
(national/regional) 
Census (national./regional.) 
Health /social insurance register 
(national./regional) 
Electoral rolls 
(national./regional) 
No information No information No 
information 
Iceland National population register 
Health /social insurance register 
Electoral rolls 
Population register Covers all Continually  
Ireland 
 
Census 
Health /social insurance register 
Electoral rolls 
Census Covers all  Continually  
Italy 
 
Electoral rolls 
Regional population register 
Census 
Health /social insurance register 
Electoral rolls if 
adults. Population 
register or health 
register if all ages. 
Health register if 
non-citizens/ 
institutional 
Different for 
different 
frames  
Annually (or 
more frequent) 
Latvia National population register Population register Covers all 
except 
institutionalised 
Continually  
Lithuania 
 
Population register (national/ 
regional) 
Health /social insurance. register 
(national/ regional) 
Population register Covers all 
except 
institutionalised 
and non-
citizens  
Continually  
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Country  Available sampling frames  Preferred 
sampling frame  
Coverage of 
population 
groups in 
preferred 
sampling 
frame 
Updating of 
preferred 
sampling 
frame 
Luxembourg National population register 
Health /social insurance register  
Health /social 
insurance register  
Covers all 
except 
European 
Commission 
personnel (5%) 
Continually  
Macedonia Census 
Health /social insurance register 
Census Covers all Continually  
Malta Census  
Electoral rolls 
Electoral rolls Covers all from 
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Netherlands 
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except non-
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Continually  
Norway 
 
National population register 
Census  
Health/ social insurance register 
Electoral rolls 
Population register Covers all Continually  
Poland 
  
National /regional population 
register 
National /regional census  
National /regional elect. rolls  
No information No information  Continually  
Portugal Census (national/ regional) 
Electoral rolls     
Health/ social insurance register  
Census Covers all 
except 
institutionalised 
Less frequent 
than annually  
Romania Population register (national/ 
regional)  
Census (national/ regional) 
Health/ social insurance. register 
(national/ regional) 
Electoral rolls (national/ 
regional) 
Population register Covers all 
except 
institutionalised   
Periodically  
110 
 
Country  Available sampling frames  Preferred 
sampling frame  
Coverage of 
population 
groups in 
preferred 
sampling 
frame 
Updating of 
preferred 
sampling 
frame 
Slovakia 
 
Population register (national/ 
register) 
Census (national/ regional) 
Population register Covers all 
except non-
citizens (not all 
ages) 
Continually 
from 2007 
Slovenia National population register 
Census 
Health/ social insurance register 
Electoral rolls    
Population register Covers all ages Continually  
Spain National population register 
Census  
Health/ social insurance. register 
Electoral rolls    
Population register Covers all Continually  
Sweden National population register Population register Covers all  Continually  
Turkey Census  Covers all 
except 
institutionalised   
Every 10 years 
UK/England  
 
Census  
Electoral rolls  
Health /social insurance register 
(regional)  
Postcode Address File (PAF) 
PAF PAF covers 
addresses, not 
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Annually (or 
more frequent) 
UK/Northern 
Ireland 
No information available No information 
available 
No information 
available 
No 
information 
available 
UK/ Scotland Census  
Electoral rolls  
Health /social insurance register 
(regional)  
PAF 
PAF PAF covers 
addresses, not 
people     
Annually (or 
more frequent) 
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O
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 r
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is
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Table 7.8 Results of a systematic review of 292 randomised controlled trials evaluating the 
effect of strategies to increase response rates in postal questionnaire surveys [23] 
Strategy Surveys, N OR 95%-CI p-value for 
heterogeneity 
Monetary incentive vs no incentive 49 2.02 1.79-2.27 .001 
Incentive with questionnaire vs by the return 10 1.71 1.29-2.26 .001 
Non-monetary incentive vs no incentive 45 1.19 1.11-1.28 .001 
Shorter vs longer questionnaire 40 1.86 1.55-2.24 .001 
Colored ink vs standard 1 1.39 1.16-1.67  
More personalised questionnaire vs less 38 1.16 1.06-1.28 .001 
Recorded delivery vs standard 6 2.21 1.51-3.25 .01 
Stamped return envelope vs franked 14 1.26 1.13-1.41 .001 
1st class outward mail vs other class 1 1.12 1.02-1.23  
Precontact (“alert letter”) vs not 28 1.54 1.24-1.92 .001 
Follow-up (reminder) by non-response vs not 12 1.44 1.22-1.70 .001 
Reminder including questionnaire vs without   6 1.41 1.02-1.94 .001 
More vs less interesting questionnaire 2 2.44 1.99-3.01  
“User friendly” lay-out vs standard 1 1.46 1.21-1.75  
Factual questions only vs additional questions 1 1.34 1.01-1.77  
More relevant questions first vs later 1 1.23 1.10-1.37  
Sensitive question included vs not 6 0.92 0.87-0.98  
More general question first vs later 1 0.80 0.67-0.96  
Sent from university vs others  13 1.31 1.11-1.54 .001 
Reason for not participating requested vs not 1 1.32 1.05-1.66  
Stresses the benefit to society vs other appeal 8 1.00 0.84-1.20  
Response deadline given vs not 4 1.00 0.84-1.20  
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8. ELEMENTS FOR A CORE MODULE AND ADDITIONAL TOPICS 
FOR HES 
 
Moushumi Chaudhury1, Paola Primatesta1 
1University College London, Health and Social Survey Research Group, London, UK 
 
A HES can vary in size and complexity, from an interview with a few measurements 
and/or blood samples, to a comprehensive health examination taking several hours to 
complete. In order to recommend modules to cover elements of a ‘core’ (basic) component of 
a HES, it is important to refer to those measurements that have been included in previous 
HESs. When reviewing the most recent surveys (as described in Chapter 4) it became evident 
that certain topics were recurrent in most of the surveys considered over the period, and 
indeed some of these topics referred to measurements for which a detailed protocol was 
available and validated at the national/international level, both in terms of examinations (as 
discussed in further details in Chapter 9) and questions. These measurements are also usually 
gathering information on diseases or risk factors for diseases with high prevalence (e.g. 
CVD), that address important public health concern globally.  
Additional measurements of a HES can be targeted to specific age groups or specific sub-
samples of the participants (e.g. tests on functional capacity carried out for the elderly). This 
chapter identifies those topics that were most commonly included in HESs, both in terms of 
examinations and questionnaires, and lists additional topics that can be of importance to 
selected subpopulations, to obtain data on specific health conditions or to assess specific 
health services utilisation.  These topics were also included in some, albeit fewer, national 
HESs.  
8.1 IMPORTANCE OF HES AS DATA SOURCE  
Table 8.1 details the importance of HES as a source of information, at present or 
potentially in the future, for selected health topics in European countries. The information is 
derived from the FEHES questionnaire: (total number of countries/contact persons was 32, 
see details in Chapter 4). 
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Most FEHES contact persons considered HESs as an important source of information for 
the risk factors for major chronic diseases, as well as for the prevalence of diabetes, 
cardiovascular diseases and respiratory diseases (Table 8.1). HESs were considered as an 
important source of information for the prevalence of musculoskeletal diseases and mental 
health problems, and on measurements for functional capacity, but a few considered them not 
important at all.    
8.2 MOST COMMON MEASUREMENTS 
8.2.1 EXAMINATIONS 
A summary of the health examinations that are recurrent in all (or most) of previous 
national HESs, and the order of these measurements are shown in Table 8.2. Almost all the 
surveys considered have a ‘core’ content of anthropometric measurements, blood pressure 
measurements and blood samples (mainly for lipid analyses, except Croatia). In the countries 
with extensive comprehensive surveys this set of measurements is targeted to all age groups.  
The discussion relating to the protocol for these measurements is provided in Chapter 9. 
Height was measured in all countries, while weight was measured in all countries with 
the exception of Croatia where it was self-reported.  
The sequence the measurements were taken was also similar in most countries. For 
example, in all the previous HESs, blood pressure was measured before taking the blood 
samples. This is due to the recognition that blood taking can be a potentially stressful 
procedure for some participants, and this could affect their blood pressure levels. 
For all the topics described above relevant questions were also asked, for example in the 
case of blood pressure or blood measurement of lipids to gather information on treatment, 
awareness and management of the conditions hypertension and hyperlipidemia. (Tables 8.3 
and 8.4) 
8.2.2 QUESTIONS 
The national HESs also collect basic information to characterise the surveyed population.  
Table 8.5 summarises those questions (demographics, health status/health disease, health 
determinants) that recurred more often in previous national HESs. Some were asked face-to-
face while in some instances a self-completion questionnaire was used. Table 8.6 shows the 
relevant questions asked on smoking habits. 
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8.3 ADDITIONAL MEASUREMENTS  
Additional modules can cover additional measurements, as described above. They can be 
of interest for specific age groups, ethnic groups, and help to collect data on specific health 
issues. The review of previous national HESs identified examinations and questions used in 
some countries. Not all but most of the additional modules tended to be included in more 
comprehensive HESs, of longer duration. 
8.3.1 EXAMINATIONS 
The Tables 8.7 and 8.8 illustrate additional examinations identified in previous national 
HESs. The discussion relating to the protocol for these measurements is provided in Chapter 
9. 
From the review of previous national HESs, lung function appeared one of the 
examinations recurring more often. Functional tests/tests of physical performance were also 
carried out in some surveys, but were restricted to older age participants. These examinations 
included a battery of tests, such as walking speed, hearing and vision test, balance tests.  
Other examinations of higher complexity are less often performed in national HESs, 
given the specific field they cover, for example bone density, which was included only in 
Finland (Health 2000).  
8.3.2 QUESTIONS 
The Tables 8.9 and 8.10 illustrate additional questions identified in previous national 
HESs. These include questions on alcohol consumption, eating habits (including consumption 
of fruit and vegetables) physical activity, respiratory health and respiratory conditions, mental 
health, oral health. Some of these questions (e.g. respiratory health and oral health) are in the 
surveys when the corresponding examinations are included, while other questions can be 
stand-alone (e.g. physical activity). 
Questions on alcohol consumption are relatively common in national HESs, given the 
important role of alcohol as a risk factor for cardiovascular disease and a health and social 
problem in its own right in some countries.  
For some topics (such as for example eating habits, or mental health), many countries 
have detailed surveys that cover the topic in great details, and these are therefore not included 
in the national HES. Chapter 5 lists the international projects that deal with specific 
recommendations to develop international standards on specific topics. 
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8.4 CONCLUSIONS 
At least height, weight, waist circumference, blood pressure and lipids were measured in 
most of the previous national HESs. The number of additional measurements varied 
considerably between surveys but in many surveys physical performance tests, lung function 
tests, ECG, etc. were included.  
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Table 8.1 Importance of HES as a sources of information* 
 Very 
important 
Somewhat 
important 
Not 
important 
at all 
Risk factors for major chronic diseases    
Blood pressure 29 3 0 
Blood lipids 30 2 0 
Body weight and height 28 4 0 
Functional capacity    
Hearing 9 17 6 
Vision 11 17 4 
Mobility 12 15 5 
Cognitive capacity 15 15 2 
Activities of daily living 13 13 5 
Prevalence of specific diseases and public health problems    
Diabetes 26 6 0 
Cardiovascular diseases 24 8 0 
Respiratory diseases 22 10 0 
Musculoskeletal problems 19 9 4 
Mental health problems 19 11 2 
* Detailed the importance of HES as a source of information (at present or potentially in the future) for selected 
health topics in European countries (FEHES questionnaire: number of countries/contact persons, total 32) 
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Table 8.3 High blood pressure/ hypertension – Relevant questions asked in national HESs. 
Country Survey Year Relevant questions asked 
Croatia Croatian Health Survey  2003 Section: use of health services: from a list of do you have 
any of the following chronic conditions: Elevated BP. 
Secondary Prevention examination question 
Czech Republic Health, Lifestyle and 
Environment  
2004 None. Measurement only 
Health 2000 2000 Perceived health: present: have you high 
BP/hypertension, treatment, current medication, last 12 
months have you visited a droctor. Previous 
measurement 
Finland 
FINRISK  2007 Diagnosed hypertension in past 12 months, last blood 
pressure measurement, used medication 
France National survey on 
nutrition and health  
2006 None. Measurement only 
Germany German national health 
examination and 
interview survey  
1998 Have you ever had any of the following diseases? Where 
did you seek this health service 
Ireland SLAN  2002 Prevention, current level, promotion and awareness 
Netherlands Continuous Quality of 
Life Survey  
2005 Medication: prescribed for?  
Cohort Norway  1994-
2003 
Used medications Norway 
Survey on living 
conditions & health, 
care and social relations  
2002 Have you ever had high BP?  
Poland WOBASZ  2005 Current, awareness, treatment, management 
Slovakia CINDI Health 
Examination Survey  
2003 None. Measurement only 
Health survey for 
England) 
2005 Awareness, treatment, control, management of 
hypertension, current hypertension levels.  
UK 
Scottish Health Survey 2003 Treatment and control of hypertension, current 
hypertension levels. Hypertension  
Canada Canadian Health 
Measures Survey ) 
2007 Awareness of high blood pressure, medication 
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Country Survey Year Relevant questions asked 
USA NHANES  2005-
2006 
Awareness.  What condition/health problem causes you 
to have difficulty …list current blood pressure status 
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Table 8.4 Hyperlipidemia - Relevant questions asked in national HESs. 
Country Survey Year Relevant questions asked 
Croatia Croatian Health Survey  2003 Section: use of health services: from a list of do 
you have any of the following chronic 
conditions Elevated blood cholesterol. This is 
from a list of chronic conditions 
Czech Republic Health, Lifestyle and 
Environment  
2004 HES only 
Health 2000 2000 Have you during the past 5 years had the 
following health examination? From list: 
measurement blood cholesterol 
Finland 
FINRISK 2007 Awareness of hyperlipidemia, last 
measurement, treatment 
France National survey on 
nutrition and health  
2006 HES only 
Germany German national health 
examination and 
interview survey  
1998 Have you ever had any of the following illness/ 
diseases? From a list High level of fat in blood, 
high cholesterol levels. This is asked from an 
extensive list 
Ireland SLAN  2002 When did you last have your blood cholesterol 
measured, with a list to time periods. 
What is the level of your cholesterol. 
Have you ever been told by your doctor you 
have. From a list: high cholesterol. 
How do you think the following affect risk of 
CHD and related diseases? With a list of values 
for Total, and LDL cholesterol . 
Questions asked in the General Health Status. 
Quite detailed questions. Not all the sections of 
the questions were added into this table 
Netherlands Continuous Quality of 
Life Survey  
2005 Nothing found in this survey 
Cohort Norway   1994-
2003 
Medication Norway 
Survey on living 
conditions & health, 
care and social relations 
2002 Nothing found in this survey 
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Country Survey Year Relevant questions asked 
Poland WOBASZ  2005 Have you ever been told by a doctor you have 
raised cholesterol level. 
 How old where you when you were doctor 
diagnosed a raised cholesterol level?  
Drugs prescribed by your dry to lower 
cholesterol. 
Have you been talking lipid lowering drugs 
within the last 3 days . 
Are you on any special diet prescribed by your 
doctor or other medical worker in order to 
lower your cholesterol  level. 
Have you measured your cholesterol level 
within the last 12 months? 
Quite detailed questions  in comparison with 
other surveys listed here 
Slovakia CINDI Health 
Examination Survey  
2003 HES only 
Health survey for 
England 
2005 Have you ever had your blood cholesterol level 
measured by a doctor or nurse? 
When was the last time your blood cholesterol 
level was measured by a doctor? 
Thinking about the last time your blood 
cholesterol level was measured, were told it 
was…with a list of ranges. 
Has a doctor or a nurse told you to lower your 
cholesterol? 
Have you done things to lower your 
cholesterol? 
Has your doctor or nurse explained high 
cholesterol in a way you could understand? 
Have doctors or nurses taken your preferences 
into account when making treatment decisions 
about your high cholesterol?  
The focus of this survey was for those aged 65 
and over. These questions were asked from this 
age 
UK 
Scottish Health Survey 2003 Same as for Health Survey for England 
Canada Canadian Health 
Measures Survey  
2007 Has the blood cholesterol measured. Awareness 
of elevated cholesterol. Medication 
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Country Survey Year Relevant questions asked 
USA NHANES  2005-
2006 
Has the cholesterol ever been measured. When 
was cholesterol last measured. Has ever been 
told that cholesterol is high. Medication. 
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Table 8.5 Common questions in countries with previous national HES. 
Questions about Country Surveys Year 
Age Sex Education General 
health 
CVD Smoking 
/tobacco 
use 
Croatia Croatian Health 
Survey  
2003 X X X X none X 
Czech 
Republic 
Health, Lifestyle 
and Environment  
2004 X X none none none none 
Health 2000 2000 X X X X X X Finland 
FINRISK 2007 X X X X X X 
France National survey 
on nutrition and 
health  
2006 X X none none none none 
Germany German national 
health 
examination and 
interview survey  
1998 X X X X X X 
Ireland SLAN 2002 X X X X none X 
Netherlands Continuous 
Quality of Life 
Survey  
2005 X X X X (for 
children 
only) 
 X 
Cohort Norway  1994-
2003 
X X X X none X Norway 
Survey on living 
conditions & 
health, care and 
social relations  
2002 X X X X none X 
Poland WOBASZ  2005 X X X X X X 
Slovakia CINDI Health 
Examination 
Survey  
2003 X X none none none none 
UK Health survey for 
England 
2005 X X X X X X 
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Questions about Country Surveys Year 
Age Sex Education General 
health 
CVD Smoking 
/tobacco 
use 
Scottish Health 
Survey 
2003 X X X X X X 
Canada Canadian Health 
Measures Survey  
2007 X X X X X X 
USA NHANES  2005-
2006 
X X X X X X 
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Table 8.6 Smoking - Relevant questions asked in national HESs. 
Country Survey Year Relevant questions asked 
Croatia Croatian Health 
Survey  
2003 Family members or you that smoke. Passive smoking 
knowledge. Former smoker, current smoker. Stop/ 
reducing smoking. Advice to stop 
Czech Republic Health, Lifestyle and 
Environment  
2004 No smoking questions 
Health 2000 2000 Have you ever smoked, current and former smoking status, 
when did you last smoke, have you tried to give up 
smoking. 
Finland 
FINRISK 2007 Have you ever smoked, current and former smoking status, 
age when started smoking, when did you last smoke, 
amount and type smoked, have you ever tried stop 
smoking, use of snuff, exposure to environmental tobacco 
smoke 
France National survey on 
nutrition and health  
2006 No smoking questions 
Germany German national 
health examination 
and interview survey  
1998 No smoking questions 
Ireland SLAN  2002 Current smoking, Former smoker, Tried to stop, passive 
smoking.  Some of the questions ask about the current and 
past in the same question 
Netherlands Continuous Quality 
of Life Survey  
2005 No smoking questions 
Cohort Norway  1994-
2003 
How long have you smoked. Type of tobacco smoked. 
Daily smoking status. Amount smoked.  
Norway 
Survey on living 
conditions & health, 
care and social 
relations  
2002 Current smoking. How many. 
Poland WOBASZ 2005 Current smoking, daily, at what age started, tried to stop 
smoking, Former smoker (when did you stop), passive 
smoker. This is quite detailed 
Slovakia CINDI Health 
Examination Survey  
2003 HES only 
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Country Survey Year Relevant questions asked 
Health survey for 
England  
2005 Have you ever smoked? Current and past. The age you 
started to smoke, How many smoked in the last week (5 
questions in Total), exposure to 2nd hand smoke .Basic 
smoking section. The questions were asked in CAPI but 
only web trend tables were shown, No smoking chapter 
reported 
UK 
Scottish Health 
Survey 
2003 Current smoking, exposure to second hand smoke (passive 
smoking), frequency and pattern of current smoking, the 
number, type and tar content of cigarettes smoked by 
current smokers. Past smoking behaviour, desire to give up 
smoking, medical advice to stop smoking. For women, 
smoking behaviour during pregnancy 
Canada Canadian Health 
Measures Survey  
2007 Smoking status. Age when started smoking. Type of 
tobacco smoked. Amount smoked. 
USA NHANES  2005-
2006 
Current smoking, Stop/reduce smoking, Former smoker 
(when did you quit, day, week, months), Average amount 
smoked a day, Past 30 days did you smoke. How old were 
you when you first started to smoke? 
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In chapter 8, an overview was given of the risk factors and the biological measurements 
included to the previous health examination surveys (HES) in Europe. The aim of this chapter 
is to review the state of arts of the measurement procedures, to give an overview of the used 
measurements and protocols in recent European and other major HESs, and to make 
conclusions from these. The conclusions should be relevant for the assessment of the 
feasibility of a HESs in Europe, and from the basis for the preparation of recommendations 
for future European HES. Where relevant, measurement procedures recommended by other 
Projects of the Health Monitoring Programme of the Public Health Programme of the EU, 
such as the European Health Risk Monitor (EHRM) Project [1], will be used as a reference, 
and their suitability will be assessed. 
The information on the procedures used in earlier HESs comes mainly from the 
European Health Interview & Health Examination Surveys Database [2] and also from 
specific survey protocols like the EHRM [1], WHO STEPS [3] and WHO MONICA Protocol 
[4] (See Chapter 4 .1). 
9.1 HEIGHT MEASUREMENT 
There is evidence from several studies that the use of self-reported weight and height 
usually lead to underestimations of obesity prevalence rates because on average subjects tend 
to over-report body height [5]. Therefore, in health surveys, actual weight and height should 
be measured [6]. 
9.1.1 CRITICAL ISSUES OF THE MEASUREMENT PROCEDURE 
Critical for the measurement of height are the choice and calibration of the measurement 
device, clothing and position of the subject, and position of the measurer when reading the 
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measurement value. Relevant for standardization are also instructions concerning subjects 
who cannot stand up. 
9.1.2 EARLIER RECOMMENDATIONS 
The EHRM Project made in year 2002 a review of earlier recommendations and a 
proposal for the standard procedure for measuring height in a European HES [1, 7]. To avoid 
rounding bias, it was recommended to record height to the resolution of the height rule. Self-
reported height was not considered acceptable in any circumstances.  
9.1.3 PROCEDURES USED IN PREVIOUS HESS 
In most previous HESs, height was measured using a portable stadiometer (Table 9.1). In 
most surveys, height was measured to the nearest 0.1 cm but in many surveys also to the 
nearest 0.5 cm. In many of the surveys, height was not measured if the subject was not able to 
stand (wheelchair bound). These are all in accordance with the EHRM recommendation. 
9.1.4 CONCLUSION 
Height is one of the simple measurements, where standardization is needed to ensure the 
use of the similar procedures between observers and comparability between surveys. The 
EHRM recommendation is still up-to-date, and is not in conflict between the standards used 
earlier European HESs. 
9.2 WEIGHT MEASUREMENT 
There is evidence from several studies that the use of self-reported weight leads to 
underestimations of obesity prevalence rates because, on average, the subjects tend to under-
report their body weight. This concerns especially the obese [5]. Therefore, actual weight 
should be measured in HESs. 
9.2.1 CRITICAL ISSUES OF THE MEASUREMENT PROCEDURE 
Critical for the measurement of weight are the choice and calibration of the measurement 
device, clothing of the subject and the measurement procedure of the measurer. Relevant for 
standardization are also instructions concerning pregnant women, wheelchair bound 
individuals, or persons who have difficulty standing steady. 
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9.2.2 EARLIER RECOMMENDATIONS 
The EHRM Project made in year 2002 a review of earlier recommendations and a 
proposal for the standard procedure for measuring height in a European HESs [1, 7]. A 
specific detail of the EHRM standard is that it recommends the use of a traditional beam 
balance scale which was considered the most reliable instrument. Electronic floor scales have 
often replaced the beam balance scale in recent HESs because they are easier to obtain and 
operate, and they are easier to transport. However, they are usually difficult or impossible to 
calibrate. To avoid rounding bias, it was recommended to record weight to the resolution of 
the scale. Self-reported weight was not considered acceptable in any circumstances. 
The EU directive on medical devices (93/42/EC [8], updated in 2007 [9]) sheds new light 
to the usability of electronic scales. According to it, scales are acceptable for medical use if 
they can be calibrated. Such scales also have to be stabilized in each place where they are set 
up. This is because their reading is dependent on the gravity, which varies slightly between 
places.  
9.2.3 PROCEDURES USED IN PREVIOUS HESS 
In many previous HESs weight was measured using an electronic scale and only in few 
surveys, a balanced beam scale was used (see Table 9.2). In all surveys considered in this 
review, the respondents were asked to remove their outdoor clothes, shoes and outer garments 
before measuring weight. In some surveys weight was not measured in pregnant women, 
wheelchair bounded individuals or persons who have difficulty standing steady. This is in 
accordance with the EHRM recommendation. In most surveys, weight has been measured to 
the nearest 0.1 kg but in one survey also to the nearest 0.5 kg. 
9.2.4 CONCLUSIONS 
Like height, weight is also one of the simple measurements, where standardization is 
needed to ensure the use of the similar procedures between observers and comparability 
between surveys. The EHRM recommendation is up-to-date, and is not in conflict between 
the standards used in most earlier European surveys. However, electronic scales that meet the 
criteria of the EU directive (see above) can also be used. 
9.3 WAIST AND HIP CIRCUMFERENCES 
Waist and hip circumference (and the derived waist-to-hip ratio) are widely used as 
indicators of abdominal obesity. It is getting more evident that the waist circumference may 
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be a better reflection of the accumulation of intra-abdominal or visceral fat than the waist-to-
hip ratio. Because of the postulated role of the visceral fat depot in health risks associated with 
obesity, waist circumference is now the preferred measure in the context of population studies 
[10]. Waist to hip ratio and waist circumferences are significantly associated with the risk of 
incident CVD events and type 2 diabetes [11, 12].  
9.3.1 CRITICAL ISSUES OF THE MEASUREMENT PROCEDURE 
The measurements of waist and hip circumferences are more difficult than those of 
weight and height because the results are sensitive to the contraction of muscles by the subject 
and the location and tightness to the measuring tape.  
9.3.2 EARLIER RECOMMENDATIONS 
The EHRM Project made in year 2002 a review of earlier recommendations and a 
proposal for the standard procedure for measuring height in a European HESs [1, 7]. 
According to the EHRM standard, waist circumference should be measured at a level midway 
between the lower rib margin and iliac crest, and hip circumference should be measured as the 
maximal circumference over the buttocks. For both measurements, the tape should be in 
horizontal position all around the body. 
9.3.3 PROCEDURES USED IN PREVIOUS HESS 
Most surveys have used a measuring tape (metal or plastic) (Table 9.3) and procedures 
similar to what was recommended by the EHRM Project. All measurements were taken in 
standing position without any clothing, or with light underwear. The protocols used to 
measure waist and hip circumferences were the same for almost all the surveys. Subjects were 
asked to stand with feet little apart, weight evenly on both feet. The distance between feet 
should be 10-15 cm. Waist circumference was measured between the lower rib margin and 
iliac crest. The subject was asked to breath gently and the measurement was done while 
breathing gently out. To ensure that the measurement tape is in one level, in some surveys the 
subject was asked to turn on place for 90 degrees. EHRM proposed the use of a mirror with 
horizontal grid lines. Hip circumference was measured over the buttocks. In most surveys, 
waist and hip circumferences were measured to the nearest 0.1 cm but in some surveys also to 
the nearest 0.5 cm. One survey measured to the nearest 1 cm. In NHANES, the hip 
circumference was not measured (only the waist circumference). 
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9.3.4 CONCLUSIONS 
The measurement technique for waist and hip circumferences is more demanding than 
for weight and height, and therefore the standardization requires more training and quality 
control. The EHRM recommendation is up-to-date, and is not in conflict between the 
standards used in most of the earlier European surveys. 
9.4 BLOOD PRESSURE 
Raised blood pressure is a risk factor for cardiovascular diseases such as coronary heart 
disease, heart failure, hypertensive renal disease and cerebrovascular disease. 
9.4.1 CRITICAL PROCEDURE ISSUES 
The possible sources of error in the blood pressure measurement can be divided in to 
three categories: observer bias, faulty equipment and failure to standardize the techniques of 
measurement [13]. Critical issues relating to the observer bias like hearing problems, terminal 
digit preference etc. is discussed in Chapter 10 while issues relating to equipment and their 
use are discussed in this Chapter. 
One of the most critical issues is the choice of the blood pressure measuring device. In 
the last decades the blood pressure has been measured with a mercury sphygmomanometer, 
which is still being seen as the gold standard. Due to toxicity of the mercury, various mercury 
containing products have been already banned or their use is restricted in number of 
countries.[14] Therefore, mercury sphygmomanometers have been widely replaced with non-
mercury devices, primarily with automated devices. The very recent Directive 2007/51/EC of 
the EU [15] states that: 
“Mercury… 1. May not be placed on the market: 
(a) in fever thermometers; 
(b) in other measuring devices intended for sale to the general public (e.g. 
manometers, barometers, sphygmomanometers, thermometers other than fever 
thermometers). 
….. 
3. By 3 October 2009 the Commission shall carry out a review of the availability 
of reliable safer alternatives that are technically and economically feasible for 
mercury-containing sphygmomanometers and other measuring devices in healthcare 
and in other professional and industrial uses. 
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On the basis of this review or as soon as new information on reliable safer 
alternatives for sphygmomanometers and other measuring devices containing mercury 
becomes available, the Commission shall, if appropriate, present a legislative proposal 
to extend the restrictions in paragraph 1 to sphygmomanometers and other measuring 
devices in healthcare and in other professional and industrial uses, so that mercury in 
measuring devices is phased out whenever technically and economically feasible.” 
We also asked the national contact persons of the FEHES network about the regulations 
and practices in their countries. There were replies from 19 countries (Table 9.4). In all 
countries, it is still allowed to use the mercury sphygmomanometers. In some countries, it is 
not possible to buy new mercury sphygmomanometers and also obtaining service and 
calibration for old devices is getting difficult.  
For evaluation of the accuracy and validity of the automated blood pressure measurement 
devices, three validation protocols have been used: 
1. British Hypertension Society protocol from 1990 [16] which was revised in 1993 [17].  
2. Association for the Advancement of Medical Instruments protocol from 1987 [18] 
which was revised in 1992 [19]. 
3. European Society of Hypertension International Protocol from 2002 [20]. 
These validation protocols have been developed to assess the accuracy and validity of the 
blood pressure measurement devices for clinical use as well as for home measurements. All 
three protocols are rather similar and generally if device passes the validation by one protocol 
it also does so by the other protocol. Differences between the protocols have been reported 
elsewhere. [21, 22]  
The validation results of the British Hypertension Society (BHS) protocol are reported 
separately for systolic and diastolic blood pressure with grading from A to D [17]. Both 
Association for the Advancement of Medical Instruments (AAMI) protocol [19] and 
International Protocol [20] use grading pass or fail. Grading are based on absolute difference 
between the mercury sphygmomanometer and the test device (mmHg) falling in categories ≤ 
5mmHg, ≤ 10mmHg, and ≤ 15mmHg in the BHS and International Protocols and in 
categories ≤ 5mmHg, and ≤ 10mmHg in the AAMI Protocol. 
Therefore, the maximum bias they allow for the devices to be considered accurate and 
valid are way too large for meaningful comparisons on blood pressure mean values and the 
prevalence of high blood pressure in the population.  
The algorithms used by the automated devices are business secrets and under constant 
development. Therefore, devices from two different manufacture or two different types of 
same brand from the same manufacture may use different algorithms to determine the blood 
pressure. This may create serious comparability problems with the results. 
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When auscultation methods are used for the determination of blood pressure, the use of 
stethoscope is needed. The use of the bell of the stethoscope is generally recommended to 
permit more accurate auscultation of the Korotkoff sounds. [23, 24] From studies in the 
1980’s there is evidence that use of the bell of the stethoscope provides higher systolic blood 
pressure (2 mmHg) and lower diastolic blood pressure (0-2 mmHg) results than the use of the 
diaphragm. [24, 25] Later studies have not found any difference in the blood pressure results 
between bell and diaphragm [26, 27]. There are also results suggesting that new electronic 
stethoscopes with low-frequency or high-frequency amplification provide 1-2 mmHg higher 
systolic blood pressure results than conventional acoustic stethoscopes [27]. 
 The used cuff size has shown to affect the blood pressure levels. Too narrow cuff 
overestimates and too wide cuff underestimates the blood pressure. It has been recommended 
that the cuff width should be at least 40% of the upper arm circumference. [28-30] The 
American Heart Association recommendations have also provided correction factors when 
ideal cuff width is not used [29]. For the length of the cuff, it has also been shown that too 
short cuff overestimates and too long cuff underestimates the blood pressure. It has been 
recommended that the cuff length should be at least 80% of the upper arm circumference. [29, 
30]  
There is evidence that strenuous exercise, eating a meal, drinking of alcohol or caffeine 
containing beverages and smoking affect the blood pressure levels. Strenuous exercise may 
decrease systolic blood pressure by 18-22 mmHg and diastolic blood pressure by 7-9 mmHg, 
the eating generally results only modest decreases in blood pressure and effects of alcohol and 
caffeine containing drinks depend on persons drinking habits. Smoking creates a peak 
increase in blood pressure (10 mmHg for systolic and 8 mmHg for diastolic blood pressure) 
for 30 minutes. [31] 
Other persons have tendency to have a higher blood pressure levels when the blood 
pressure is measured in the physicians’ office than at home. Also the blood pressure can be 
higher when measured by a physician than by a nurse or a medical student. This phenomenon 
is known as the “white coat hypertension” [32, 33]. Therefore, it is usually recommended that 
nurses rather than physicians should measure the blood pressure in population surveys. 
The posture of the subject during the blood pressure measurement has marked influence 
to the blood pressure. It has been reported, that systolic blood pressure is on average 3-10 
mmHg higher and diastolic blood pressure on average 1-5 mmHg lower in supine posture 
than in sitting. [34-36] Also, the position of arm in relation to heart has an effect on blood 
pressure. When the arm is resting on the arm rest of the chair or on the desk which usually is 
not on the level of heart, the systolic blood pressure may be 10 mmHg and diastolic blood 
pressure 11 mmHg higher than the when arm is at the level of the heart. [36-39] 
Blood pressure in the right arm is often higher than in the left arm. The difference 
between right and left arm is 1-3 mmHg in systolic and 1 mmHg in diastolic blood pressure. 
[40, 41] 
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Blood pressure is affected by physical exercise and stress [31]. Coming to the 
examination site may require walking and stair climbing. Furthermore, coming to the 
examination may be a stressful event for the subject. As exercise may cause post-exercise 
hypertension up to 8 mmHg for systolic blood pressure and 4 mmHg for diastolic blood 
pressure and also stress may increase blood pressure [31, 42] it is recommended that the 
subject rests before the blood pressure measurement. 
Average drops in the systolic blood pressure of 9 and 14 mmHg, respectively, have been 
reported after a resting period of four and eight minutes prior to the blood pressure 
measurement. The decrease was less evident in the diastolic blood pressure, amounting 3 and 
4 mmHg, respectively, for the same resting periods. These results are consistent with the 
results of other studies that also report a decrease of similar magnitude within the first five to 
ten minutes of rest.  [42] It has been recommended that at least five minutes of rest should be 
allowed before the measurement of blood pressure. [43] 
 When sequential blood pressure measurements are done in the frequency of few 
minutes, both systolic and diastolic blood pressure tends to decrease in time. The difference 
between two sequential measurements disappears after four measurements for diastolic blood 
pressure and after eight measurements for systolic blood pressure. [40, 41]  
9.4.2 EARLIER RECOMMENDATIONS 
Because of lack of evidence about the possibility to standardize automated devices in 
such a way that they can be used to assess long-term trends in blood pressure in the 
population, the EHRM Project still recommended the use of the mercury sphygmomanometer 
[1]. The EHRM recommendation continued: “This may change when the accuracy of future 
automated devices is found to be sufficient in validation against the simple mercury 
sphygmomanometer.” 
Now, when EU has set the Directive 2007/51/EC which may lead to the total ban of the 
mercury sphygmomanometers, it is essential to study existing alternatives; automated blood 
pressure measuring devices and aneroid sphygmomanometers, for the mercury 
sphygmomanometer.  
To avoid bias due to measurement technique, EHRM Project recommended that blood 
pressure should be measured in sitting position from right arm after 5 minutes rest. The upper 
arm circumference should be measured for the selection of correct size cuff. Three 
measurements, one minute apart should be taken using the bell of the stethoscope. [1] 
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9.4.3 PROCEDURES USED IN PREVIOUS HESS 
9.4.3.1  DEVICES 
Blood pressure measuring device 
From 15 surveys, in six the mercury sphygmomanometer, in eight the automatic device 
and in one both mercury sphygmomanometer and automated device was used. From three 
surveys the type of automatic device in not known. From known automated devices, all 
except one (Dinamap 8100) have passed at least one of the validation protocols. (Table 9.5) 
 
Bell or diaphragm of the stethoscope 
 
In all surveys, where the mercury sphygmomanometer was used, the bell of the 
stethoscope was used and the blood pressure was measured to the nearest 2 mmHg while in 
the surveys where automated devices were used, the blood pressure was recorded with the 
resolution of 1 mmHg. (Table 9.5) 
 
Cuff sizes 
In three of the surveys from which we had information about only one cuff size was 
available. In most of the surveys, at least three different cuff sizes were available with varying 
lengths. (Table 9.5)  
9.4.3.2  PROCEDURES 
Instruction for the subject before measurement  
In most surveys, subjects received some instructions before coming to the blood pressure 
measurement. Generally, these instructions told to avoid strenuous exercise, eating, drinking 
anything else than water, smoking and use of drugs affecting the blood pressure before the 
blood pressure measurements. (Table 9.6)  
 
Posture of the subject and arm during measurement of blood pressure 
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In all surveys the blood pressure was measured in sitting position. In surveys from which 
information is available, the arm was positioned so that the antecubital fossa was at the level 
of the heart. (Table 9.6) 
 
Right or left arm 
In all surveys, except in the Netherlands, the blood pressure was measured from right 
arm. In five of them, the use of left arm was allowed in predefined situations, when the use of 
right arm was not possible. In all these cases, the use of left arm instead of right one was 
recorded. (Table 9.6) 
 
Resting before and between measurements 
The resting period before the blood pressure measurement was usually 5-10 minutes, in 
most cases 5 minutes. Between subsequent measurements of the same person, the resting 
period varied from 30 seconds to 5 minutes. In most of the surveys, the rest between the 
measurements was 1 minute. (Table 9.6)  
 
Number of measurements 
In six surveys, two measurements were taken while in eight surveys three measurements 
were taken. In one survey, a total of six measurements were taken. (Table 9.6)  
 
Protocol 
In six surveys, MONICA protocol and in two surveys EHRM protocol was used. In some 
of these surveys, the original protocol was slightly changed. Other surveys used their own 
blood pressure measurement protocols, which are very similar to the MONICA and ERHM 
protocols, except in those cases where mercury sphygmomanometer was replaced with the 
automated blood pressure measurement device. (Table 9.6)  
9.4.4 CONCLUSIONS 
Blood pressure measurement is one of the difficult measurements to standardize because 
of the many potential sources of error. EHRM [1] recommended the use of the mercury 
sphygmomanometer. In many of the recent surveys, mercury sphygmomanometers were 
replaced by a variety of automated blood pressure measurement devices. This reflects the 
latest developments in the legislation against the use of mercury containing devices and 
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increasing availability of alternative devices. However, it is not clear how to ensure 
comparable results between surveys and in time when automated devices are used.   
The stethoscope and cuff questions are already properly taken into account in resent 
surveys as well as required instructions to the subject before coming to the measurement, 
posture of the subject and arm, the use of right arm for the measurement and the resting 
periods before and between measurements. From these points, EHRM recommendations are 
up-to-date. 
EHRM recommended that on three subsequent measurements are taken, and the mean of 
the second and third are used from reporting the blood pressure. In recent surveys over half 
already had at least three measurements. Adding the third measurement will increase the time 
of examination, but will also stabilize the effect of higher results in the first measurement. 
9.5 BLOOD COLLECTION 
Venous blood samples are usually collected for the measurement of blood lipids and 
glucose. Many other determinations can be carried out, often on deep frozen samples. Today 
serum and plasma samples are used also for analyses of fatty acids and lipoproteins, of 
biomarkers reflecting nutrition (vitamins, flavonoids), of antibodies as infection markers and 
indicators of inflammation. The past 10 years have seen a surge in analyses of DNA, 
extracted from whole blood. We will focus mainly on aspects relevant for the measurement of 
blood lipids and glucose. 
The major constituents of plasma lipids are cholesterol and triglycerides. Total 
cholesterol has since the 1950s been a known risk factor of cardiovascular diseases, 
particularly coronary heart disease. Cholesterol is synthesized in the liver and transported in 
the blood mainly in the form of low density lipoprotein (LDL) cholesterol and high density 
lipoprotein (HDL) cholesterol. A high concentration of LDL-cholesterol and a low 
concentration of HDL-cholesterol in the blood are associated with an increased risk of 
cardiovascular disease. Blood lipids can be measured from serum and from plasma. The level 
of LDL-cholesterol used to be derived from the levels of total cholesterol, HDL-cholesterol 
and triglycerides using the so called Friedewald formula. In the recent years, direct methods 
for the analysis of LDL-cholesterol have become available, and the measurement of 
triglycerides is no longer needed for this. 
Glucose is a reducing monosaccharide that serves as the principal fuel of all the tissues. It 
enters the cell through the influence of insulin. Lack of insulin or resistance to its action at the 
cellular level causes diabetes. Plasma fasting glucose is determined to assess high blood 
glucose levels pointing to diabetes.  
These considerations are the basis for the current practice of drawing blood samples for 
relatively immediate separation into plasma and serum, and whole blood samples for later 
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DNA extraction. Samples are divided into small aliquots. Typically, most of these are stored 
for later analyses at -70°C or -80°C and as an optimum in liquid nitrogen at around – 200°C. 
For survey practice this means that a cold chain must be set up. 
9.5.1 CRITICAL ISSUES OF THE BLOOD COLLECTION AND STORAGE 
There are a number of sources that influence the lipid and glucose concentrations in 
blood samples.  Here is a summary of the review done by the EHRM Project on issues that 
are critical for the measurement of blood lipids and glucose [1]. For the part of the direct 
measurement of LDL-cholesterol, the information is not necessarily up-to-date, and more 
information is expected to emerge in the coming years. Also, some of the information on the 
processing of samples for glucose analyses has been updated.  
 
Seasonal and daily variation 
Several studies have suggested that cholesterol levels are higher in the fall and winter 
than in spring and summer. There is greater amplitude in seasonal variability in women and in 
people with hypercholesterolemia [44]. There is no evidence that people would have marked 
within-day variation [45].  
Knowledge of intra individual variability of Fasting Plasma Glucose (FPG) concentration 
is essential for meaningful interpretation of the survey results. Biological variation includes 
within- and between-subject variation. In a study from the NHANES III fasting plasma 
glucose was highest in those examined in the early morning (fasten for 8 hours) and declined 
throughout the morning. Afternoon fasting glucose values were more stable and were similar 
to late morning levels. Length of fast (Morning > 8 hours: afternoon > 4 hours) was not an 
important factor [46], but the population standard deviation was wider for the afternoon than 
for the morning measurements. Early morning rises in fasting glucose levels and insulin 
requirements (the “dawn phenomenon”) have been observed in patients with type 2 diabetes 
and in some, but not all, studies of non-diabetic persons. Nocturnal elevations in growth 
hormone and early morning increases in cortisol secretion have been explored as contributors 
to this phenomenon [46]. 
 
Fasting before the sample collection 
If fasting glucose, lipoprotein fractions and fasting triglycerides are to be measured, the 
samples should be collected after a fasting period. For glucose alone, 8 hours fasting has been 
recommended [47, 48]. In practice this means overnight fasting and blood sampling in the 
mornings. Because of the diurnal variation, it is important that both the fasting period and the 
time of blood sampling is recorded. 
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For triglyceride measurement, the fasting period should be minimally 8 hours [49] and 
maximally 14 hours. Too long fasting causes major changes in energy metabolism with 
implications for blood triglycerides.  
For the measurement of cholesterols, fasting is not considered essential. If fasting blood 
samples are necessary then the examinations should start early in the morning, and only those 
examined in the morning are used for the assessment of triglycerides and fasting glucose.  
 
Strenuous exercise and alcohol consumption 
There is evidence that strenuous exercise just before blood drawing can decrease the total 
cholesterol level. Nevertheless, in normal survey situations, it is unlikely that people have 
strenuous exercise just before the blood drawing. Excess alcohol use and several medications 
like hypertension drugs and oral contraceptives have an effect on total cholesterol level. [45]  
 
Position of the subject and use of tourniquet 
Several studies have reported that the posture of the subject during the blood drawing can 
have an effect on the total cholesterol level. The total cholesterol levels tend to be lower in 
supine posture and increase when the subject rises to sitting posture and gets higher again 
when the subject is standing.  
During the blood drawing, use of a tourniquet should be avoided. The prolonged venous 
occlusion may increase total cholesterol level by 2-5%. [45] 
 
Serum or plasma 
There is a difference between total cholesterol levels measured from plasma and serum in 
the same subject. The difference depends on the anticoagulant used and its concentration. 
When EDTA is used as the coagulant, plasma cholesterol concentrations are lower than those 
in serum samples [35, 50]. The glucose metabolism continues in the samples until blood cells 
have been separated from the serum. For glucose analysis, plasma is preferred (see 
Centrifuging and storage before centrifuging below). 
 
Centrifuging and storage before centrifuging 
For cholesterol analysis: The time, temperature and force of centrifuging should be 
standardized. For serum this concerns also the time allowed for clotting before centrifuging. 
For serum samples, in general, blood should be allowed to clot at least half an hour and then 
be centrifuged at room temperature (15-24°C) and 1500G or more for at least 10 minutes. The 
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usually recommended upper limit for storage before centrifuging is 2 hours, although even a 
longer storage does not seem to influence cholesterol levels. For plasma samples, 
centrifugation can be done immediately. 
For glucose analysis: Before centrifuging, the glucose concentration declines on average 
by 5% during the first half an hour and by 10% over a 2-4 h period. The main decrease occurs 
during the first hour after blood sampling. Therefore, due to the clotting time, serum has a 
decreased glucose concentration. Preservatives which stop the glycolysis can be added to the 
blood samples immediately. In particular citric acid combined with fluoride maintains the 
glucose level for up to 8 hours in room temperature, and even after that the decline in glucose 
is very small over 24 hours. [51, 52] To our knowledge, this method is in common use in 
Finland, but not so in most other countries. For example, the new WHO expert group 
recommendation [49] does not mention it, and suggests immediate centrifuging as the 
solution to the decline of glucose in the first hours. The preservative also acts as 
anticoagulant, and hence centrifuging produces plasma. 
 
Hemolysis 
Hemolysis may occur during blood drawing and handling. It will result in higher 
cholesterol values, if the direct "Liebermann-Burchard" method is used. For enzymatic 
methods, only a gross hemolysis has an increasing effect on cholesterol. Lipemia can affect 
the triglyceride measurements by interfering with absorbance measurement. Standard 
instructions should specify what to do with hemolyzed samples. 
 
Storage after centrifuging 
It is usually recommended that isolation of HDL should be done on the day of blood 
sample collection. Storage of fresh samples for more than three days at +4°C leads to a 
reduction in HDL cholesterol levels of about 8.2% to 14.9%. Storage of frozen samples for 
more than 14 days at -20°C leads to a decrease in HDL cholesterol levels, whereas storage at 
lower temperatures does not produce such modifications.  
Storage using refrigeration or at room temperature between centrifuging and analysis of 
cholesterol and triglycerides does not seem to be crucial if the material is analyzed within a 
few days and bacterial contamination is avoided. Freezing in appropriate vials is acceptable at 
a temperature of -20°C for 1 year or at a temperature of -60°C for a longer period.  
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9.5.2 EARLIER RECOMMENDATIONS 
The EHRM Project made in year 2002 a review of earlier recommendations and a 
proposal for the standard procedure for the collection and storage of blood samples for the 
measurements of lipids and glucose in a European HES. [1, 7]  
9.5.3 PROCEDURES USED IN PREVIOUS HESS 
Table 9.8 summarizes the instructions given to the subject before the survey examination, 
position of the subject during the blood collection, use of tourniquet, types of collected 
samples and the fasting status of the subjects. Instructions for the subjects before coming to 
the blood sampling were given in 10 surveys. In almost all surveys the blood drawing was 
done while the person was sitting. The only exception was in the UK, where the persons were 
in the supine position during the blood drawing. In all surveys, a tourniquet was used and it 
was removed or loosened after the blood started to flow in the tube. The amount and type of 
collected blood samples varied considerably between surveys. Some surveys collected only 
few tubes while in others 10 tubes were collected with different anticoagulants and 
preservatives. In 7 surveys the subjects were asked to fast before coming to the examination 
(4 -12 hours). In 6 surveys the blood collection was done in non-fasting subjects. 
Table 9.9 shows the type of blood sample used, and the handling and storage of the 
samples on the field and before the lipid analysis. In all reviewed surveys, lipids were 
measured from serum samples. The handling of the samples before centrifugation was quite 
similar between surveys, i.e. samples were staying in room temperature for 20-30 minutes 
before they were centrifuged. Centrifuging time was for all the surveys more or less the same 
(10-12 minutes). The rotational speed was different between the surveys (1600 – 3800 rpm). 
The storage of the blood samples in the field differed between the surveys. In some surveys 
the blood samples were stored in the freezer (within 1 hour after the collection) while in other 
surveys the samples were stored at room temperature for 24 hours before the samples were 
transported to the laboratory. The long time storage was for almost all surveys in -70 or -
80ºC. In one survey the blood samples were kept frozen at -20ºC. 
Glucose was measured in 6 surveys, and for 3 surveys information on this is not yet 
available. Glucose was measured in plasma, using Fluoride Citrate (FLSi), Sodium Fluoride 
(NaF) or Sodium Citrate (Na Cit) as preservative, or in serum (Table 9.10). Centrifuging time 
was for all the surveys more or less the same (10-12 minutes). The rotational speed varied 
between the surveys (2800 – 3800 rpm). The storage of the blood samples in the field 
differend between the surveys. In some surveys the blood samples were stored in the 
refrigerator within 1 hour after the collection, and at the end of the day frozen at -20ºC. In 
some surveys, the samples were immediately frozen and in others they were cooled and sent 
by courier to the laboratory. The long-time storage was in most surveys in -70ºC or -80ºC, 
with few exceptions were the samples were stored at -20ºC. 
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9.5.4 CONCLUSIONS 
For lipid and glucose measurements, the organizers of earlier surveys seem to have been 
aware of good standardizable practices. For many of these there are no good alternatives. 
Deviation from the optimal procedure usually implies lower quality. The EHRM 
recommendation is mostly up to date, but needs to be checked for the details for the 
preparation of glucose samples. The procedures used in the recent surveys are also in 
accordance with the EHRM procedures. Ideally, the laboratory analyses are done without 
delay using fresh samples. However, this is not often logistically possible for a national HES. 
Therefore, the recommendation should provide instructions both for rapid transfer of unfrozen 
samples to the laboratory and a less rapid transfer and storage of frozen samples. 
The scope of valuable uses of the blood samples is much wider than lipids and glucose 
alone. This should be prepared for in future HESs. Therefore, it is advisable to collect several 
small aliquots of serum, plasma and whole blood, and store them appropriately for future 
analyses. 
9.6 LABORATORY PROCEDURES 
9.6.1 CRITICAL ISSUES OF THE MEASUREMENT PROCEDURE 
Various direct enzymatic methods are nowadays available for the measurement of 
cholesterols and glucose. Enzymatic assays can be used in automated or manual methods with 
inexpensive instruments. They allow a good precision provided that they are used with care 
and the measurement instruments are calibrated properly. Accreditation of the laboratory 
provides assurance of the ability to operate with care. Particularly important for the 
calibration is the secondary calibrator, which should be real human serum or plasma, ideally 
in the same form as the survey blood samples. Only with such calibrators one can get a 
reasonable assurance that there are no matrix effects, i.e. that there is no interference from 
substances in the samples which are not being measured. For the reliability of the secondary 
calibrator, it should be traceable to an internationally recognized reference method. 
In addition, to assure comparability between laboratories and the assessment of trends 
over time, external quality control organized by a common reference laboratory will be 
needed.  In the USA this is organized by the Centres for Disease Control and Prevention 
(CDC) [53]. CDC also has a certification program for clinical diagnostic products for 
cholesterols. In Europe, there has been no such external quality control since the activities of 
the WHO Regional Lipid Reference Centre (WHO-RLRC) in Prague, Czech Republic, 
stopped in the 1990s. 
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9.6.2 EARLIER RECOMMENDATIONS 
The EHRM Project made in year 2002 a proposal for the standard procedure for the 
laboratory procedures for the measurement of cholesterol, triglycerides and glucose in a 
European HES [1, 7]. This included a proposal for the establishment of a reference laboratory 
for the standardization of the measurements across Europe, but the recommendation has not 
been implemented so far. Major changes after the EHRM proposal are that direct methods for 
the analysis of HDL- and LDL-cholesterol have become well established, and therefore have 
replaced fully the former procedures which were more complex.  
9.6.3 PROCEDURES USED IN PREVIOUS HESS 
Table 9.11 shows a summary of the analysis methods used for the measurement of total 
and HDL-cholesterol and glucose in recent HESs. All, from which information is available, 
used enzymatic methods, except in Czech Republic, where dry chemistry was used in the 
field. The latter is an alternative method, which uses capillary blood samples, and gives 
results immediately in the field. We have not considered this method more thoroughly 
because it is seldom the method of choice in a HES, where venous samples are usually 
collected anyway for different measurements. None of these surveys, which all were from the 
2000s, reported using direct methods for the measurement of HDL-cholesterol. 
All surveys, except two, reported the use of a central laboratory to which all samples of 
the survey were transferred. In the Czech survey, which measured only total cholesterol, dry 
chemistry was used in the field, and the French survey also used a field laboratory. 
9.6.4 CONCLUSIONS 
Various good enzymatic laboratory methods are available for the analysis of cholesterols 
and glucose, and there is a certification program for the cholesterol assays. International 
standardization is possible, but requires careful calibration and analysis (preferably in an 
accredited laboratory), and a common reference laboratory for external quality control. 
9.7 MEASUREMENT OF PHYSICAL FUNCTIONING  
The assessment of level of physical functioning has traditionally relied on administration 
of questionnaires that collected self-report of proxy information on activities and abilities. In 
recent years, in an attempt to enhance the ability to quantify the memory and candour 
influence on self-report, direct physical performance measures have been developed. These 
tools objectively evaluate specific aspects of physical function by having the individual 
perform standard tasks.   
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A growing body of evidence has demonstrated that these physical performance measures 
add important information in the assessment of older adults [54]. Performance measures have 
been shown to identify functional problems that the individual or family did not report [55, 
56]. In addition performance based measures have been demonstrated to predict strongly 
outcomes such as mortality [57, 58], falls [59, 60], institutionalisation [57, 58, 61], and other 
health service utilisation [62, 63]. In non-disable older persons, performance measures have 
been shown to be predicting subsequent disability onsets [62].  
Measures of physical functioning e.g. functional ability, mobility, and physical activities 
are frequently used in population surveys because they are socially relevant and interpretable.  
There are only a few standardised tests for assessing physical performance in large 
populations [64, 65].  However, a variety of performance tests have been developed for use in 
institutions [66, 67] and also among community-dwelling older persons [57, 60, 64, 68-72]. 
Due to the current limitations only tests and test batteries designed to describe physical 
functioning of community dwelling older adults suitable also for large populations and high-
function populations are reviewed here. In general, performance based tests may be 
categorised by either the domain of functioning they assess (e.g., upper extremity versus 
lower extremity) or the complexity of the functioning they assess (more basic physiologic 
abilities, such as grip strength, versus more complex tasks, such as putting on a blouse).  The 
test of upper body, low extremity and also some of the best known and most often used 
performance batteries (combinations of many tests) designed for the community dwelling 
elderly population and adults are presented here.  Attention is focused on instruments 
developed for clinical or population-based research and highly structured to permit uniform 
data collection from a number of participants.  
In addition to review of performance based instruments of physical functioning the 
current recommendations and initiatives to develop these recommendations are presented. An 
overview of the current situation of the used measurements in national HESs in Europe and in 
USA as well as in Canada will be described. This information is based on the HIS/HES 
database [2] and the survey manuals/protocols. 
9.7.1 TESTS OF UPPER BODY FUNCTIONING 
For the upper body performance-based measurement include tests of manual dexterity, 
physical strength and range of motion. Although impairments in lower body function have 
been found to be stronger predictors of the initial onset of disability, both lower body and 
upper body impairments are associated with dysfunction in later years [73, 74]. Upper body 
function is important in executing many normal everyday activities such as household chores 
(dressing, bathing, and eating instead of complex, strenuous activities like shopping and 
housekeeping; [73-75]). Performance tests of upper extremity function have been shown to be 
an important marker of functional dependency [71]. Older individuals who perform poorly on 
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tests of manual dexterity tend to use more health care resources [75, 76], including 
intermediate and long-term care [61, 72]. It has also been found that poor grip strength is a 
strong predictor of disability [77, 78], morbidity [79] and mortality [80, 81]. 
9.7.1.1 CRITICAL ISSUES OF THE MEASUREMENT PROCEDURES 
Manual dexterity 
Standardized assessment test of manual dexterity include the Pegboard Test or Williams’ 
board with fasteners, however unlike many  performance based tests these require special 
equipments [75].  
 
Strength  
Handgrip strength testing has long been used as a tool in the clinical assessment of hand 
and wrist injury but it is also easy to use in surveys [82, 83]. Hand grip strength is often used 
as an indicator of overall muscle strength in population studies. It has been shown to be 
powerful predictor of mortality, but the mechanism remains unclear [81, 84, 85]. In addition 
there is some evidence that hand grip strength predicts functional limitations and disability 
[78]. 
A wide range of instruments is available to measure both static and dynamic grip 
strength; however, most instruments measure static grip strength. Grip strength measurement 
devices fall into three basic categories: hydraulic, pneumatic and mechanical [83, 86, 87]. 
Jamar dynamometer (hydraulic instruments) device is the most widely reported and 
recommended measure of grip strength [64, 86, 88, 89], and appears to be also the most 
widely used. It is inexpensive, simple to use, versatile in its applications, and has been found 
to be accurate [90], reliable [91-95] and reproducible [91, 94] in its measurements.  
It is generally agreed that for the measurement of hand grip strength the most critical 
points are posture of the subject during the measurement and the instructions of device use 
[86, 96]. There are, however, wide ranges of protocols and positions that have been developed 
for grip strength testing [83]. Depending on the purpose of the assessment, the testing position 
may vary. [97] studied the short term reliability of grip strength measurement and the effect of 
posture (standing, sitting and supine) and grip span. They recommend using interval 
measurement with a 1-minute rest after each set. In addition the influence of posture and grip 
span should be considered to maximize data accuracy. 
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Range of motion 
One of the earliest test measuring joint functions was Jefferys et al [98] set of test 
measuring motor impairment. It consisted of movements for both upper and lower extremities 
which were scored by the lay interviewer according to the performance of examinee. Keitel 
[99] and his co-workers have proposed parallel index, Functional Test, intended to reflect the 
degree of functional limitations of the joints. The items were developed as a clinical tool in 
rheumatology. However Jette et al [73] have adapted parts of the test in community dwelling 
elderly including seven movements measuring function of hands and upper extremities and 
three for lower extremities function. The joint function test conducted in a Finnish National 
health examination survey [100-102] and Netherlands 2001 has same features as Jettes [73] 
and Keitels tests and it have also been originally adapted from the field of rheumatology. The 
joint function test [101, 102] involves 10 separate movements, the first four of which were 
designed t test lower limb function and the remaining six upper limb function (see Table 
9.6.1) The information on reliability and validity of the test is week. For example in the 
Health 2000 survey the number of cases in the upper limb components of the joint function 
tests was very low (prevalence less than 5%) as majority of the subjects made no mistakes in 
the test. [102]. 
9.7.1.2  EARLIER RECOMMENDATIONS 
No recommendations exist for measuring manual dexterity, range of motion or grip 
strength in the population health survey settings. For testing range of motion or dexterity there 
are no common recommendations or standards. American Society of Hand Therapists [103] 
has recommended standard posture for testing hand grip strength. Curb et al [64] recommend 
to measure grip strength either by strength or handheld dynamometer for high functioning 
populations. 
9.7.1.3  PROCEDURES USED IN PREVIOUS HESS 
Four surveys have included examination procedures related to measurement of 
functioning of upper extremity. In the two Finnish surveys and in the Dutch HES there has 
been a similar joint function test (Table 9.12); walking on even ground, walking on tiptoes, 
upstairs walking, squatting, elevation of the upper arms, extension of the elbow joints, flexion 
of the elbow joints, volar flexion of the wrists, flexion of the fingers to the palm, opposition of 
the thumbs. In Finland the test was performed only for those over 55 years and over whereas 
in the Netherlands there were no age limits. The test involved 10 separate movements, the 
first four of which were designed to test lower limb function and the remaining six upper limb 
functions: Each of the component tests were performed in sequence following the examiner’s 
demonstration. The subjects’ performances were rated as normal (0), degraded (1) or failed 
(2) on the basis of detailed classification instructions. 
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Hand grip strength have been measured in the Finnish Health 2000 surveys, Health 
Survey for England 2005 and Canadian health measures survey 2007 (Table 9.12). In the 
Health 2000 handgrip strength was measured with a computer-based instrument (Good 
Strength, IGS01, Metitur Oy, Jyväskylä). The method was developed from that used by 
Viitasalo et al. [104]. In the British and Canadian surveys the measurement were conducted in  
by a Gripometer (UK) and Smedley III hand dynamometer (Canada) in a standing position 
and measurements were repeated three times from both hands.  
9.7.1.4  CONCLUSIONS 
The measurement of upper extremity functioning is reliable in the population survey 
settings.  As the grip strength measurement have been shown to be relevant measurement 
from the public health perspective and predict overall mortality it should be included in the 
measurement procedures of upper extremity in HESs. The hand grip strength measure global 
functional deficits and appears to be clinically important. As many devices and protocols 
exist, standardisation is needed to ensure the use of comparable devices and procedures and 
comparability of between surveys.  
Measures of fine motor skill e.g. manual dexterity, upper extremity range of motion and 
other functions which affect overall ability to accomplish tasks encountered in daily living 
could easily be added to the national population surveys if finer detail or knowledge of a 
specific function is needed. However the reliability and the ability of these tests to 
discriminate between the most highly functioning individuals and individuals who merely 
have good function need to be future examined. 
9.7.2 TESTS OF LOWER EXTREMITY 
Good lower extremity functioning is necessary for mobility and is thus a critical element 
of independence in the community. Tests of gait speed, standing balance and time to rise from 
a chair have been used to evaluate lower extremity function in a community dwelling elderly 
[57]. These tests accurately predict disability across populations [105]. In addition they have 
been found to predict mortality and nursing home admission in representative samples of 
older adults [57] and indicate disability in non-disabled persons over age 70 years [62]. They 
have the additional advantage of being quite independent of changing environmental 
conditions. 
Gait speed has been shown to have a graded relationship with mobility and activity of 
daily living disability in the non-disabled population [62]. It predicts further nursing home 
admission, morbidity and mortality [57]. Sonn [106] proved that women and men who stayed 
independent when aged over 70’s had significantly higher maximal walking speed than those 
who became or already were dependent. Further-more lower body function is strongly 
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associated with incidence of falling: usual walking speed of less than 0.6 meters/ second is 
associated with increased risk of falls [59].  
The ability to under take physically demanding activities of daily living requires an 
adequate level of aerobic endurance especially during ageing. Walking a certain distance in 
some time reflects functional capacity and performance, walking ability as well as lower 
extremity function. 
Rising from a chair is a function needed daily, and therefore perquisite for independent 
living. It requires sufficient strength of lower extremities, although the relationship with 
strength and chair stand is not linear [107, 108].  Poor performance in chair stand tests is 
associated with adverse health outcomes in older persons [57, 62]. Lower body muscular 
strength has been well established as a major factor in maintaining functional mobility and 
preventing or delaying the onset of disability [57, 62, 74]. As apart of lower extremity 
performance test battery, multiple chair raises has been shown to be predictive of subsequent 
disability among non-disable persons [105]. 
Balance is required to maintain a position, remain stable while moving from one position 
to another, perform acts of daily living, and move freely in the community.  
9.7.2.1  CRITICAL ISSUES OF THE MEASUREMENT PROCEDURES 
Walking and strength related tests 
Gait speed is based on the performance of individuals on a timed walk test being 
computed by dividing the distance a person walks by the time it takes him/her to cover the 
distance. It is usually measured over a relatively short distance and its measurement does not 
include endurance as a factor. Guralnik et al [105] believe that a 4-meter walk is a good 
distance because it has been demonstrated to be feasible in the home as well as in the clinical 
settings and that a longer distance may (only) improve measurement accuracy.   
Regardless of the measurement method, gait speed measurements are considered highly 
reliable in people without known impairments that should affect gait [109]. Gait speed is a 
simple performance measure, easily and quickly assessed in the clinical as well as in research 
settings [105, 110].  In the clinical settings, testing usually takes less than 1 minute. 
Hoyemans et al [111] have reported the correlation of retest reliability for gait speed to be 
0.90 and Jette and colleagues [112] reported that the infraclass correlation coefficient (kappa) 
for 8-foot walk was 0.76. Guralnik et al [105] have demonstrated that walking speed alone is 
nearly as good a predictor of disability outcomes as a full performance battery of the lower 
extremity. In addition it has been stated that walking tests are more reliable than other 
performance based measures in elderly people, such as timed chair stand and weight lift 
[112]. 
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It has been suggested that the 2-minute walking test may not discriminate well enough, 
but the 12-minute test may be unnecessarily long [113]. However, most community-dwelling 
elderly persons can quickly and safely perform the 6 -minute walking test [114].The purpose 
of the test is to see how far the participant can walk in six minutes [114]. The 6-minute walk 
test has been found to be reliable and valid in relation to other performance and self-reported 
indicators of physical functioning [115]. It is easy to conduct and it can provide reasonably 
reliable and valid information of physical endurance in older adults. The results moderately 
reflect overall physical functional performance [116]. 
Csuka and McCarty [117] developed a timed-stand test. It involves recording the amount 
of time required to stand up 10 times. Modifications of this test have been developed. The 
most commonly used version is five-chair stands test [57]. It has relatively high and stable 
interpreter (retest) reliability. However in the Finnish Health 2000 survey the reliability for 
the chair stand test was good or moderate [102]. Curb et al [64] have increased the number to 
10 rises in order to provide better discrimination in healthy populations. The 10 time rise was 
found to be feasible, highly reliable (r=84) as well as easy and quick to conduct (2 minutes).  
 
Balance 
Balance can be measured either by laboratory tests or performance- based tests. 
However, there are no generally accepted ways of performing the actual balance test, or 
analysing data even in the simplest static tests. Era et al [118] have reported that there are 
discrepancies in balance measures in recording periods from a few seconds up to several 
minutes, different standards for positions of the feet and arms, and different practices in the 
use of fixed marks for visual stabilisation, among others [118].  
Many of the balance test have been developed for clinical settings. For example The 
Timed Up and Go Test (TUG) was originally developed as a clinical measure of balance in 
elderly people. The test measures the time it takes a subject to stand up from an armchair, 
walk a distance of 3 meters, turn, walk back to the chair, and sit down. The original test has 
been modified by timing the task and it has been proposed to use it as a short test of basic 
mobility skills for frail community-dwelling elderly. The test is quick and does not require 
special equipment or training [119]. Shumway-Cook [120] et al reported that the TUG is a 
sensitive (87%), specific (87 %) measure for identifying community-dwelling adults who are 
at risk to fall. However the disadvantage of this test is that it measures only few aspects of 
balance [121] 
 One of the best known functional balance tests is the Berg Balance Scale (BBS, [122]). 
It was developed as a performance–oriented measure of balance in elderly individuals. Items 
include simple mobility tasks (e.g. transfers, standing unsupported, sit-to stand) and more 
complex tasks (e.g. Tandem standing, turning 360 degree, single-leg stand). Other similar test 
includes the Functional independence measures [123] and the continuous scale Physical 
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Function Performance test [124]. Also Romberg balance test measuring the balance and 
vestibular system have been modified and used in the population survey settings [125].  
Guralnik et al [57] developed a test battery specifically to assess mobility in older adults 
(see chapter 9.6.3). The test of standing balance includes tandem, semi-tandem, and side-by 
side stand for 10 seconds [57]. The test has been found to be reliable and valid [57, 102, 126] 
but it was too easy to discriminate among many individuals, with nearly half of the subjects 
obtaining perfect scores [57, 126]. The experience of the Finnish Health 2000 Examination 
survey supports the finding; the test had a ceiling effect up to 60 years of age and in addition 
its reliability was found fair (kappa=0.45 [102]). Despite these drawbacks the test is widely 
used also in the population survey settings. 
Curb et al [64] recommend one leg stand as a part of performance battery for highly 
functioning populations (e.g [127, 128]). One leg stand requires minimal equipment and it 
takes approximately 3 minutes to perform,  in addition it was found to be quite reliable 
(r=0.69) and discriminating between functional levels among persons with 35 to 70 years age 
range. On leg stand has been shown to be feasible, reliable and valid method for assessing 
balance also in middle aged persons [128]. Also MacArthur measures included single leg 
stand, modified by asking the participants to hold the position for up too 30 seconds [57, 126].  
To increase the discrimination power there has been initiatives to include measures of 
Balance that required standing on a foam pad to reduce tactile input [125]. There is also some 
experience on using force platform electronic techniques in population based settings [64, 
102]. The electronic system makes it possible to measure postural control in different static 
and dynamic testing conditions and it helps to train and analyse balance and postural 
asymmetry through visual feedback. Although electronic devices offer significantly more 
information, they are more expensive and less portable than many of the practical measures 
currently in use [64].  
9.7.2.2  EARLIER RECOMMENDATIONS 
No recommendations exist for measuring lower extremity strength or balance in the 
population health survey settings. However there are some initiatives in EU-level to 
harmonies the assessment of physical functioning. For example European Network for action 
on ageing and physical activity EUNAAPA [129] aims to get consensus on most appropriate 
assessment on instruments for elderly aiming at physical activity, physical functioning and 
functional performance. Prevention of Falls Network Europe ProFaNE [130] is a thematic 
network with 25 partners focusing on the issue of prevention of falls and improvement of 
postural stability amongst elderly people. It focuses on assessment of balance function that 
can be used for fall prediction and the assessment of outcome of fall intervention programmes 
for older people. The aim is to produce recommendations about balance assessment in the 
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context of fall interventions for older people. When available these recommendations could 
be adaptable also for population survey settings.  
9.7.2.3  PROCEDURES USED IN PREVIOUS HESS 
In the Finnish Health 2000 and Finrisk 1997 as well as in the Dutch national examination 
survey the joint function test (see table 9.13) included the measurement of range of motion of 
lower extremities.  
The walking speed for over a relatively short distance was measured in the Finnish 
Health 2000 surveys, and in the health survey for England. In the Finnish survey the 
measurement was done at  6.1 meters [131] distance using maximal walking speed where as 
in the UK survey the distance was 2.4 meters conducted at participants own natural pace. In 
both test the stopwatch was started at the beginning of the test and stopped when the subject 
crossed the end line.  Both in the Finnish Health 2000 survey as well as UKs survey the 
elderly participants (in Finland above 55 and in UK above 65) conducted timed chair stand 
test, which is widely applied in assessments of functional capacity in older people. In Finland 
they used a standard chair with no arm rests and a seat height of 43 cm from the floor. The 
back of the chair was placed against the wall. The subjects were asked to sit down in the 
chair, with their hands across their chest and feet slightly apart. From this position, they were 
asked to stand up once and if succeeded the rise was repeated 5 times as quickly as possible. 
In England there was no standard chair height but the chair has to be with no arm rest. The 
test protocol was similar to Finnish one, but the UK HES included also 10 rise chair stand test 
for a sub-sample of 65 to 69 years old. 
Standing balance has been measured in four HESs. The Finnish Health 200 survey was 
the only survey using electronic equipment for the measurement. Balance was measured in 
the health examination using a computer-based measurement system (Good Balance, IGB01, 
Metitur Oy, Jyväskylä) and by following the protocol introduced by Guralnik et al. [57] 
including  four different measurements of balance; 1) Feet side by side, eyes open (30 s), 2) 
Feet side by side, eyes closed (30 s), 3) Semi-tandem (20s), 4) tandem (20s). At home health 
examinations and during equipment malfunctions, balance was measured using a simple field 
test [57], without the computerised system. For this test, the subjects were to remain standing 
in a semi-tandem position for 10 seconds. If successful, they were then asked to stand in a 
tandem position again for 10 seconds. If the subjects were unable to stand for 10 seconds in 
the semi-tandem position, they were asked to take an easier position, with their feet side by 
side, touching each other (10 seconds).  
The Finnish FINRISK 2007 measured and tested a more discriminating balance 
measurement protocol for a sub sample of 25 to 74 years old participants. Also the Health 
survey for England used more demanding position for a sub sample of 65 to 69 years old; the 
balance was measured in full tandem position (30 seconds) and in addition in one leg (30 
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seconds). The NHANES included measurement of balance and vestibular system trough 
observing the sway of position applied from Romberg test. 
9.7.2.4  CONCLUSION 
There exists no general recommendation on how to measure lower extremity function or 
balance in the population health survey settings. Measurement methods vary considerably. 
International recommendations and standardisation of methods is required to enable the 
comparability between surveys. 
9.7.3 PHYSICAL PERFORMANCE BATTERIES  
Several physical performance test batteries have been designed for the assessment of 
physical functioning. Many of the upper extremity tests and lower extremity test presented 
earlier (chapters 9.6.1-9.6.2) are parts of wider test batteries. Although walking speed alone 
can predict physical functioning quite well (see Chapter 9.6.2), the full battery of lower 
extremity tests is likely to be a better instrument by which to assess performance and change 
over time. More accuracy may be gained by using the full battery because measuring a 
specific construct with multiple measures increases reliability [105].  
 
Physical Performance Test, PPT 
Reuben & Sui (1990) developed the Physical Performance Test (PPT). The test assesses 
several domains of physical functioning, using observed performance of tasks stimulating 
activities of daily living of various degrees of difficulty. The tasks include upper body 
strength and dexterity, mobility, balance, co-ordination, and endurance. The test includes 
specific ADL activities (eating, transferring, and dressing) and IADL activities (upper 
extremity strength necessary to perform laundering; climbing stairs essential in using public 
transportation).  The test includes writing a sentence, simulated eating, turning 360 degrees, 
putting and removing a jacket, lifting a book and putting it on a shelf, picking up a penny 
from the floor, a 50-foot walk test and climbing stairs (scored as two items). The PPT can be 
also completed by a seven item test (does not include stairs). 
 
A short lower extremity battery- EPESE 
A short lower extremity battery- EPESE (Established Populations for Epidemiologic 
Studies of the Elderly) is a test developed specifically to assess mobility in older adults [105, 
132]. The test battery includes a short battery of items to measure strength, balance and gait 
speed. The total time to perform these tests takes from 10 to 15 minutes [57]. The test of 
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standing balance includes tandem, semi-tandem, and side-by-side stand for 10 seconds. The 
walking speed test is performed over an 8-feet (2,44 meters) distance. The ability to rise from 
the chair includes five rises without the help of the arms. Good to excellent test-retest 
reliability of these tests has been demonstrated [126, 133]. 
 
Health-related fitness test battery, HRFTB 
The health –related fitness test battery has been developed by the UKK Institute in 
Finland. The battery is designed for middle-aged adults, but it has been proven to be safe also 
for older adults with minor changes in the test protocol [134]. The test includes the walking 
test for cardio respiratory fitness (2-km Walk Test), four muscular strength and endurance 
tests (leg muscular power [jump and reach]), leg strength [one-leg squat], upper-body strength 
[modified push-ups], and trunk muscular endurance [static back extension]), and two 
flexibility tests for musculoskeletal fitness (trunk side-bending, knee extension range of 
motion), a balance test for motor fitness (one-leg standing), and measures of weight and 
height to calculate body mass index (BMI) [135]. The test has been designed to measure 
health related fitness of individuals and populations in order to evaluate the amount and type 
of physical activity needed to promote health. 
 
Functional Fitness Test Battery 
Rikli and Jones [65, 136] have developed a functional fitness test battery. The complete 
battery consists of six tests (and one alternative) designed to assess physiologic parameters 
associated with independent functioning and physical mobility in older adults. The items of 
the battery cover lower and upper body strength, aerobic endurance, lower and upper body 
flexibility and agility/dynamic balance. The body mass index is also included in the test 
battery to estimate body composition. The lower body strength is measured by a 30-s chair-
stand-test. The 30-second time limit makes it possible for all individuals to receive a score 
(compared to 5 stand chair test). The arm-curl test measures upper body strength and involves 
determining the number of times a hand weight (5lb for women, 8lb for men) can be curled 
through a full range of motion in 30 seconds. The 6-minute walk test is used to determine the 
distance that can be walked in 6 minutes. A 2-minute walk test (the 2-min step in place) can 
be used as an alternative. In addition to these tests, the flexibility of the lower body is 
measured trough chair sit- and reach test and the upper back scratch test measures the 
shoulder range of motion. The modified timed up-and-go test measures the mobility and 
balance. The distance has been changed to 8 feet. 
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The Groningen Fitness Test for the elderly (GFE) 
The Groningen Fitness Test for the Elderly has been developed for field-based 
assessment of fitness in healthy people over 55 years of age [137]. The battery consists of six 
test items for objective measurement of fitness and a questionnaire for subjective evaluation 
of fitness. It includes measures of walking, strength, flexibility, reaction power, and manual 
dexterity. The test can be used in studies concerning the relationships between fitness and 
physical activity, health, and performance in instrumental activities of daily living (IADL). 
 
Continuous-Scale physical functional performance test (CS-PFP) 
Continuous-Scale physical functional performance test (CS-PFP) is an instrument 
designed to measure physical function reflecting abilities in several separate physical domains 
[110]. The test consists of a battery of 15 everyday tasks, ranging from easy to demanding, 
that describe the physical domains of upper and lower body strength, upper body flexibility 
and, balance and co-ordination, and endurance. Tasks include carrying a pan of water a 
distance of one meter and carrying and then pouring from a jug of water into a cup. In 
addition to tasks of basic instrumental activities of daily living the tasks include walking as 
far as possible in six minutes. 
9.7.3.1  CRITICAL ISSUES OF THE MEASUREMENT PROCEDURES 
The tasks of the PPT test can be administered and scored by a layperson with minimal 
training and the test can be completed in less than 10 minutes and requires only a few simple 
props [68]. PPT was found to be reliable and demonstrated concurrent and construct validity 
when compared to other measures of functional status.  
The EPESE test battery has been shown to have good test-retest reliability over a wide 
range at least in a fairly old population [112]. The battery has been successful in classifying 
large populations of community-dwelling older adults into broad categories by functional 
status, but still there are some problems with the instrument. The problems of balance tests 
have been already discussed (see chapter 9.6.2) In addition to these problems it was found 
that approximately 22% of the target population could not complete a 5-time chair-stand test 
of lower body strength [132].  
The HRFTP battery has been evaluated systematically for its reliability, safety, 
feasibility, and validity. The inter-rated intra-class correlation coefficients (kappa) for one-leg 
balance, trunk side bending, push-up strength, leg power, and leg strength have been found to 
be good ranging from .89 to 1.00. and the mean test-retest differences ranged from small to 
moderate, varying from 0.6% to 12.1 % [138]. In addition test-retest correlation coefficients 
have been found to be high for dynamic back extension and the 2-km walking test [139].  
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The Fuctional Fitness Test Battery has been shown to be feasible and safe to complete. 
The content validity of each test has been demonstrated by literature review and expert 
opinion [65, 116, 136]. 
In a pilot study the correlation between instrumental activities of daily living and 
objective fitness was. It can be concluded that the GFE is a valid contributor of performance 
of IADL. 
Continuous-Scale physical functional performance test is a valid, reliable measure of 
physical function, applicable to a wide range of functioning. It has minimal floor and ceiling 
effects and it is suitable for both research and clinical purposes [110, 124, 140].  
9.7.3.2  EARLIER RECOMMENDATIONS 
No recommendations exist for using a certain physical performance test batteries in the 
population health survey settings. Curb et all (2006) have proposed and recommended a 
performance battery for high functioning populations including measurement of balance 
trough unassisted single leg stand and trough measurement of balance platform ‘foam pad, 
eyes closed test’, grip strength measurement with handheld dynamometer or electronic 
strength measurement, timed 10 chairs stand, 6 minute walking test and rapid 10 foot walk as 
well as elbow flexion and knee extension strength using strength chair. This initiative is so far 
the only one aimed to the development of full simple set of test battery suitable for research 
settings to quickly (31 minutes the whole battery) assess global functional level.  
9.7.3.3  PROCEDURES USED IN PREVIOUS HESS 
In the pervious HES only Guralnik test EPES test battery have been used partly and 
modified in the Finnish Health 2000 survey and National Survey for England 2005. (Table 
9.11 and 9.12) 
9.7.3.4  CONCLUSIONS 
Standard recommendations on reliable and discriminating physical performance battery 
could enable international comparability between countries/ surveys. There is some evidence 
[64] that several simple tests used today are not particularly reliable, and only few 
discriminate between different levels of functioning. There is a need to recommend 
internationally accepted full test battery covering the most important parts of functioning, 
discriminating different levels of functioning and being reliable. 
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9.7.4 GENERAL CONCLUSION ON MEASURING PHYSICAL FUNCTIONING IN HES 
The use of performance measures in cross-cultural and international studies is not 
common but it still has obvious advantages. Cultural, language, and social differences 
between populations may greatly limit the validity of comparisons of self-reported 
functioning and disability. Cognitive impairments, culture, language and education have 
much less influence on performance tests, compared to self-report methods. Furthermore, they 
are essential for understanding time trends in functional capacity. In addition tests on physical 
functioning are quite safe to conduct. In addition measuring the functional level offers also a 
convent way to compare the impact of different types of disease on different populations at 
different times [141]. The measurements can also provide important information about the 
need for assistance in personal care, ability to live independently and prognosis. From the 
public health perspective, knowing the health and functional status of the ageing population is 
important so that interventions can be targeted towards the right population groups [134] as 
performance measures have been shown to improve with intervention. The evidence on the 
importance of measurement of physical functioning is strong. 
There are already many examples on wide HESs covering the measurement of physical 
functioning. Health 2000 survey is maybe the most comprehensive health examination survey 
in Europe in the area of physical functioning. In addition to the tests mentioned above 
psychomotor reaction time (computer assisted measurement) a musculoskeletal fitness test: 
back extension for the endurance capacity of the trunk extensor muscles (see Chapter 9.7) was 
measured. In the recent years also other comprehensive HESs has taken the measurement of 
functioning in the measurement procedures. Such examples are UK, USA and Canada. 
However the comparability of the results on physical functioning between surveys is poor. 
The test protocols vary in the scope and in the meanings of the tests.  
There is a growing need to standardise the measurement methods used in different areas 
of health care and research setting. EUNAAPA [129] and ProFaNE [130] are EU-level 
examples on the project aiming at recommending standard measures of physical functioning. 
At national level for example in Finland there is also an initiative to review, evaluate and 
recommend common measures of functioning for population based survey settings among 
other [142]. The idea of internationally standardised measurement of physical functioning is 
commendable, but the work has just being started.  
9.8 PHYSICAL FITNESS  
Fitness is a strong physiological indicator of health risk, which can be objectively 
measured. Low fitness and obesity act largely as independent risk factors. A study of 21 925 
men, with a follow-up on average of 8 years found that unfit lean men had a higher risk of all-
caused and CVD mortality, than men who were fit and obese.[143] A number of studies with 
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varying methodologies and population composition have confirmed that fitness is at least as 
important as obesity as a predictor of disease risk [144-146]. 
The physical fitness tests include tests like Canadian Fitness Test [147], Åstrand-
Ryhming step test [148], Harvard step test [149], Queen’s College step test [150], Siconolfi’s 
step test [151], YMCA step test [152], Chester Step test [153] and Polar fitness test [154, 
155].  
9.8.1 CRITICAL ISSUES OF THE MEASUREMENT PROCEDURE 
The limitation of many of the current instruments of performance based measurement of 
physical functioning (Chapter 9.7) is that physical impairments often are not detected until 
late in the disability process. Thus, such instruments are not suitable for younger people e.g. 
high functioning [136]. Several fitness tests (treadmill and cycle ergometer tests, bench step 
tests etc.) have been developed and validated for describing physical capacity of younger 
people. However many of them are inappropriate for older adults (too difficult or even risky). 
In addition, these protocols often require expensive equipment or extensive training for test 
technicians and have therefore been judged not to feasible for use in clinical or population 
survey settings [136]. On the other hand, there are at least some examples of large scale 
population surveys having successfully employed such methods [82]. 
9.8.2 EARLIER RECOMMENDATIONS 
No recommendations exist for measuring physical fitness in survey settings. 
9.8.3 PROCEDURES USED IN PREVIOUS HESS 
In 4 previous HES surveys (3 countries) physical fitness was measured. In USA and 
Canada Cardiovascular fitness was measured by using the sub maximal exercise test 
(treadmill) and the mCAFT (using a 8 stepping stages). In Finland the Polar Fitness test was 
used and the musculoskeletal fitness test. (Table 9.14) 
9.8.4 CONCLUSIONS 
There exists no general recommendation on how to measure physical fitness in the 
population health survey settings. Measurement methods vary considerably.  
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9.9 ANKLE BRACHIAL INDEX 
The ankle-brachial pressure index (ABI), also known as the ankle arm index, compares 
the systolic blood pressure of the ankle to that of the arm (brachial). This standard non-
invasive test assesses the severity of peripheral arterial occlusive disease (PAOD).  
The ankle brachial index is a good predictor of subsequent cardiovascular events and 
improves on predictions by conventional risk factors alone. It is a simple and accurate and 
could be included in routine screening of cardiovascular disease. It is concluded that the 
accuracy of determining ABI in PAOD patients with intermittent claudication was minimally 
affected by the method chosen to obtain brachial systolic blood pressure [156]. 
9.9.1 CRITICAL ISSUES OF THE MEASUREMENT PROCEDURE 
Critical for the measurement of the ankle brachial index are the choice and the calibration 
of the measurement device.   
9.9.2 EARLIER RECOMMENDATIONS 
Since its introduction in 1950, a variety of methods of measurements and calculation 
have been used to establish the ankle brachial index. A study was made of analyses of the 
methods used to assess the ankle brachial index  [157]. Based on this analysis, a 
recommendation was made, that is needed to allow comparison and meta-analysis of future 
results.  
9.9.3 PROCEDURES USED IN PREVIOUS HESS 
In the period 2000 – 2007, the ankle brachial index was not included to any of the 
national HESs in Europe. In USA, the Atherosclerosis risk in communities (ARIC) study has 
measured ABI [158]. 
9.9.4 CONCLUSION 
For the measurement of ankle brachial index there is no standardized recommendation.  
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9.10  VISION TEST 
Adequate visual function is an important factor for functional ability [68]. Decreased 
vision increases substantially with age and has a great impact on society as well as on a 
person’s quality of life and sense of independence by increasing the need for health and social 
services and institutionalization. Causes for visual impairment are largely remediable, 
especially un-operated cataract and uncorrected refractive errors. 
9.10.1  CRITICAL ISSUES OF THE MEASUREMENT PROCEDURE 
Performance-based measurement of visual function supplements self-reported 
assessment of vision, so it is recommended to evaluate them both. The most widely used and 
standardized test of visual function is measurement of visual acuity. In seeing tests 
environment and equipment (calibration) may affect the results obtained. Those responsible 
for conducting the examination must be trained experts. Good instructions help the subjects to 
perform as intended. Instruments must be calibrated to yield correct readings. 
9.10.2  EARLIER RECOMMENDATIONS 
Both distance and near vision have been evaluated by standard card or chart in national 
survey settings  [159]. Although the measurement technique is quite easy, a correct technique 
is a pre-requisite for correct results. At this moment there is no standardized recommendation 
to measure vision. 
9.10.3  PROCEDURES USED IN PREVIOUS HESS 
Only in two previous HESs a vision test has been conducted. In both surveys, the vision 
was tested while subject was using their own glasses, if had once. Tests included both 
distance vision (40 meters) and near vision (40 cm). (Table 9.15)  
9.10.4  CONCLUSION 
Although the measurement technique is easy, it requires trained staff, and calibrated 
instruments.  
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9.11  HEARING TEST 
Hearing function has been assessed in many health surveys. The tests have been 
developed mainly in clinical practice settings. Hearing ability is usually measured with an 
audiometer. Audiometry has to do with an individual's sensitivity or tolerance. It also 
concerns discrimination levels, the ability to distinguish speech from background noise, or the 
ability to recognise pitch.  
9.11.1  CRITICAL ISSUES OF THE MEASUREMENT PROCEDURES 
In hearing tests environment and equipment (calibration) may affect the results obtained. 
Those responsible for conducting the examination must be trained experts. Good instructions 
help the subjects to perform as intended. Instruments must be calibrated to yield correct 
readings. 
9.11.2  EARLIER RECOMMENDATIONS 
The hearing test is easy and quick to conduct and there are no known risks associated 
with the hearing examination. At this moment there is no standardized recommendation to 
measure hearing. 
9.11.3  PROCEDURES IN PREVIOUS HESS 
Only in two previous HESs, the hearing test has been conducted. In both surveys, the 
special sound proof cabin was used for the test. Finnish Health 2000 survey tested 500 and 
1000 Hz while NHANES had much broader range of Hz to test. (Table 9.16) 
9.11.4  CONCLUSION 
Although the measurement is easy and quick to conduct, other important factors are 
difficult to standardize.  
9.12  BONE DENSITY 
Osteoporosis is a serious public health issue, affecting up to 1 in 2 women and 1 in 5 men 
over the age of 50 years. The common osteoporotic fractures occur at the spine, wrist and hip. 
For the patient affected by osteoporosis, these fractures are associated with significant 
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morbidity and, in the case of hip and spine fractures, an excess mortality. The treatment of 
osteoporotic fractures is also associated with a significant healthcare cost for society. 
 Bone mineral density can be measured with a Single x-ray absorptiometry (SXA) and 
dual x-ray absorptiometry (DXA).  
9.12.1  CRITICAL ISSUES OF THE MEASUREMENT PROCEDURE 
Required trained staff, expensive materials.  
9.12.2  EARLIER RECOMMENDATIONS 
Currently, measurement of bone mineral density using dual energy X-ray absorptiometry 
is the gold standard for the diagnosis of osteoporosis [160]. 
9.12.3  PROCEDURES USED IN PREVIOUS HESS 
In three previous HESs a bone mineral density has been measured as well with a SXA as 
a DXA. The used devices in all three surveys have been different but all of them have been 
large, non-mobile devices. The location from which the bone mineral density was measured 
had also varied. (Table 9.17) 
9.12.4  CONCLUSION 
Although the measurement is easy and quick to conduct, other important factors are 
difficult to standardize.  
9.13  LUNG FUNCTION 
Lung function is measured by spirometry. Of main interest are indices of airway 
obstruction: the FEV1 (forced expiratory volume in one second), the FVC (forced vital 
capacity) and the derived ratio FEV1/FVC. Lung function tests should not be performed 
within one month of a myocardial infarction, and results are likely to be suboptimal in 
subjects with chest or abdominal pain of any cause, oral or facial pain exacerbated by a 
mouthpiece, stress incontinence, dementia or a confusional state.  
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9.13.1  CRITICAL ISSUES OF THE MEASUREMENT PROCEDURE 
Different types of equipment are available for spirometry. Most electronic spirometers 
contain a device for measuring gas flow. The flow can be measured from the pressure drop 
across a tube with known resistance to flow (pneumotachograph), by counting the number of 
revolutions per unit of time of a small turbine (electric turbine) or from ultrasound transit time 
up and down a tube (ultrasonic). Two types of pneumotachographs are available (Fleisch and 
Lilly), of which the Fleisch is considered to be more reliable. Pneumotachographs are 
particularly sensitive to temperature, atmospheric pressure and condensation of water vapour 
and therefore require very frequent calibration. A potential advantage of using turbine and 
ultrasonic devices is that they depend less on calibration for reliable results. Well-known 
manufacturers of spirometric equipment are Vitalograph (pneumotachographs [161]), Micro 
Medical Ltd (electric turbine devices [162]) and an example of the more recently developed  
ultrasonic devices is the EasyOne [163]. 
Besides the method of measuring gas flow, spirometric equipment varies in size and ease 
of re-location (from hand-held portable devices to office spirometers), in costs of equipment 
and accessories (for ultrasonic devices a relatively expensive new mouthpiece is required for 
every subject), whether flow-volume and volume-time curves are displayed during testing, in 
memory capacity for storing tests and in available software.  
To guarantee the accuracy and reliability of the pulmonary function testing system used, 
the manufacturer has to guarantee that the system meets all specifications issued by the 
ATS/ERS [164]. The user is responsible for ensuring that the equipment’s measurements 
remain accurate, and results furthermore depend on the cooperation between subject and 
examiner. For optimal quality control, both flow-volume and volume-time displays are 
recommended. Many portable spirometers may not meet this recommendation, but have 
advantages in their relatively low cost and ease of re-location. 
9.13.2  EARLIER RECOMMENDATIONS 
At this moment there is no standardized recommendation to measure lung function. 
9.13.3  PROCEDURES USED IN PREVIOUS HESS 
In 5 previous HESs  lung function was measured. In all surveys FVC, FEV and PEF was 
measured. In Ireland only PEF was measured. In 3 surveys the devices they used was a 
Vitalograph spirometer. (Table 9.18) 
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9.13.4  CONCLUSION 
The measurement is difficult to conduct, and the needed material is expensive. The 
measurement is difficult to standardize. 
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gh
t 
an
d 
W
ei
gh
t S
ca
le
  
0,
1 
cm
 
Po
la
nd
  
W
O
B
A
SZ
 
20
05
 
M
O
N
IC
A
 P
ro
to
co
l [
4]
: M
ea
su
re
d 
w
ith
ou
t s
ho
es
, f
ee
t t
og
et
he
r,
 b
ac
k 
as
 
st
ra
ig
ht
 a
s 
po
ss
ib
le
, f
ac
in
g 
fo
rw
ar
ds
. U
pr
ig
ht
 p
os
iti
on
 w
ith
ou
t o
ut
er
 g
ar
m
en
ts
 
an
d 
sh
oe
s 
H
ei
gh
t r
ul
e 
0,
5 
cm
 
Sl
ov
ak
ia
  
 
C
IN
D
I 
H
ea
lth
 
E
xa
m
in
at
io
n 
Su
rv
ey
  
20
03
 
A
da
pt
ed
 E
H
R
M
 P
ro
to
co
l [
1]
: S
ta
nd
in
g,
 d
re
ss
ed
 
 
0,
1 
cm
 
20
0 
 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
H
ea
lth
 S
ur
ve
y 
fo
r 
E
ng
la
nd
 
 
20
05
 
M
ea
su
re
m
en
t p
os
iti
on
: w
ith
ou
t s
ho
es
, f
ee
t f
la
t o
n 
th
e 
ce
nt
re
 o
f 
th
e 
ba
se
 p
la
te
, 
fe
et
 to
ge
th
er
, h
ee
ls
 a
ga
in
st
 th
e 
ro
d,
 b
ac
k 
as
 s
tr
ai
gh
t a
s 
po
ss
ib
le
 (
no
t l
ea
ni
ng
 
on
 th
e 
ro
d)
, a
rm
s 
ha
ng
in
g 
lo
os
el
y 
by
 th
e 
si
de
, f
ac
in
g 
fo
rw
ar
ds
. P
er
so
n 
sh
ou
ld
 
ke
ep
 th
ei
r 
ey
es
 f
oc
us
ed
 o
n 
a 
po
in
t s
tr
ai
gh
t a
he
ad
, t
o 
br
ea
th
e 
in
 d
ee
pl
y 
an
d 
to
 
st
re
tc
h 
to
 th
ei
r 
fu
lle
st
 h
ei
gh
t. 
C
om
m
en
t:
 N
ot
 m
ea
su
re
d 
fr
om
 c
ha
ir
 b
ou
nd
 p
er
so
ns
, i
f 
pe
rs
on
 is
 to
o 
un
st
ea
dy
 
on
 th
ei
r 
fe
et
 f
or
 th
e 
m
ea
su
re
m
en
t, 
pe
rs
on
 f
in
ds
 it
 p
ai
nf
ul
 to
 s
ta
nd
 o
r 
st
an
d 
st
ra
ig
ht
, e
ld
er
ly
 p
er
so
n 
is
 to
o 
st
oo
pe
d 
to
 o
bt
ai
n 
a 
re
lia
bl
e 
m
ea
su
re
m
en
t. 
If
 p
er
so
n 
ha
s 
a 
ha
ir
 s
ty
le
 w
hi
ch
 s
ta
nd
s 
w
el
l a
bo
ve
 th
e 
to
p 
of
 th
ei
r 
he
ad
 o
r 
tu
rb
an
, t
hi
s 
sh
ou
ld
 b
e 
m
ar
ke
d 
on
 m
ea
su
re
m
en
t c
ar
d.
 
Po
rt
ab
le
 s
ta
di
om
et
er
  
0,
1 
cm
 (
if
 
be
tw
ee
n 
tw
o 
m
ill
im
et
er
s,
 
ro
un
di
ng
 to
 
th
e 
ne
ar
es
t 
ev
en
 
m
ill
im
et
er
) 
 
U
K
  
 
Sc
ot
tis
h 
H
ea
lth
 S
ur
ve
y 
 
20
03
 
M
ea
su
re
m
en
t p
os
iti
on
: w
ith
ou
t s
ho
es
, f
ee
t f
la
t o
n 
th
e 
ce
nt
re
 o
f 
th
e 
ba
se
 p
la
te
, 
fe
et
 to
ge
th
er
, h
ee
ls
 a
ga
in
st
 th
e 
ro
d,
 b
ac
k 
as
 s
tr
ai
gh
t a
s 
po
ss
ib
le
 (
no
t l
ea
ni
ng
 
on
 th
e 
ro
d)
, a
rm
s 
ha
ng
in
g 
lo
os
el
y 
by
 th
e 
si
de
, f
ac
in
g 
fo
rw
ar
ds
. P
er
so
n 
sh
ou
ld
 
ke
ep
 th
ei
r 
ey
es
 f
oc
us
ed
 o
n 
a 
po
in
t s
tr
ai
gh
t a
he
ad
, t
o 
br
ea
th
e 
in
 d
ee
pl
y 
an
d 
to
 
st
re
tc
h 
to
 th
ei
r 
fu
lle
st
 h
ei
gh
t. 
C
om
m
en
t:
 I
f 
pe
rs
on
 h
as
 a
 h
ai
r 
st
yl
e 
w
hi
ch
 s
ta
nd
s 
w
el
l a
bo
ve
 th
e 
to
p 
of
 th
ei
r 
he
ad
 o
r 
tu
rb
an
, t
hi
s 
sh
ou
ld
 b
e 
m
ar
ke
d 
on
 m
ea
su
re
m
en
t c
ar
d.
 
Po
rt
ab
le
 s
ta
di
om
et
er
 
0,
1 
cm
 (
if
 
be
tw
ee
n 
tw
o 
m
ill
im
et
re
s,
 
ro
un
di
ng
 to
 
th
e 
ne
ar
es
t 
ev
en
 
m
ill
im
et
re
) 
 
C
an
ad
a 
 
 
C
an
ad
ia
n 
H
ea
lth
 
M
ea
su
re
s 
Su
rv
ey
 2
00
7 
20
07
 
Pe
rs
on
 s
ho
ul
d 
re
m
ov
e 
hi
s/
he
r 
fo
ot
w
ea
r 
an
d 
m
ov
e 
or
 r
em
ov
e 
ha
ir
 o
rn
am
en
ts
, 
je
w
el
le
ry
, b
un
s 
an
d 
br
ai
ds
 f
ro
m
 th
e 
to
p 
of
 th
e 
he
ad
. P
er
so
n 
st
an
ds
 e
re
ct
, a
rm
s 
ha
ng
in
g 
at
 th
e 
si
de
s,
 f
ee
t t
og
et
he
r,
 h
ee
ls
, b
ut
to
ck
s 
an
d 
ba
ck
 a
nd
 h
ea
d 
in
 
co
nt
ac
t w
ith
 th
e 
ve
rt
ic
al
 b
ac
kb
oa
rd
 o
f 
th
e 
st
ad
io
m
et
er
. B
od
y 
w
ei
gh
t s
ho
ul
d 
be
 
ev
en
ly
 d
is
tr
ib
ut
ed
 a
nd
 b
ot
h 
fe
el
 a
re
 f
la
t o
n 
th
e 
fl
oo
r.
 P
er
so
n 
lo
ok
s 
st
ra
ig
ht
 
ah
ea
d.
 
C
om
m
en
t:
 I
f 
pe
rs
on
 n
ot
 a
bl
e 
to
 s
ta
nd
 u
na
ss
is
te
d 
D
ig
ita
l S
ta
di
om
et
er
 
0,
1 
cm
 
20
1 
 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
U
SA
 
 
N
H
A
N
E
S 
 
20
05
-
20
06
 
Pe
rs
on
 is
 a
sk
ed
 to
 r
em
ov
e 
ha
ir
 o
rn
am
en
ts
, j
ew
el
le
ry
, b
un
s,
 a
nd
 b
ra
id
s 
fr
om
 
th
e 
to
p 
th
e 
he
ad
. P
er
so
n 
st
an
ds
 w
ith
 h
ee
ls
 o
f 
bo
th
 f
ee
t t
og
et
he
r 
an
d 
th
e 
to
es
 
po
in
te
d 
sl
ig
ht
ly
 o
ut
w
ar
d 
at
 a
pp
ro
x.
 6
0o
 a
ng
le
. B
od
y 
w
ei
gh
t i
s 
ev
en
ly
 
di
st
ri
bu
te
d 
an
d 
bo
th
 f
ee
t a
re
 f
la
t o
n 
th
e 
fl
oo
r.
 T
he
 h
ee
ls
, t
he
 b
ut
to
ck
s,
 
sh
ou
ld
er
 b
la
de
s 
an
d 
th
e 
ba
ck
 o
f 
th
e 
he
ad
 s
ho
ul
d 
be
 in
 th
e 
ve
rt
ic
al
 c
on
ta
ct
 w
ith
 
ba
ck
bo
ar
d.
 M
ea
su
re
m
en
t i
s 
ta
ke
s 
w
hi
le
 p
er
so
n 
is
 b
re
at
hi
ng
 d
ee
pl
y 
in
. 
C
om
m
en
t:
 I
f 
pe
rs
on
 h
as
 h
ea
r 
pi
ec
e 
an
d 
he
/s
he
 r
ef
us
es
 to
 r
em
ov
e 
it,
 th
e 
he
ig
ht
 
of
 th
e 
he
ar
 p
ie
ce
 is
 m
ea
su
re
d 
an
d 
re
co
rd
ed
. A
ls
o 
if
 p
er
so
n 
re
fu
se
s 
to
 r
em
ov
e 
hi
s/
he
r 
sh
oe
s,
 th
e 
he
ig
ht
 o
f 
th
e 
he
el
 o
f 
th
e 
sh
oe
s 
w
ill
 b
e 
m
ea
su
re
d 
an
d 
re
co
rd
ed
. I
n 
bo
th
 o
f 
th
es
e 
ca
se
s 
he
ig
ht
 w
ill
 b
e 
m
ea
su
re
d.
 
Fi
xe
d 
st
ad
io
m
et
er
 
w
ith
 a
 v
er
tic
al
 
ba
ck
bo
ar
d 
an
d 
a 
m
ov
ea
bl
e 
he
ad
bo
ar
d 
0,
1 
cm
 
  
20
2 
 
T
ab
le
 9
.2
 W
ei
gh
t m
ea
su
re
m
en
t p
ro
to
co
ls
, d
ev
ic
es
 a
nd
 a
cc
ur
ac
y 
of
 th
e 
m
ea
su
re
m
en
t i
n 
th
e 
pr
ev
io
us
 H
ES
s 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
C
ro
at
ia
  
 
C
ro
at
ia
n 
H
ea
lth
 
Su
rv
ey
  
20
03
 
M
O
N
IC
A
 P
ro
to
co
l [
4]
 
 
 
C
ze
ch
 r
ep
ub
lic
 
H
ea
lth
 L
if
es
ty
le
 a
nd
 
E
nv
ir
on
m
en
t  
20
04
 
M
O
N
IC
A
 P
ro
to
co
l [
4]
: M
ea
su
re
d 
in
 s
ta
nd
in
g 
po
si
tio
n 
w
ith
ou
t s
ho
es
 a
nd
 
ou
te
r 
ga
rm
en
ts
 
B
ea
m
-b
al
an
ce
 s
ca
le
 
0,
2 
kg
 
H
ea
lth
 2
00
0 
 
20
00
 
Su
bj
ec
t w
as
 b
ar
ef
oo
te
d.
 A
t f
ir
st
 th
e 
so
le
 a
nd
 b
al
m
s 
w
er
e 
w
ip
ed
 w
ith
 s
pe
ci
al
 
el
ec
tr
ol
yt
ic
 to
w
el
s.
 S
ub
je
ct
s 
w
er
e 
as
ke
d 
to
 s
ta
nd
 o
n 
th
e 
de
vi
ce
 f
ee
t o
n 
th
e 
el
ec
tr
od
es
 a
nd
 g
ri
p 
ha
nd
 e
le
ct
ro
de
s 
so
 th
at
 th
um
b 
an
d 
ba
lm
 h
av
e 
pr
op
er
 
co
nt
ac
t t
o 
th
e 
el
ec
tr
od
es
. S
ub
je
ct
 is
 s
ta
nd
in
g 
ha
nd
s 
on
 s
id
e,
 s
lig
ht
ly
 d
ep
ar
t 
fr
om
 th
e 
bo
dy
. A
ge
 a
nd
 th
e 
he
ig
ht
 in
 th
e 
ac
cu
ra
cy
 to
 th
e 
1 
cm
 w
er
e 
im
pu
te
d 
to
 th
e 
de
vi
ce
 f
ro
m
 th
e 
pr
ev
io
us
 h
ei
gh
t m
ea
su
re
m
en
t. 
M
ea
su
re
m
en
t 
to
ok
 a
bo
ut
 2
 m
in
ut
es
. 
C
om
m
en
t:
 N
ot
 c
on
du
ct
ed
 f
or
 th
e 
su
bj
ec
ts
 w
ith
 p
ac
em
ak
er
s 
B
od
y 
co
m
po
si
tio
n 
an
al
yz
er
  
 
Fi
nl
an
d 
 
 
FI
N
R
IS
K
 
20
07
 
W
ei
gh
t i
s 
m
ea
su
re
d 
in
 th
e 
lig
ht
 c
lo
th
in
g,
 w
ith
ou
t o
ut
er
 g
ar
m
en
ts
, s
ho
es
 a
nd
 
dr
es
s 
co
at
s.
 M
ak
e 
su
re
 th
at
 s
ub
je
ct
 d
oe
s 
no
t h
av
e 
ke
ys
, w
al
le
t o
r 
ot
he
r 
th
in
gs
 in
 h
is
/h
er
 p
oc
ke
ts
. S
ub
je
ct
 is
 s
ta
nd
in
g 
in
 th
e 
m
id
dl
e 
of
 th
e 
sc
al
e,
 
w
ei
gh
t e
ve
nl
y 
di
st
ri
bu
te
d 
on
 b
ot
h 
fe
el
. 
C
om
m
en
t:
 I
f 
su
bj
ec
t i
s 
he
av
ie
r 
th
an
 th
e 
m
ax
im
um
 w
ei
gh
t p
os
si
bl
e 
to
 
m
ea
su
re
 b
y 
th
e 
sc
al
e 
or
 s
ub
je
ct
 is
 im
m
ob
ile
, t
he
 s
el
f 
re
po
rt
ed
 w
ei
gh
t i
s 
re
co
rd
ed
 a
nd
 th
e 
co
m
m
en
t i
s 
m
ad
e 
on
 th
e 
fo
rm
. I
f 
m
ob
ile
 s
ub
je
ct
 r
ef
us
es
 
fr
om
 th
e 
m
ea
su
re
m
en
t, 
se
lf
 r
ep
or
te
d 
w
ei
gh
t i
s 
no
t a
cc
ep
te
d.
 
B
al
an
ce
d 
be
am
 s
ca
le
 
 
0,
1 
kg
  
20
3 
 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
Fr
an
ce
  
 
N
at
io
na
l S
ur
ve
y 
on
 
nu
tr
iti
on
 a
nd
 h
ea
lth
  
20
06
 
W
H
O
 r
ec
om
m
en
da
tio
ns
 [
16
5]
. l
ig
ht
 c
lo
th
in
g 
E
le
ct
ro
ni
c 
sc
al
e 
 
0,
1 
kg
 
G
er
m
an
y 
 
 
G
er
m
an
 n
at
io
na
l 
he
al
th
 e
xa
m
in
at
io
n 
an
d 
in
te
rv
ie
w
 s
ur
ve
y 
 
19
98
 
M
ea
su
re
d 
w
ith
ou
t s
ho
es
 , 
st
an
di
ng
 a
nd
  l
ig
ht
 c
lo
th
in
g 
E
le
ct
ro
ni
c 
 
0,
1 
kg
 
Ir
el
an
d 
 
 
SL
A
N
 
 
20
06
 
E
H
R
M
 P
ro
to
co
l [
1]
; M
ea
su
re
d 
w
ith
ou
t h
ea
vy
 o
ut
er
 g
ar
m
en
ts
 (
ja
ck
et
s,
 
co
at
s,
 tr
ou
se
rs
, s
ki
rt
s 
et
c)
 a
nd
 s
ho
es
, w
ei
gh
t d
is
tr
ib
ut
ed
 e
ve
nl
y 
to
 b
ot
h 
fe
et
. 
N
ot
 m
ea
su
re
d 
fr
om
 p
re
gn
an
t w
om
en
, w
he
el
ch
ai
r 
bo
un
d 
in
di
vi
du
al
s 
or
 
pe
rs
on
s 
w
ho
 h
av
e 
di
ff
ic
ul
ty
 s
ta
nd
in
g 
st
ea
dy
. 
C
om
m
en
t: 
N
ot
 m
ea
su
re
d 
fr
om
 p
re
gn
an
t w
om
en
, w
he
el
ch
ai
r 
bo
un
d 
in
di
vi
du
al
s 
or
 p
er
so
ns
 w
ho
 h
av
e 
di
ff
ic
ul
ty
 s
ta
nd
in
g 
st
ea
dy
. 
B
al
an
ce
d 
be
am
 s
ca
le
  
0,
1 
/ 0
,2
 k
g 
 
N
et
he
rl
an
ds
  
 
N
et
he
rl
an
ds
 H
ea
lth
 
E
xa
m
in
at
io
n 
Su
rv
ey
  
 
20
01
 
W
ei
gh
t i
s 
m
ea
su
re
d 
in
 th
e 
lig
ht
 c
lo
th
in
g,
 w
ith
ou
t o
ut
er
 g
ar
m
en
ts
, s
ho
es
 a
nd
 
dr
es
s 
co
at
s.
 M
ak
e 
su
re
 th
at
 s
ub
je
ct
 d
oe
s 
no
t h
av
e 
ke
ys
, w
al
le
t o
r 
ot
he
r 
th
in
gs
 in
 h
is
/h
er
 p
oc
ke
ts
. S
ub
je
ct
 is
 s
ta
nd
in
g 
in
 th
e 
m
id
dl
e 
of
 th
e 
sc
al
e,
 
w
ei
gh
t e
ve
nl
y 
di
st
ri
bu
te
d 
on
 b
ot
h 
fe
et
. 
U
se
d 
th
e 
av
ai
la
bl
e 
de
vi
ce
s 
at
 th
e 
he
al
th
 
ce
nt
re
 
0,
5 
kg
 
N
or
w
ay
  
 
C
oh
or
t N
or
w
ay
  
 
19
94
-
20
03
 
H
U
B
R
O
; M
ea
su
re
d 
w
ith
ou
t s
ho
es
 a
nd
 w
ith
 li
gh
t c
lo
th
in
g 
E
le
ct
ro
ni
c 
H
ei
gh
t a
nd
 
W
ei
gh
t s
ca
le
  
0,
1 
kg
  
Po
la
nd
  
 
W
O
B
A
SZ
  
 
20
05
 
M
O
N
IC
A
 P
ro
to
co
l [
4]
; W
ith
ou
t o
ut
er
 g
ar
m
en
ts
 a
nd
 s
ho
es
 
C
om
m
en
t:
 p
or
ta
bl
e 
ba
th
ro
om
 s
ca
le
s 
(a
t h
om
e)
. 
B
au
er
 p
or
ta
bl
e 
ba
la
nc
e 
0,
2 
kg
  
20
4 
 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
Sl
ov
ak
ia
  
 
C
IN
D
I 
H
ea
lth
 
E
xa
m
in
at
io
n 
Su
rv
ey
  
20
03
 
E
H
R
M
 P
ro
to
co
l [
1]
; s
ta
nd
in
g,
 d
re
ss
ed
 
 
C
al
ib
ra
te
d 
di
gi
ta
l 
w
ei
gh
tin
g 
m
ac
hi
ne
 
0,
1 
kg
 
H
ea
lth
 S
ur
ve
y 
fo
r 
E
ng
la
nd
  
20
05
 
M
ea
su
re
d 
w
ith
ou
t s
ho
es
, h
ea
vy
 o
ut
er
 g
ar
m
en
ts
, h
ea
vy
 je
w
el
le
ry
, l
oo
se
 
ch
an
ge
 a
nd
 k
ey
s.
 M
ea
su
re
m
en
t p
os
iti
on
: f
ee
t t
og
et
he
r,
 h
ee
ls
 a
ga
in
st
 th
e 
ba
g 
ed
ge
 o
f 
th
e 
sc
al
e,
 a
rm
s 
ha
ng
in
g 
lo
os
el
y 
at
 th
ei
r 
si
de
s,
 h
ea
d 
fa
ci
ng
 f
or
w
ar
ds
. 
C
om
m
en
t:
 N
ot
 m
ea
su
re
d 
fr
om
 c
ha
ir
 b
ou
nd
 p
er
so
ns
, i
f 
pe
rs
on
 is
 to
o 
un
st
ea
dy
 o
n 
th
ei
r 
fe
et
 f
or
 th
e 
m
ea
su
re
m
en
t, 
pe
rs
on
 f
in
ds
 it
 p
ai
nf
ul
 to
 s
ta
nd
 
or
 s
ta
nd
 s
tr
ai
gh
t, 
el
de
rl
y 
pe
rs
on
 is
 to
o 
st
oo
pe
d 
to
 o
bt
ai
n 
a 
re
lia
bl
e 
m
ea
su
re
m
en
t o
r 
pe
rs
on
 is
 p
re
gn
an
t. 
E
le
ct
ro
ni
c 
ba
th
ro
om
 
sc
al
es
 
0,
1 
kg
  
U
K
  
 
Sc
ot
tis
h 
H
ea
lth
 
Su
rv
ey
 
20
03
 
M
ea
su
re
d 
w
ith
ou
t s
ho
es
, h
ea
vy
 o
ut
er
 g
ar
m
en
ts
, h
ea
vy
 je
w
el
le
ry
, l
oo
se
 
ch
an
ge
 a
nd
 k
ey
s.
 M
ea
su
re
m
en
t p
ro
to
co
l: 
fe
et
 to
ge
th
er
, h
ee
ls
 a
ga
in
st
 th
e 
ba
g 
ed
ge
 o
f 
th
e 
sc
al
e,
 a
rm
s 
ha
ng
in
g 
lo
os
el
y 
at
 th
ei
r 
si
de
s,
 h
ea
d 
fa
ci
ng
 
fo
rw
ar
ds
. 
C
om
m
en
t:
 N
ot
 m
ea
su
re
d 
fr
om
 p
re
gn
an
t w
om
en
. 
E
le
ct
ro
ni
c 
ba
th
ro
om
 
sc
al
e 
0,
1 
kg
 
C
an
ad
a 
 
 
C
an
ad
ia
n 
H
ea
lth
 
M
ea
su
re
s 
Su
rv
ey
  
20
07
 
Pe
rs
on
 is
 a
sk
ed
 to
 r
em
ov
e 
hi
s/
he
r 
fo
ot
w
ea
r,
 a
ny
 h
ea
vy
 a
cc
es
so
ri
es
 a
nd
 
em
pt
y 
th
ei
r 
po
ck
et
s.
 P
er
so
n 
is
 a
sk
ed
 to
 s
te
p 
on
 th
e 
ce
nt
er
 o
f 
th
e 
sc
al
e 
fa
ci
ng
 
m
ea
su
re
r,
 h
an
d 
at
 th
e 
si
de
 a
nd
 lo
ok
in
g 
st
ra
ig
ht
 a
he
ad
. 
C
om
m
en
t:
 N
ot
 m
ea
su
re
d 
of
 p
er
so
n 
is
 n
ot
 a
bl
e 
to
 s
ta
nd
 u
na
ss
is
te
d 
T
er
m
in
al
 s
ca
le
 
0,
1 
kg
 
20
5 
 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
U
SA
 
 
N
H
A
N
E
S 
 
 
20
05
-
20
06
 
O
nl
y 
un
de
rw
ea
r,
 w
om
en
 s
ho
ul
d 
w
ea
r 
un
de
rp
an
ts
. T
he
 p
er
so
n 
is
 s
ta
nd
in
g 
in
 
th
e 
ce
nt
er
 o
f 
th
e 
sc
al
e 
pl
at
fo
rm
 f
ac
in
g 
th
e 
re
co
rd
er
, h
an
ds
 a
t s
id
e,
 a
nd
 
lo
ok
in
g 
st
ra
ig
ht
 a
he
ad
 (
T
ol
ed
o 
el
ec
tr
on
ic
 w
ei
gh
t s
ca
le
).
 
C
om
m
en
t:
 I
f 
pe
rs
on
 is
 w
ei
gh
in
g 
m
or
e 
th
an
 2
00
 k
g 
(4
40
 p
ou
nd
s)
, w
ei
gh
t 
sh
ou
ld
 b
e 
m
ea
su
re
d 
us
in
g 
tw
o 
Se
ca
 d
ig
ita
l s
ca
le
s 
E
le
ct
ro
ni
c 
w
ei
gh
t s
ca
le
 
an
d 
di
gi
ta
l s
ca
le
 
 
 
20
6 
 
T
ab
le
 9
.3
 W
ai
st
 a
nd
 h
ip
 c
irc
um
fe
re
nc
e 
m
ea
su
re
m
en
t p
ro
to
co
ls
, d
ev
ic
es
 a
nd
 a
cc
ur
ac
y 
of
 th
e 
m
ea
su
re
m
en
ts
 in
 th
e 
pr
ev
io
us
 H
ES
s 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
C
ro
at
ia
  
C
ro
at
ia
n 
H
ea
lth
 S
ur
ve
y 
 
20
03
 
W
ai
st
: M
ea
su
re
d 
at
 th
e 
um
bi
lic
al
 le
ve
l 
Pl
as
tic
 s
tr
ip
e 
m
et
er
 
 
C
ze
ch
 R
ep
ub
lic
 
H
ea
lth
 L
if
es
ty
le
 a
nd
 
E
nv
ir
on
m
en
t  
20
04
 
M
O
N
IC
A
 P
ro
to
co
l [
4]
:  
M
ea
su
re
d 
in
 s
ta
nd
in
g 
po
si
tio
n 
in
 u
nd
er
ga
rm
en
ts
 
be
lt 
m
ea
su
re
 
0,
5 
cm
 
H
ea
lth
 2
00
0 
 
20
00
 
Su
bj
ec
t h
ad
 r
em
ov
ed
 a
ll 
cl
ot
he
s 
fr
om
 th
e 
up
pe
r 
bo
dy
 a
nd
 a
ls
o 
ou
te
r 
ga
rm
en
ts
 
fr
om
 th
e 
lo
w
er
 b
od
y.
 T
he
 s
ub
je
ct
 w
as
 s
ta
nd
in
g 
fe
et
 li
ttl
e 
ap
ar
t. 
 
W
ai
st
 c
ir
cu
m
fe
re
nc
e 
w
as
 m
ea
su
re
d 
be
tw
ee
n 
th
e 
lo
w
er
 r
ib
 m
ar
gi
n 
an
d 
ili
ac
 
cr
es
t. 
M
ea
su
re
r 
w
as
 s
itt
in
g 
in
 f
ro
nt
 o
f 
th
e 
su
bj
ec
t. 
T
he
 m
ea
su
re
m
en
t w
as
 
ta
ke
n 
w
hi
le
 s
ub
je
ct
 w
as
 b
re
ad
in
g 
ge
nt
ly
 o
ut
. 
H
ip
 c
ir
cu
m
fe
re
nc
e 
w
as
 m
ea
su
re
d 
fr
om
 th
e 
w
id
es
t p
ar
t o
f 
th
e 
hi
p.
 
C
om
m
en
t:
 I
f 
pe
rs
on
 w
as
 n
ot
 a
bl
e 
to
 s
ta
nd
 o
r 
w
as
 p
re
gn
an
t (
ov
er
 2
0 
w
ee
ks
) 
th
e 
m
ea
su
re
m
en
t w
as
 n
ot
 c
on
du
ct
ed
. 
M
ea
su
re
m
en
t t
ap
e 
0,
5 
cm
 
Fi
nl
an
d 
 
 
FI
N
R
IS
K
  
20
07
 
Su
bj
ec
t i
s 
as
ke
d 
to
 r
em
ov
e 
ou
te
r 
ga
rm
en
ts
, d
re
ss
 c
oa
ts
 a
nd
 s
w
ea
te
rs
 a
nd
 to
 
em
pt
y 
th
ei
r 
po
ck
et
s 
as
 w
el
l a
s 
to
 o
pe
n 
be
lts
 a
nd
 o
th
er
 p
os
si
bl
e 
tid
e 
cl
ot
he
s 
on
 
th
e 
w
ai
st
. S
ub
je
ct
 s
ta
nd
s 
fe
et
 li
ttl
e 
ap
ar
t, 
w
ei
gh
t e
ve
nl
y 
on
 b
ot
h 
fe
et
. T
he
 
di
st
an
ce
 b
et
w
ee
n 
fe
et
 is
 1
0-
15
 c
m
. M
ea
su
re
 is
 s
itt
in
g.
  
W
ai
st
 c
ir
cu
m
fe
re
nc
e 
is
 m
ea
su
re
d 
be
tw
ee
n 
th
e 
lo
w
er
 r
ib
 m
ar
gi
n 
an
d 
ili
ac
 
cr
es
t. 
Su
bj
ec
t i
s 
as
ke
d 
to
 b
re
at
h 
ge
nt
ly
 a
nd
 th
e 
m
ea
su
re
m
en
t i
s 
do
ne
 w
hi
le
 
br
ea
di
ng
 g
en
tly
 o
ut
. T
o 
en
su
re
 th
at
 th
e 
m
ea
su
re
m
en
t t
ap
e 
in
 o
n 
le
ve
l, 
th
e 
su
bj
ec
t c
an
 b
e 
as
ke
d 
to
 tu
rn
 o
n 
pl
ac
e 
fo
r 
90
 d
eg
re
es
. 
H
ip
 c
ir
cu
m
fe
re
nc
e 
is
 m
ea
su
re
d 
ov
er
 th
e 
bu
tto
ck
s 
M
ea
su
re
m
en
t t
ap
e 
0,
5 
cm
 
20
7 
 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
Fr
an
ce
 
N
at
io
na
l s
ur
ve
y 
on
 
nu
tr
iti
on
 a
nd
 h
ea
lth
  
20
06
 
W
H
O
 P
ro
to
co
l [
16
5]
: C
lo
th
in
g:
 n
o 
M
ea
su
re
m
en
t t
ap
e 
1 
cm
 
G
er
m
an
y 
 
 
G
er
m
an
 n
at
io
na
l h
ea
lth
 
ex
am
in
at
io
n 
an
d 
in
te
rv
ie
w
 s
ur
ve
y 
19
98
 
 
N
ot
 e
la
st
ic
 
m
ea
su
ri
ng
 ta
pe
 
 
Ir
el
an
d 
 
 
SL
A
N
 
 
20
06
 
W
ai
st
 E
H
R
M
 P
ro
to
co
l [
1]
; P
os
iti
on
: M
id
lin
e 
of
 th
e 
pa
rt
ic
ip
an
t's
 a
rm
pi
t, 
at
 th
e 
m
id
po
in
t b
et
w
ee
n 
th
e 
lo
w
er
 p
ar
t o
f 
th
e 
la
st
 r
ib
 a
nd
 th
e 
to
p 
of
 th
e 
hi
p 
i.e
. a
t t
he
 
na
ve
l o
r 
la
rg
es
t p
oi
nt
 a
t w
hi
ch
 th
e 
st
om
ac
h 
pr
ot
ru
de
s 
to
 th
e 
fr
on
t. 
C
lo
th
in
g:
 P
re
fe
ra
bl
y 
on
 b
ar
e 
sk
in
, b
ut
 w
he
re
 p
re
fe
rr
ed
 b
y 
th
e 
pa
rt
ic
ip
an
t o
ve
r 
lig
ht
 c
lo
th
in
g 
C
om
m
en
t:
 N
o 
hi
p 
m
ea
su
re
d.
 
T
ap
e 
m
ea
su
re
 
 
N
et
he
rl
an
ds
  
 
N
et
he
rl
an
ds
 H
ea
lth
 
E
xa
m
in
at
io
n 
Su
rv
ey
  
20
01
 
M
ea
su
re
d 
in
 a
 s
ta
nd
in
g 
po
si
tio
n 
w
ith
ou
t h
ea
vy
 o
ut
er
 g
ar
m
en
ts
.  
W
ai
st
: M
ea
su
re
d 
in
 th
e 
m
id
dl
e 
po
in
t o
f 
th
e 
ili
ac
 c
re
st
 a
nd
 th
e 
lo
w
es
t r
ib
 w
hi
le
 
th
e 
su
bj
ec
t w
as
 b
re
at
hi
ng
 o
ut
.  
H
ip
: m
ea
su
re
d 
fr
om
 th
e 
w
id
es
t p
oi
nt
. 
M
ea
su
re
m
en
t t
ap
e 
0,
5 
cm
 
20
8 
 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
N
or
w
ay
  
 
C
oh
or
t N
or
w
ay
  
19
94
-
20
03
 
M
ea
su
re
m
en
ts
 m
ad
e 
w
ith
 a
 f
le
xi
bl
e 
st
ee
l d
ev
is
e 
 
W
ai
st
 c
ir
cu
m
fe
re
nc
e 
as
 m
ea
su
re
d 
at
 th
e 
um
bi
lic
us
 w
hi
le
 s
ub
je
ct
 s
ta
nd
in
g 
an
d 
br
ea
th
in
g 
no
rm
al
ly
. I
n 
ob
es
e 
pe
rs
on
s,
 if
 u
m
bi
lic
us
 n
ot
 o
n 
th
e 
w
id
es
t, 
w
ai
st
 
w
as
 m
ea
su
re
d 
at
 it
s 
m
ax
im
um
 b
et
w
ee
n 
th
e 
lo
w
er
 r
ib
 a
nd
 th
e 
ili
ac
 c
re
st
 o
n 
th
e 
w
id
es
t. 
H
ip
 c
ir
cu
m
fe
re
nc
e 
w
as
 m
ea
su
re
d 
at
 th
e 
m
ax
im
um
 c
ir
cu
m
fe
re
nc
e 
ar
ou
nd
 th
e 
bu
tto
ck
s.
 
A
 f
le
xi
bl
e 
st
ee
l 
de
vi
se
 w
ith
 s
ca
le
 
un
til
 1
50
 c
m
.  
1 
cm
 
Po
la
nd
 
W
O
B
A
SZ
  
20
05
 
M
O
N
IC
A
 P
ro
to
co
l [
4]
: M
ea
su
re
m
en
t i
n 
st
an
di
ng
 p
os
iti
on
, w
ith
ou
t h
ea
vy
 
ou
te
r 
ga
rm
en
ts
 
In
se
rt
io
n 
ta
pe
 
0,
5 
cm
 
Sl
ov
ak
ia
 
C
IN
D
I 
H
ea
lth
  
20
03
 
C
IN
D
I 
Pr
ot
oc
ol
 [
16
6]
: S
ta
nd
in
g 
M
ea
su
re
 ta
pe
 
0,
1 
cm
 
U
K
 
H
ea
lth
 S
ur
ve
y 
fo
r 
E
ng
la
nd
 
 
20
05
 
R
em
ov
in
g 
al
l o
ut
er
 la
ye
rs
 o
f 
cl
ot
hi
ng
, s
uc
h 
as
 ja
ck
et
s,
 h
ea
vy
 o
r 
ba
gg
y 
ju
m
pe
rs
, c
ar
di
ga
ns
 a
nd
 w
ai
st
co
at
s,
 s
ho
es
 w
ith
 h
ee
ls
, t
ig
ht
 g
ar
m
en
ts
 in
te
nd
ed
 
to
 a
lte
r 
th
e 
sh
ap
e 
of
 th
e 
bo
dy
, s
uc
h 
as
 c
or
se
ts
, l
yc
ra
 b
od
y 
su
its
 a
nd
 s
up
po
rt
 
tig
ht
s 
an
d 
be
lts
. P
oc
ke
ts
 s
ho
ul
d 
be
 e
m
pt
ie
d.
 M
ea
su
re
d 
w
hi
le
 s
ta
nd
in
g 
er
ec
t i
n 
a 
re
la
xe
d 
m
an
ne
r 
(f
oo
ts
 a
bo
ut
 2
0-
30
 c
m
 a
pa
rt
) 
an
d 
br
ea
th
in
g 
no
rm
al
ly
, a
rm
s 
ha
ng
in
g 
lo
os
el
y 
at
 th
ei
r 
si
de
.  
W
ai
st
 m
ea
su
re
d 
w
hi
le
 th
e 
pa
rt
ic
ip
an
t w
as
 b
re
at
hi
ng
 o
ut
 g
en
tly
, f
ro
m
 th
e 
m
id
w
ay
 b
et
w
ee
n 
th
e 
ili
ac
 c
re
st
 a
nd
 th
e 
lo
w
es
t r
ib
.  
H
ip
 m
ea
su
re
d 
fr
om
 th
e 
w
id
es
t c
ir
cu
m
fe
re
nc
e 
ov
er
 th
e 
bu
tto
ck
s 
an
d 
be
lo
w
 th
e 
ili
ac
 c
re
st
. 
C
om
m
en
t:
 M
ea
su
re
m
en
t n
ot
 ta
ke
n 
is
 p
er
so
n 
is
 c
ha
ir
 b
ou
nd
, h
as
 a
 c
ol
os
to
m
y/
 
ile
os
to
m
y.
 
In
se
rt
io
n 
ta
pe
 
ca
lib
ra
te
d 
in
 m
m
, 
w
ith
 a
 m
et
al
 b
uc
kl
e 
at
 o
ne
 e
nd
. 
0,
1 
cm
 
20
9 
 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
T
he
 S
co
tti
sh
 H
ea
lth
 
Su
rv
ey
 
 
20
03
 
R
em
ov
in
g 
al
l o
ut
er
 la
ye
rs
 o
f 
cl
ot
hi
ng
, s
uc
h 
as
 ja
ck
et
s,
 h
ea
vy
 o
r 
ba
gg
y 
ju
m
pe
rs
, c
ar
di
ga
ns
 a
nd
 w
ai
st
co
at
s,
 s
ho
es
 w
ith
 h
ee
ls
, t
ig
ht
 g
ar
m
en
ts
 in
te
nd
ed
 
to
 a
lte
r 
th
e 
sh
ap
e 
of
 th
e 
bo
dy
, s
uc
h 
as
 c
or
se
ts
, l
yc
ra
 b
od
y 
su
its
 a
nd
 s
up
po
rt
 
tig
ht
s 
an
d 
be
lts
. P
oc
ke
ts
 s
ho
ul
d 
be
 e
m
pt
ie
d.
 M
ea
su
re
d 
w
hi
le
 s
ta
nd
in
g 
er
ec
t i
n 
a 
re
la
xe
d 
m
an
ne
r 
(f
oo
ts
 a
bo
ut
 2
0-
30
 c
m
 a
pa
rt
) 
an
d 
br
ea
th
in
g 
no
rm
al
ly
, a
rm
s 
ha
ng
in
g 
lo
os
el
y 
at
 th
ei
r 
si
de
.  
W
ai
st
 m
ea
su
re
d 
w
hi
le
 th
e 
pa
rt
ic
ip
an
t w
as
 b
re
at
hi
ng
 o
ut
 g
en
tly
, f
ro
m
 th
e 
m
id
w
ay
 b
et
w
ee
n 
th
e 
ili
ac
 c
re
st
 a
nd
 th
e 
lo
w
es
t r
ib
.  
H
ip
 m
ea
su
re
d 
fr
om
 th
e 
w
id
es
t c
ir
cu
m
fe
re
nc
e 
ov
er
 th
e 
bu
tto
ck
s 
an
d 
be
lo
w
 th
e 
ili
ac
 c
re
st
. 
C
om
m
en
t:
 M
ea
su
re
m
en
t n
ot
 ta
ke
n 
is
 p
er
so
n 
is
 c
ha
ir
 b
ou
nd
, h
as
 a
 c
ol
os
to
m
y/
 
ile
os
to
m
y 
In
se
rt
io
n 
ta
pe
 
ca
lib
ra
te
d 
in
 m
m
, 
w
hi
t a
 m
et
al
 b
uc
kl
e 
at
 o
ne
 e
nd
. 
0,
1 
cm
 
21
0 
 
C
ou
nt
ry
 
Su
rv
ey
 
Y
ea
r 
P
ro
to
co
l 
E
qu
ip
m
en
t 
A
cc
ur
ac
y 
 
C
an
ad
a 
 
 
C
an
ad
ia
n 
H
ea
lth
 
M
ea
su
re
s 
Su
rv
ey
 
20
07
 
N
o 
cl
ot
hi
ng
 o
n 
th
e 
m
ea
su
re
m
en
t a
re
a.
 P
er
so
n 
st
an
ds
 e
re
ct
 in
 a
 r
el
ax
ed
 m
an
ne
r 
w
ith
 a
rm
s 
ha
ng
in
g 
lo
os
el
y 
at
 th
e 
si
de
s.
  
W
ai
st
 m
ea
su
re
m
en
t: 
L
an
dm
ar
k 
bo
th
 s
id
es
 o
f 
th
e 
re
sp
on
de
nt
 b
y 
pa
lp
at
in
g 
th
e 
bo
tto
m
 o
f 
th
e 
ri
b 
ca
se
 a
nd
 th
e 
to
p 
of
 th
e 
ili
ac
 c
re
st
. M
ak
e 
a 
sm
al
l m
ar
k 
at
 e
ac
h 
bo
ny
 la
nd
m
ar
k 
an
d 
a 
m
ar
k 
at
 th
e 
m
id
-p
oi
nt
 b
et
w
ee
n 
th
es
e 
tw
o 
la
nd
m
ar
ks
 
us
in
g 
a 
w
as
ha
bl
e 
m
ar
ke
r.
 S
ta
nd
in
g 
on
 th
e 
re
sp
on
de
nt
’s
 s
id
e,
 p
la
ce
 th
e 
m
ea
su
re
m
en
t t
ap
e 
ar
ou
nd
 th
e 
tr
un
k 
in
 a
 h
or
iz
on
ta
l p
la
ne
 a
t t
he
 le
ve
l m
ar
ke
d 
on
 th
e 
ri
gh
t s
id
e 
of
 th
e 
tr
un
k.
 E
ns
ur
e 
th
at
 ta
pe
 is
 h
or
iz
on
ta
l. 
A
pp
ly
 te
ns
io
n 
to
 
th
e 
ta
pe
. I
ns
tr
uc
t t
he
 r
es
po
nd
en
t t
o 
br
ea
th
 n
or
m
al
ly
. T
ak
e 
th
e 
m
ea
su
re
m
en
t a
t 
th
e 
en
d 
of
 a
 n
or
m
al
 e
xp
ir
at
io
n.
 
H
ip
 m
ea
su
re
m
en
t: 
W
ea
ri
ng
 o
nl
y 
lig
ht
 c
lo
th
in
g,
 th
e 
re
sp
on
de
nt
 s
ho
ul
d 
st
an
d 
er
ec
t i
n 
a 
re
la
xe
d 
m
an
ne
r 
w
ith
 a
rm
s 
ha
ng
in
g 
lo
os
el
y 
at
 th
e 
si
de
s 
an
d 
w
ei
gh
t 
ev
en
ly
 d
is
tr
ib
ut
ed
 o
n 
bo
th
 f
ee
t. 
St
an
di
ng
 o
n 
th
e 
re
sp
on
de
nt
’s
 r
ig
ht
 s
id
e,
 p
la
ce
 
th
e 
m
ea
su
ri
ng
 ta
pe
 a
ro
un
d 
th
e 
bu
tto
ck
s.
 T
he
 m
ea
su
re
m
en
ts
 in
 ta
ke
n 
ov
er
 th
e 
cl
ot
hi
ng
. T
he
 ta
pe
 p
la
ce
d 
in
 a
 h
or
iz
on
ta
l p
la
ne
 a
t t
he
 m
ax
im
um
 c
ir
cu
m
fe
re
nc
e 
of
 th
e 
hi
ps
 o
r 
bu
tto
ck
s 
re
gi
on
. 
C
om
m
en
t:
 N
ot
 m
ea
su
re
d 
fr
om
 p
re
gn
an
t w
om
en
 (
> 
12
 w
ee
ks
).
 
T
ap
e 
m
ea
su
re
 
(1
50
cm
) 
0,
1 
cm
 
U
SA
 
N
H
A
N
E
S 
 
 
20
05
-
20
06
 
Pe
rs
on
 s
ta
nd
s 
so
 th
at
 m
ea
su
re
r 
is
 s
ta
nd
in
g 
be
hi
nd
 a
nd
 to
 th
e 
ri
gh
t f
ro
m
 th
e 
pe
rs
on
.  
W
ai
st
 c
ir
cu
m
fe
re
nc
e,
 b
et
w
ee
n 
th
e 
up
pe
rm
os
t l
at
er
al
 b
or
de
r 
of
 th
e 
ri
gh
t i
liu
m
 
an
d 
th
e 
m
id
ax
ill
ar
y 
lin
e 
of
 th
e 
bo
dy
. T
he
 c
or
re
ct
 p
os
iti
on
in
g 
of
 th
e 
m
ea
su
re
m
en
t t
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Table 9.4 Legal restrictions and other limitations for the use of mercury 
sphygmomanometers 
Country Is it allowed to use mercury 
sphygmomanometers in the country? 
Are there any limitations for the use of 
mercury sphygmomanometers in the 
country? 
Austria Yes No 
Belgium Yes It is getting difficult to find mercury 
sphygmomanometers on the Belgium market. 
Czech Republic Yes No 
Denmark Yes No 
Estonia Yes No 
Finland Yes No 
France Yes, but not in all examination centres No 
Germany Yes No 
Greece Yes No 
Hungary Yes No 
Italy Yes No 
Lithuania Yes No 
Luxembourg Yes No 
Macedonia Yes No 
Malta Yes No 
Netherlands Information not available Information not available 
Norway Yes Mercury devices not sold in the country any 
longer and also difficult to obtain service and 
calibration. 
Poland Yes No 
Slovakia Yes No 
Sweden Yes Mercury sphygmomanometers cannot be any 
longer cleaned or tested, which makes their use 
impossible. 
UK Information not available Information not available 
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Table 9.15 Protocols and used devices for the vision tests in the previous HESs 
Country Survey Year Name of 
measurement 
With or 
without 
glasses 
Procedure 
Finland Health 2000  2002 PrecisionVision 
Letter Chart Acuity 
Tests, Oriola 
With own 
glasses 
4 meter and 40 cm for all 
respondents  
Distance Visual Acuity Test (for 
4 meters) and Near Vision Test 
(for 40 centimetres) In at least 
350 lux and 9-11 lux lightning. 
USA NHANES  2003 Autorefractor/ 
Keratometer and 
Lensmeter 
With own 
glasses 
4 meter and 40 cm 
A) 12 years old and older when 
glasses are available, the best 
corrective vision. 
B) 12 years and older, current 
prescription. 
C) 50 years old and older, near 
visual acuity. 
Exclusion Criteria: Any 
evidence of injury (eye patch or 
bandage) or severe infection 
(i.e., purulent discharge with 
redness in eye) in both eyes. 
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Table 9.16 Protocols and used devices for hearing tests in the previous HESs 
Country Survey Year Name of 
measurement 
/ device 
Hz Room Comments 
Finland Health 
2000  
2000 Micromate 
304 , Madsen 
Electronics 
Audiometry 
500/ 1000/ 
2000 hz 
 The air conduction hearing 
threshold. 
Three frequencies 500, 1000 
and 2000 Hz tested with 
25dB-15dB- 5dB in a silent 
room. 
The lowest stimulation level 
was 5 dB 
USA NHANES  2003 Otoscope, 
tympanometer, 
audiometry, 
bioacoustic 
Simulator, 
Sound Level 
Meter 
Audiometry 
500-8000, 
1000, 2000, 
3000, 4000, 
5000 Hz 
Special sound 
proof cabine  
DEVICES:  
a) Otoscope: The Welch-
Allyn 25020 otoscope  
b) Tympanometer: The Micro 
Audiometers Earscan Acustic 
Impedence tympanometer  
c) Audiometry: The 
Interacoustics Model AD226 
d) Bioacustic Simulator: The 
Quest Model BA-201-25  
e) Sound Level Meter and 
Accessories: The Quest 
Model 1800  
Evaluation of hearing 
sensitivity and physiological 
function of middle and outer 
ear. 
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Talbe 9.17 Used devices and protocols for bone mineral density measurement in the previous 
HESs 
Country Survey Year Name of measurement / 
device 
Location Comments 
Finland Health 2000  2000 Sahara Clinical Bone 
Densitometer, Hologic  
Heel Bone mineral 
density 
Norway Cohort Norway 1994-
2003 
SXA: Osteometer DTX-100 / 
DXA: Lunar DPX-L  
SXA: distal and 
ultradistal radius / 
DXA: hip, total 
body and calcaneus 
 
USA NHANES  2003 Dual-energy X-ray 
Absorptiometry (DXA), 
Hologic QDR 4500A 
Arm The participant 
lies in supine 
position 
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Table 9.18 Used devices and protocols for lung functon measurement in the previous HESs 
Country Survey Year Type of device Measurement Comments 
Finland Health 2000 2000 Vitalograph 2150 FVC  
FEV 
PEF 
Bronkodilatation if FEV % 
lower thand 70% 
Ireland SLAN  2006 Microlife PF100 
peak flow digital 
meter 
PEF  
Health Survey 
for England  
2002 Portabel spirometer 
(Vitalograph  
Escort spirometer) 
FVC  
FEV 
PEF 
For those ages 7-24 years UK 
Scottish Health 
Survey  
2003 Vitalograph Micro 
spirometer 
FVC  
FEV 
PEF 
Measured if room temperature 
between 5-35C. Correct 
technique demonstrated first, 5 
technically satisfactory blows  
record 
Canada Canadian 
Health 
Measures 
Survey  
2007 Koko spirometer FVC 
FEV1 
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10. QUALITY ASSURANCE PROCEDURES 
 
Lucie Viet1 , Hanna Tolonen2, Kari Kuulasmaa2,  Monique Verschuren1 
1National Institute for Public Health and the Environment, Bilthoven, the Netherlands 
2 National Public Health Institute, Helsinki, Finland 
 
This chapter provides an overview of the quality assurance procedures that have been 
implemented in previous health examination surveys. Because information on quality control 
procedures are not always (extensively) reported in papers about the surveys, the information 
from previous surveys was collected by a specific questionnaire (‘Questionnaire of Survey 
Quality Assurance Procedures’, see Annex 4) sent to FEHES country contact persons. 
Quality control procedures can be implemented in different stages of the survey. In 
addition to choosing proper methods for the measurements it is important to take precautions 
before, during and after the study to ensure the best possible quality for the measurements and 
to facilitate proper interpretation of the results. It is important to avoid bias in measurements 
because a systematic bias which can lead to biased estimates. Before the actual study can be 
started, the selected personnel have to be trained properly. During the survey, performance of 
the fieldworkers has to be monitored and devices calibrated in regular bases. If needed, the 
fieldworkers should be retrained. After the fieldwork is completed, is it important to evaluate 
the collected data by checking possible inconsistent values.  
This chapter describes used training protocols, existence of written manuals and quality 
assurance protocols, and quality assurance procedures for different measurements. 
10.1 PROTOCOLS AND MANUALS 
10.1.1  CRITICAL ISSUES 
Protocols and manuals are the basis of collecting standardized data.  
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10.1.2 PREVIOUS HESS 
In all previous surveys, a written manual was available in the native language of the 
country. In 3 surveys a protocol for quality assurance was available and also the results of the 
quality assurance were documented. (Table 10.1) In one survey there was no protocol for 
quality assurance but the results of the quality assurance were documented. 
10.1.3 CONCLUSIONS 
In many cases the quality assurance procedures are planned for the survey, but they are 
not properly documented. Also, the results of the quality assurance procedures are rarely 
reported. 
10.2  TRAINING 
10.2.1  CRITICAL ISSUES 
Proper use and interpretation of the protocols has to be achieved through extensive 
training (and re-training) of the fieldworkers, in order to standardize all the measurements 
between the fieldworkers and between countries. A training seminar has to be conducted to 
practice all the measurements and get feed back on the performance. Fieldworkers should be 
aware of the critical issues for each measurement, and have some background knowledge in 
order to be capable to answer possible questions of the participants. 
10.2.2  PREVIOUS HESS 
In all previous surveys the personnel followed training varying from 2-15 days (table 
10.2). During this training all the topics of the examination were discussed such as the aim, 
methods and protocols. Training was given by expert people (nurses, doctors, epidemiologist 
or laboratory analyst).  
10.2.3 CONCLUSIONS 
The training of the fieldworkers is generally organized, but the extent of the training 
varies considerably between the countries.  
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10.3 QUALITY ASSURANCE OF HEIGHT MEASUREMENT 
10.3.1  CRITICAL ISSUES 
Critical for the quality assurance of the measurement of height is the calibration of the 
measurement device, before during and after the survey. E.g. when the measurement device is 
connected to the wall, the proper adjustment has to be checked. Furthermore, fieldworkers 
have to be instructed on the way how to read the scales, especially when the respondent is 
much taller than the fieldworker. Relevant for standardization is also site visits during the 
survey and the quality control of the data after the survey. 
10.3.2  PREVIOUS HESS 
In all previous HESs the measuring device was checked before the survey by the 
supplier, or by fieldworkers using a standardized rod (Table 10.3). During the previous 
surveys the measuring device was checked in almost all surveys. The frequency of the 
checking varied from daily to once a year. No calibration of the equipment was done in any 
previous survey after the fieldwork period. 
In some of the previous surveys, field visits were conducted during the survey period for 
quality assurance of the measurement. During these field visits (performed once a month or 
on an irregular basis), the coordinator of the project or epidemiologist used a checklist to 
verify the protocols that have been followed. If it was observed that the measurements were 
not performed according to the protocol, the fieldworkers would be retrained or corrections 
were made. After the survey the data was checked for extreme values. 
10.3.3  CONCLUSIONS 
For measuring height, the device was calibrated before and during the survey. During the 
survey period, performance of the measurements was be checked in the field, and if necessary 
fieldworkers would be retrained. Also after the survey the data was checked for extreme 
values. 
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10.4  QUALITY ASSURANCE OF WEIGHT MEASUREMENT 
10.4.1  CRITICAL ISSUES 
Critical for the quality assurance of the measurement of weight is the calibration of the 
measurement device, before during and after the survey. Furthermore, instruction on 
removing heavy garments and shoes, emptying pockets etc. should be standardized, as well as 
rules whom to exclude from the measurements (e.g. pregnant women). Relevant for 
standardization is also site visits during the survey and the quality control of the data after the 
survey. 
10.4.2  PREVIOUS HESS 
In some previous HESs, a new device was used for the survey, and it was assumed to be 
accurate (Table 10.4). In other previous surveys, the devices were calibrated by using a 
reference weights.  
In some of the previous surveys, the scales were not calibrated during the survey period, 
while in some; the devices were calibrated daily or on irregular basis, by the fieldworkers. 
Calibration after the survey was not generally conducted. 
For quality assurance of the measurement, field visits were conducted in some of the 
previous surveys during the survey period. During this field visits (once a month or on 
irregular basis), the coordinator of the project or epidemiologist used a checklist to verify the 
protocols that were followed. In one survey also double measurements were conducted. If 
irregularities were observed, the fieldworkers would be retrained or corrections were made. 
After the survey the data was checked on extreme values in five previous surveys. 
10.4.3   CONCLUSIONS 
For measuring weight, the device was not always calibrated before and during the 
survey. During the survey period the measurements were checked in the field by observing 
the performance of the field workers. Also after the survey the data was checked for extreme 
values. 
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10.5  QUALITY ASSURANCE MEASURING WAIST AND HIP 
CIRCUMFERENCES 
10.5.1  CRITICAL ISSUES 
Before the survey it is important to train the fieldworkers properly, because waist and hip 
circumference measurements are extremely sensitive to measurement error. For the 
measurement of waist and hip circumference the position of the tape round the participants’ 
waist and hip is a critical point in the measurement. Also the position of the participant can 
have an effect on the outcomes of the measurements. Furthermore, the tapes should be 
checked for ‘stretching’ during the course of the study. 
10.5.2  PREVIOUS HESS 
In almost all previous HESs, new tapes for measuring waist and hip circumference were 
used, assuming it was accurate (Table 10.5). In one previous survey all the tapes were 
checked with a calibrated rod. During and after the survey the tapes were not calibrated. In 
one survey, a new tape was changed every month. Quality assurance during the survey was 
done by field visits in all previous surveys. During these field visits (once a month or on 
irregular basis), the coordinator of the project or the epidemiologist used a checklist to verify 
if the protocols were followed properly. In one survey, also double measurements were 
conducted. If irregularities were observed, the fieldworkers were retrained or corrections were 
made. After the survey the data was checked for extreme values. 
10.5.3   CONCLUSIONS 
The measuring tape was not calibrated. During the survey period the measuring of waist 
and hip circumference was checked in the field. Also after the survey, the data was checked 
for extreme values 
10.6  QUALITY ASSURANCE OF BLOOD PRESSURE MEASUREMENT 
10.6.1  CRITICAL ISSUES 
It is important to avoid bias in blood pressure measurement because a systematic bias of 
a few mmHg can be significant for the interpretation of the results. Important aspects of the 
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methods are proper equipment and its correct use and proper measurement procedures. The 
possible sources of error in the blood pressure measurement can be divided in to three 
categories: observer bias, faulty equipment and failure to standardize the 
techniques/circumstances of the measurement [1]  
Critical issues relating to the observer bias are: 
• hearing test, 
• training and testing or certification with standardized taped examples of 
Korotkoff sounds,  
• testing or certification using a Y-tube stethoscope, 
• repeated measurements of the same subjects, and 
• evaluation of terminal digit preference. 
 
Critical issues relating to the equipment are: 
• measurement devices should be checked and calibrated on a regular basis 
 
Critical issues relating to the technique/circumstances are: 
• use of the proper cuff-size, 
• control of room temperature, and 
• resting time before and between the measurements. 
 
Quality control during the survey: 
• checking terminal digit preference, 
• checking intra-measurer variation, and 
• regularity of the checks. 
10.6.2  PREVIOUS HESS 
In the previous surveys, the calibration of the device before the survey was generally 
done by the manufacturer using a standard procedure (Table 10.6).  
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In one survey, the mercury sphygmomanometers were checked daily by fieldwork 
personnel. Automatic devices were calibrated 3 times per year or once in 2 years. Previous 
surveys did not calibrate the used device after the survey. In a few surveys quality control 
during the survey was conducted by making field visits or double measurements. In case of 
any problems the fieldworkers were retrained. In one survey, the fieldworkers rotated between 
the survey sites. Also the measurement results were checked weekly by the central office. In 
one survey there was a rotation program for the automatic device. In all previous surveys the 
data was checked after the survey was finished. 
10.6.3  CONCLUSIONS 
The level of quality assurance procedures varied considerably between surveys. All 
surveys had some quality control during the survey and generally fieldwork personnel were 
re-trained if some problems were observed. 
10.7  QUALITY ASSURANCE OF THE BLOOD SAMPLES – COLLECTON AND 
ANALYSIS 
10.7.1  CRITICAL ISSUES 
Proper calibration of the measurement instruments is essential for the precision and 
accuracy of the measurements. In addition to fixing the procedures to be used for the 
measurements, it is important that the fieldworkers involved in the measurements are fully 
familiar with the measurements and have the skills to carry them out. Especially, the 
fieldworkers who draw the blood samples and prepare them for transfer to the laboratory, as 
well for the laboratory personnel.  
10.7.1.1 INTERNAL QUALITY CONTROL (IQC) 
The purpose of internal quality control is to check the short and long term stability of 
measurements. A good performance is necessary for successful participation in an external 
quality control program and for reliable analysis of the survey samples. 
10.7.1.2 EXTERNAL QUALITY CONTROL (EQC) 
EQC is a retrospective process of assessment of performance, particularly of inaccuracy 
or bias with respect to mean values. EQC permits comparison of results between laboratories 
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measuring the same analyte. An EQC scheme for an analyte or group of analytes distributes 
aliquots of the same samples to participating laboratories, which are blind to the concentration 
of the analytes. Samples are assayed shortly after they arrive at the laboratory. Results are 
returned to the scheme organizers, who issue a laboratory specific report giving at least the 
following data: 
• Mean values, usually for all methods and for method groups; 
• A measure of the between-laboratory precision; 
• The bias of the results obtained by that laboratory. 
10.7.2  PREVIOUS HESS 
In previous surveys the procedure for taking blood samples during the fieldwork was 
checked during the field visits and using checklist on irregular basis. For the quality 
assessment for analyze lipids, in all surveys an internal quality scheme was used. In most of 
the surveys also an external quality scheme was used. For the measurement of glucose, all 
surveys followed an internal quality scheme. In most of the surveys also an external quality 
scheme was used. (Table 10.7) 
10.7.3  CONCLUSIONS 
All laboratories which analyzed the lipid and glucose in previous surveys, had a IQC and 
most also took part to the EQC. Like IQC also the EQC should be taken into account when 
starting a HES. 
10.8  QUALITY ASSURANCE OF PHYSICAL PERFORMANCE AND FITNESS 
TESTS 
10.8.1  CRITICAL ISSUES 
No recommendations exist for measuring manual dexterity, range of motion or grip 
strength in the population health survey settings. For testing the range of motion or dexterity 
there are no common recommendations or standards. Also there are no quality assurance 
procedures for these measurements.  
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10.8.2  PREVIOUS HESS 
10.8.2.1 PHYSICAL PERFORMANCE 
The physical performance tests were included only into one survey. There was no 
calibration before the survey. During the survey there was a site visit during which the 
performance of the fieldworkers was checked against the protocol step by step once per 
survey period. (Table 10.8) 
10.8.2.2 PHYSICAL FITNESS 
Physical fitness tests were not included to any of the surveys. 
10.8.3  CONCLUSIONS 
For the measurement of physical performance and physical fitness, the proper training of 
the personnel doing the measurements is important. 
10.9 QUALITY ASSURANCE OF VISION AND HEARING TESTS 
10.9.1 CRITICAL ISSUES 
In hearing tests environment and equipment (calibration) may affect the results obtained. 
The most widely used and standardized test of visual function is measurement of visual 
acuity. In seeing and hearing tests environment and equipment (calibration) may affect the 
results obtained. Those responsible for conducting the examinations (hearing and vision) must 
be trained experts. Good instructions help the subjects to perform as intended. Instruments 
must be calibrated to yield correct readings. 
10.9.2 PREVIOUS SURVEYS 
The vision and hearing tests were not included into any of the previous surveys. 
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10.9.3  CONCLUSIONS 
For both hearing and vision tests it is important to monitor the settings on which the 
measurements are done, to train the personnel well as well as check the used devices 
regularly. 
10.10  QUALITY ASSURANCE OF BONE DENSITY AND LUNG FUNCTION 
MEASUREMENTS 
10.10.1 CRITICAL ISSUES 
To guarantee the accuracy and reliability of the pulmonary function testing system used 
for measuring lung function, the manufacturer has to guarantee that the system meets all 
specifications issued by the ATS/ERS [2]. The user is responsible for ensuring that the 
equipment’s measurements (lung function, and bone density) remain accurate, and results 
furthermore depend on the cooperation between subject and examiner. 
10.10.2 PREVIOUS SURVEYS 
10.10.2.1 BONE DENSITY 
The bone density was measured in one survey. The measurement device was calibrated 
before the survey and daily during the survey. Calibration was done by means of measuring a 
phantom. This was done by the technician or researcher who performed the measurements. 
(Table 10.9) 
Calibration after the survey was done by comparing the SXA and DXA measured with 
other comparable devices. Quality control during the survey was done by audits, double 
measurement and distribution checks by senior researcher. Corrections were made only for 
the room or water temperature. After the survey all measured (photos) were checked manually 
for QA. 
10.10.2.2 LUNG FUNCTION 
The lung function was measured in one survey. The measurement device was calibrated 
by the manufacture before the survey and by the nurse at the start of each day during the 
survey. (Table 10.10) 
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During the survey, results were imputed on computer, which had a build-in system to 
check extreme values. Site visits were conducted occasionally to see that protocol was 
followed. 
10.10.3 CONCLUSIONS 
For the lung function and bone density measurements, it is important to use calibrated 
equipment and check them regularly during the survey. Personnel should be trained very well.  
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11. RESOURCES USED IN AND COST OF PREVIOUS HEALTH 
EXAMINATION SURVEYS 
 
Hanna Tolonen1, Päivikki Koponen1  
1National Public Health Institute, Helsinki, Finland 
 
11.1  INTRODUCTION 
We attempted to get an idea about the resources needed for and the costs of a national 
health examination survey (HES), and about the relative magnitude of various components of 
the total cost. A questionnaire (see Annex 5) was sent to contact persons for nine previous 
national health examination surveys in five countries: 
• Finland: Health 2000 [1], FINRISK 2002 [2], FINRISK 2007 
• Germany: Bundes-Gesundheitssurvey 1998 (BGS98) [3], Studie zur 
Gesundheit bei Kindern und Jugendlichen in Deutschland (KiGGS) 2003-2006 
[4] 
• The Netherlands: Module Endogenous Factors 2005-2006  
• Norway: Health Survey among 40-42 years old in 5 counties 1999 (HS40-42) 
[5] 
• UK: Health Survey for England 2004 [6], Scottish Health Survey 2003 [7] 
The questionnaire concerned the resources used for the planning, sampling, training, 
material preparation, equipments, field work, quality control and reporting of the results. For 
each section, cost (€) was also asked. However, it was evident that budget information was 
difficult to compare due to different ways of constructing the budget in different surveys. 
From some surveys (UK) it was not possible to obtain the budget information in detail or at 
all due to confidentiality of the budgets in cases when the organization carrying out the survey 
was selected on the basis of a call for tender.  
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Before drawing conclusions about the similarities and differences between resources 
used in and costs of the previous surveys, it is important to understand the differences in the 
survey organization, methods, and field work practices (Table 11.1, see also Chapter 4). The 
sample size of these nine HESs varied from 1,000 to 49,900 with crude response rates 
(participants/sample size) between 54% and 84%. In all surveys there were self-administered 
questionnaires; there were also face-to-face interviews in Finland, Germany and the UK.  In 
the Norwegian survey, the examinations were conducted in mobile unit, while in two UK 
surveys; all examinations were conducted at the home of the participant. In other surveys, 
either specially hired premises or existing health care facilities were used as examination 
clinics.  
It is very difficult to compare the surveys, since different combinations of measurements 
were used in each survey. The average duration of the examinations was used as an indicator 
to describe the extent of the examinations. It varied from 15 minutes, including only basic 
anthropometric measurements, blood pressure and simple blood sampling, to 240 minutes of 
extensive physical measurements, dental examinations, etc. 
11.2  PLANNING OF THE SURVEY 
The planning stage of the survey takes from a few months to a couple of years, 
depending on the scope of the survey. If the HES is limited to the few basic measurements 
(weight, height, blood pressure and total cholesterol), the planning of the survey can be done 
by a few persons (researcher/senior researcher) but in extensive HESs like the Finnish Health 
2000 survey, the planning involved over 100 persons with different fields of expertise. In 
many countries, the personnel responsible for planning the survey contents, logistics and 
organization are the staff of the public organizations such as public health institutes. 
Therefore they plan the survey as part of their other official duties. In such cases, the 
personnel costs of the planning stage are often omitted from the survey budget. (Table 11.2) 
Resources needed for planning depend also on the time interval between the surveys, the 
scope of previous surveys, and previous experience of the persons doing the planning. E.g. in 
Finland, the planning of the Health 2000 survey was based on a previous survey carried out 
20 years earlier and several changes in the survey methodology and technology had to be 
taken into account, while assuring comparability between the survey results. However, as the 
Health Survey for England is carried out continuously (every year) planning involves the 
overall programme of surveys; the core module of the survey which is repeated every year, 
and the specific modules and characteristics for each year. 
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11.3  SAMPLING 
One of the important stages of the survey organization is the determination of required 
sample size and the actual selection of the sample. In this stage, personnel with expertise in 
sampling are needed to assess the required sample size and to plan and conduct the sample 
selection. In cases where good, up-to-date sampling frames exist, like in all surveys included 
in this review, no extra effort is needed for the construction of the sampling frame. We 
obtained information only from the Finnish, Dutch and Norwegian surveys about the sample 
selection (Table 11.3). In Finland, another organization drew the sample from the national 
Population Information System (bought service) while in the Netherlands, the Municipal 
Health Centres drew their samples from the population registers. In Norway the entire birth 
cohort was examined, therefore there was no sample selection but information about the birth 
cohort needed to be obtained from the population register. 
11.4  PREPARATION OF THE MATERIALS AND INFRASTRUCTURE NEEDED 
FOR THE SURVEY 
Part of the survey organization is the preparation of the materials (leaflets, 
questionnaires, feedback letters, etc.) and infrastructure (computers, computer programs for 
booking, computer aided personal interviews (CAPI), toll-free phone numbers for participants 
to obtain more information/to change their appointments etc.). Information about the prepared 
materials and infrastructure was obtained for all surveys except for the German ones. Some 
printed materials, such as questionnaires, were prepared in all surveys. In most of the surveys, 
much additional material, such as advanced letters, information leaflets and informed consent 
forms, were also prepared and printed. The length of the questionnaires (affecting the cost) 
varied from a few pages to series of booklets. In the Finnish surveys, computer programmers 
(three persons in Health 2000 and one in FINRISK surveys) were employed to prepare the 
required computer programmes for the appointment booking system and data entry and to 
serve as computer support to the survey fieldwork staff. In the budgets obtained, no specific 
money was allocated for data management. In the Finnish surveys, the data management was 
done as part of official duties. In the UK surveys, a computer aided personal interview was 
conducted and a computer program was also used during the health examination/nurse visit, 
so specific personnel for the preparation and maintenance of CAPI system are required in 
addition to a data manger. (Table 11.4)  
11.5  TRAINING OF THE FIELDWORK PERSONNEL 
The training of the fieldwork personnel is one of the crucial steps in the survey 
organization. In all surveys reviewed, formal training was organized. The scope of the 
training is very much dependent on the extent of the survey, i.e. what measurements are 
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conducted in the survey. In Finland, in the Health 2000, which had very large number of 
different measurements, the training took 15 days while in the FINRISK surveys which are 
much more limited, the training lasted 10 days. In the Netherlands the training lasted only one 
day and in the UK two days. In the UK, only updates are needed annually since the staff is 
permanent. The training was generally organized by researchers and senior nurses with 
special expertise in the measurements. (Table 11.5) 
11.6  HEALTH EXAMINATION FIELDWORK 
The actual fieldwork costs cover hiring the personnel needed to conduct the examinations 
in the field, buying or leasing the needed equipment, and the costs of examination sites, travel 
and logistics (Table 11.6). This is the most expensive component of the survey (41%-88% of 
the total costs). Personnel costs in total (including fieldwork personnel, personnel for 
supporting activities, laboratory personnel, etc.) are the biggest individual cost (52%-71%). 
These costs are not directly comparable between surveys, due to differences in the preparation 
of the budget. For example in the Finnish surveys, the laboratory analyses are not included in 
the main survey budget since handling and analysis of the samples was part of the tasks of the 
laboratory in the National Public Health Institute, while they are included in the German 
survey budgets. Furthermore, these percentages may be affected by our interpretations of the 
budgets. The number of personnel and the length of their working period vary considerably 
between surveys. This relates to the scope of the survey and survey models. Whenever 
personal interviews are included in the surveys, the number of personnel (interviewers) 
needed for fieldwork also increases substantially. 
Information about the amount of used equipments (measurement devices, types, ect.) was 
difficult to obtain. Anyhow, these sources depend on the measurements, persons examined, 
parallel activities and duration.   
11.7  REPORTING THE SURVEY RESULTS 
In the Finnish, Norwegian, German and UK surveys, results of the survey have been 
reported in several scientific articles in local and international journals (Table 11.7). Preparing 
basic printed reports and their Internet versions is also common. This of course facilitates the 
dissemination of the results to a larger audience. It is difficult to estimate the actual resources 
used for the preparation of the basic reports, since these reports are often prepared by the 
researchers as part of their official duties without separately allocated funding, except for 
printing costs. 
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11.8  AVERAGE COST OF THE SURVEYS 
The total cost of the surveys varies from slightly over 120,000.00 € to 7,500,000.00 € 
(Table 11.8). These figures are not comparable, since the number of persons examined in 
different surveys varied considerably, as did the scope and the model of the survey. There are 
also major differences in what has been included into the provided budgets (salaries of the 
persons working in governmental institutes, laboratory analysis, piloting, etc.). In general, the 
price of the survey increases together with the number of persons examined. Of course, the 
number of measurements increases the need for additional staff and costs. Surveys with face-
to-face interviews are more expensive than those where only questionnaires are filled in by 
participants (self-administration).  
11.9  MAIN SOURCES OF FUNDING  
The sources of funding vary (Table 11.9). In general, previous HESs have been funded 
by governmental organizations. In some countries, there is one funding organization while in 
some other countries; the funds have been obtained from several different sources, including 
governmental and non-governmental organizations, such as foundations or associations for 
HES-related fields. Obtaining funding from commercial sources as well would probably be 
possible but none of the nine surveys included in this review had used any commercial 
funding. 
11.10  CONCLUSIONS 
The resources used in different surveys depend on the size (number of invited persons), 
scope and model of the survey. The more measurements we include in the survey, the more it 
will cost. It also costs more if face-to-face or telephone interviews are used instead of self-
administration of the questionnaires. These are basic elements depending on the aims and 
logistics of the survey. They may also affect the quality of the data. Understandably, the 
resources available will affect both the extent of the survey and its cost.  
In all the reviewed surveys, personnel costs were the biggest cost category, followed by 
laboratory analysis of the blood samples. However, the sample of countries available for this 
review of costs is not representative of the EU as a whole. Thus, varying salary levels may 
affect personnel costs and varying prices of the equipment and laboratory analysis the total 
cost. We hope that this analysis is useful for the planning of future surveys.  
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Table 11.2 Personnel resources used for the planning and length of the planning 
Country Survey  Year Planning 
Health  2000 Personnel resources: Done by about 130 senior researchers from 
different participating organizations with special expertise. 
Planning was mainly done by senior researches as part of their 
official duties.  
Length: Planning took about 18 months.  
2002 Personnel resources: Done by senior researchers of the National 
Public Health Institute as part of their official duties.  
Length: Planning took about one year. 
Finland 
FINRISK 
2007 Personnel resources: Done by senior researchers of the National 
Public Health Institute as part of their official duties.  
Length: Planning took about one year. 
BGS 1998 Information not available. Germany 
KiGGS 2003-
2006 
Information not available 
Netherlands Module 
Endogenous 
Factors 
2005-
2006 
Personnel resources: Done by one researcher and one senior 
researcher.  
Length: Planning took a few weeks. 
Norway HS40-42 1999 Personnel resources: Done by one physician researcher, one senior 
advisor, one advisor and one leading nurse.  
Length: Planning took about 6 months. 
Health Survey 
for England 
2004 Information not available UK 
Scottish Health 
Survey 
2003 Information not available 
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Table 11.3 Resources used for sampling 
Country Survey Year Sampling 
Health 2000 2000 By special organization from the national population register. 
Two stage sample. 
2002 By special organization from the national population register. 
Finland 
FINRISK 
2007 By special organization from the national population register. 
BGS 1998 Information not available. Germany 
KiGGS 2003-
2006 
Information not available. 
Netherlands Module 
Endogenous 
Factors 
2005-
2006 
By Municipal Health Centre from the population register. 
Norway HS40-42 1999 Whole birth cohort was invited. The information was obtained 
from the population register. 
Health Survey 
for England 
2004 3-stage household sampling with the existing sampling frames. 
No information about the organization of the sampling 
available. 
UK 
Scottish 
Health Survey 
2003 3-stage household sampling with the existing sampling frames. 
No information about the organization of the sampling 
available. 
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Table 11.6 Duration of the fieldwork, number of fieldwork personnel and % of budget for 
fieldwork and for personnel 
Fieldwork % of total budget Country Survey Year 
Duration Number of 
personnel 
Fieldwork# 
Personnel 
costs§ 
Health 2000 2000 The fieldwork 
personnel were 
employed for 8 
months. The teams 
travelled from 
survey site to the 
other. 
160 interviewers 
10 physicians 
5 dentists 
6 dental 
hygienists 
65 nurses 
89% 58% 
2002 The fieldwork 
personnel were 
employed for 3.5 
months. The teams 
travelled from 
survey site to the 
other. 
6 nurses 
12 laboratory 
assistants 
6 practical nurses 
84% 68% 
Finland 
FINRISK 
2007 The fieldwork 
personnel were 
employed for 3 
months. The teams 
travelled from 
survey site to the 
other. 
5 nurses 
10 laboratory 
assistants 
10 practical 
nurses 
75% 71% 
BGS 1998 Fieldwork lasted 6 
months 
Information not 
available 
41% 52% Germany 
KiGGS 2003-
2006 
Information not 
available 
Information not 
available 
56% 69% 
Netherlands Module 
Endogenous 
Factors 
2005-
2006 
The field work 
personnel were 
employed for 6 
months. 
  
Medical 
receptionist 
Doctors’ 
receptionist 
44% 58% 
Norway HS40-42 1999 1 year, except in 
the school holidays 
(15th of June – 20th 
of August). 
12 nurses 
3 receptionists/ 
bus drivers 
Information 
not available 
Information 
not available 
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Fieldwork % of total budget Country Survey Year 
Duration Number of 
personnel 
Fieldwork# 
Personnel 
costs§ 
Health Survey 
for England 
2004 17 months Interviewers 
Nurses 
Information 
not available 
Information 
not available 
UK 
Scottish 
Health Survey 
2003 19 months Interviewers 
Nurses 
Information 
not available 
Information 
not available 
# incl. personnel, equipments, examination site rents, logistics, travels 
§ incl. fieldwork personnel, supporting personnel, laboratory personnel, etc. 
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Table 11.7 Reporting of the results 
Country Survey Year Reporting 
Health  2000 2000 Printed basic report also published in pdf-format on the 
internet prepared by researchers and senior researchers. Later 
on number of scientific journal articles. 
2002 Printed tabulation report on the key results also in pdf-format 
on the internet prepared by researchers and senior 
researchers. Later on number of scientific journal articles. 
Finland 
FINRISK 
2007 Printed tabulation report on the key results also in pdf-format 
on the internet prepared by researchers and senior 
researchers. Later on number of scientific journal articles. 
BGS 1998 A number of scientific articles, including special supplements 
of German journals 
Germany 
KiGGS 2003-
2006 
A number of scientific articles, including special supplements 
of German journals. 
The 
Netherlands 
Module Endogenous 
Factors 
2005-
2006 
Previously reported in Public Health Forecasts. 
Norway HS40-42 1999 Basic report with comparison to the earlier surveys. 
Health Survey for 
England 
2004 Basic reports: Key findings and Methodology and 
documentation prepared by researchers and senior 
researchers (also available on the internet) 
Later on number of scientific journal articles. 
UK 
Scottish Health Survey 2003 Basic reports: Key findings and Methodology and 
documentation prepared by researchers and senior 
researchers (also available on the internet) 
Later on number of scientific journal articles. 
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Table 11.8 Total cost of the survey and an average cost per invited and per participated 
person (costs adjusted for annual inflation, reference to year 2007) 
Average cost (€) Country Survey Year Total cost (€) 
per invited per participant 
Health 2000 2000 4,954,155.00 617.00 702.00 
2002 749,990.00 55.00 78.00 
Finland 
FINRISK 
2007 812,900.00 81.00 121.00 
BGS98 1998 3,628,948.00 275,00 510.00 Germany 
KiGGS 2003-
2006 
7,516,074.00 456,00 681,00 
Netherlands Module Endogenous 
Factors 
2005-
2006 
128,528.00 129,00 197.00 
Norway HS40-42 1999 5,593,752.00 113,00 173.00 
Health Survey for 
England 
2004 Information not 
available 
Information not 
available 
Information not 
available 
UK 
Scottish Health 
Survey 
2003 3,673,463.00 271,00 450.00 
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Table 11.9 Main sources of funding 
Country Survey Year Main source of funding 
Health 2000 2000 The Ministry of Social Affairs and Health, 
National Public Health Institute (KTL), 
Social Insurance Institute of Finland (KELA), 
Finnish Institute of Occupational Health (TTL), 
Finnish Centre for Pensions, 
National Research and Development Centre for Welfare 
and Health (STAKES), 
The Local Government Pensions Institute, 
The Finnish Work Environment Fund, 
Finnish Dental Association  
2002 National Public Health Institute (KTL) for main 
component, 
for additional component from different organizations like 
the Finnish Academy 
Finland 
FINRISK 
2007 National Public Health Institute (KTL) for main 
component, 
for additional component from different organizations like 
the Finnish Academy 
BGS 1998 Ministry of Health, 
Ministry of Research and Education, 
Ministry of Agriculture and Nutrition 
Germany 
KiGGS 2003-
2006 
Ministry of Health, 
Ministry of Research and Education, 
Ministry of Agriculture and Nutrition 
Netherlands Module Endogenous 
Factors 
2005-
2006 
Ministry of Public Health, Welfare and Sports 
Norway HS40-42 1999 Governmental funds 
Health Survey for 
England 
2004 NHS Health and Social Care Information Centre UK 
Scottish Health Survey 2003 Scottish Executive 
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12. SUMMARY AND DISCUSSION: FEASIBILITY OF A EUROPEAN 
HEALTH EXAMINATION SURVEY 
 
Kari Kuulasmaa1, Arpo Aromaa1, Susanna Conti2, Sidsel Graff-Iversen3, Päivikki 
Koponen1, Paola Primatesta4, Hanna Tolonen1,  Monique Verschuren5  
1 National Public Health Institute, Helsinki, Finland 
2 Istituto Superiore di Sanita, Rome, Italy 
3 Norwegian Institute of Public Health, Oslo, Norway 
4 University College London, London, United Kingdom 
5 National Institute of Public Health and Environment, Bilthoven, Netherlands 
 
The purpose of this report was to document and assess the existing experience and 
knowledge on conducting health examination surveys (HESs). This was done in order to 
assess the feasibility of carrying out a European HES. Important in this assessment was the 
help of the FEHES network of contact persons in 32 countries. This included all EU member 
states, candidate countries, and EFTA/EEA countries (except Liechtenstein). The contact 
persons were mostly people with expertise in HESs. Therefore they reflect the expert view 
rather than the official view of the countries. Other important information sources were the 
literature and databases on literature and on surveys, such as the European Health Interview 
and Health Examination Survey Information Database (see Chapter 4). 
The topic for the assessment was a national HES in the adult population. Both "national" 
and "population" are important attributes to specify when the intention is to assess the health 
status of the population for the planning of prevention policies or the need and optimal 
allocation of health care resources. 
12.1  WHAT TO MEASURE IN A HES 
HES measurements should fulfil the following criteria:  
• The measurements must address important health topics, such as major 
modifiable risk factors of common diseases and functional limitations, or the 
prevalence of diseases and health conditions relevant for the planning and 
evaluation of health and other policies or health care; 
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• Reliable and standardizable instruments and procedures that are suitable for 
national population surveys must be available for the measurements; 
• The instruments and procedures should be acceptable to participants; and be 
ethically acceptable. 
• The information provided by the measurements should not be much more 
easily available from other data sources, such as registers or health interview 
surveys. 
 
In the past, in Europe, all national and major regional HESs have included the 
measurement of height, weight and blood pressure, and nearly all have also included waist 
and hip circumference (see Chapter 8). Most have collected blood samples for the 
measurement of lipids, in particular total and HDL cholesterol, and about half of them have 
measured blood glucose. These all fulfil the above criteria (see Chapter 9). The blood samples 
have also been used for a large number of other disease or risk markers. Other measurements 
often used that fulfil the above criteria include full respiratory function (spirometry) or peak 
expiratory flow (PEF), electrocardiography for cardiovascular function, tests for physical 
fitness, functional capacity, and mental and cognitive function. A number of other 
measurements have been used less frequently. 
All of the contact persons considered HESs important as sources of data on blood lipids, 
blood pressure, body weight, diabetes, cardiovascular diseases and respiratory diseases (see 
Chapter 4). More than half the contact persons considered HESs very important also for 
mental health problems and musculoskeletal problems. All contact persons considered 
international standardization of the measurements important, suggesting that it is considered 
important also from the national point of view that the countries can compare their results 
with those of other countries. Furthermore, countries that have experience from 
internationally standardized HESs, value the feedback obtained from external quality control 
and the ability to exchange their plans and experiences with colleagues conducting surveys in 
other countries. Lack of funding was considered to be the main obstacle for a national HES, 
but it was felt that it is much easier to obtain national funding if international coordination and 
standardization are available. 
12.2  TECHNICAL IMPLEMENTATION OF A HES 
Concerning the technical implementation of a HES, there are, in some countries, serious 
challenges to obtaining representative samples of the general population and in achieving 
sufficiently high participation rates. These are essential so that the potential response bias 
does not undermine the value of the whole survey. About half of European countries have up-
to-date population registers covering practically the entire resident population. These are ideal 
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sampling frames. Where these are not available, the best sampling frames are census lists, 
electoral rolls or postcode address lists. It is usually possible to get good representative 
samples from these sources, but the sampling may become more tedious and complex. For 
example, when the sampling frame covers only persons living in private households, 
supplementary sampling frames should be sought for institutionalized persons. If sampling is 
based on a census, it may be wise to plan the year of the HES in such a way that a fresh 
census can be used. 
It is essential that a sincere effort is made to obtain true samples of the whole population, 
and to secure high participation rates. Participation rates below 80 or 90% are too low to 
assess the prevalence of some diseases and functional limitations in the elderly. On the other 
hand in young adults and middle-aged persons findings on health behaviour and symptoms 
may be reasonably correct even at participation rates of 70 %. There has been a general 
tendency towards decreasing response rates over the past couple of decades. However, there 
are good examples from the past decade that the response rate can be kept high, although this 
requires a serious effort, and additional allocation of funds for effective recruitment 
approaches (see Chapter 7). Young adults tend to have particularly high non-response, and in 
some cases this may even be the reason for considering the exclusion of the youngest adult 
age group (below 25 years, or sometimes even below 35) from the target population. One 
reason for this is that many young adult people are working, studying or travelling far away 
from their registered address. 
The health examinations are usually carried out in clinics with specially trained 
personnel. As the clinics cannot be located far from the survey participants, a national survey 
must in practice be conducted in a limited number of locations. This can be possible in a 
representative survey by the use of a multi-stage sampling method. The clinics are established 
in the selected localities, usually in one or a few at a time, and the trained survey teams move 
from one locality to the next. In the NHANES surveys in the United States, mobile clinics are 
established in trailers, and these are moved from municipality to municipality. In the English 
and Scottish surveys, the measurements are done in participants' homes, but then the selection 
of measurements has to be fairly simple. It is possible that different approaches, depending on 
the national characteristics, will be adopted for the European HES in different countries. 
Of the measurements mentioned above for which standardized methods are available, 
there is specific concern about the measurement of blood pressure (see Chapter 9). The 
current gold standard of blood pressure measurement is based on the use of the mercury 
sphygmomanometer, but there are pressures against the use of mercury and there are practical 
advantages of automated measurement. For the time being there is no proven alternative to 
the mercury sphygmomanometer. It is especially problematic that no alternative method that 
would ensure comparability over time is available. However, there is rapid development of 
automated blood pressure measurement devices, and it can be expected that reliable 
alternatives will be available before the mercury sphygmomanometer must be abandoned for 
use in HESs. Another concern is about blood glucose. This must be measured from samples 
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taken after overnight fasting. Therefore, it is usually practical to do it only in the subgroup of 
the subjects that are measured in the mornings. 
12.3  EXPERTISE AND EXPERIENCE IN THE COUNTRIES 
There appears to be more expertise in carrying out a HES in the European countries than 
we first anticipated. Some form of a national HES has been implemented in the past or is 
currently ongoing in 13 of the 32 countries (see Chapter 4). According to the FEHES contact 
persons, in 22 of the countries there is no difficulty at all in finding the necessary expertise in 
national research or public health organizations, and in no country was this seen to be very 
difficult. Nevertheless, receiving international expert advice for HESs was considered 
important in 30 countries (see Chapter 4). 
It is advisable that countries without earlier experience of large HESs keep the number of 
different measurements limited in their first HES. This is because a HES is a complex 
process, where the quality tends to suffer if all relevant aspects are not given sufficient 
attention throughout the survey, or if the examinations take too long for the participants.  
Another challenge to cross-European standardization concerns the countries which 
already have an established HES system. When the locally used standard differs from the 
agreed European standard (whatever it will be), the country may have to choose between 
comparability between countries and the ability to monitor trends over time. In each case, 
specific attention will be needed to find a satisfactory solution to dealing with this problem. 
12.4  INTERNATIONAL COORDINATION 
Past experiences suggest that the only way to obtain comparable data is to use joint 
protocols and international co-ordination, training and quality control. In order that 
international comparability of the HES data be possible, a responsible body will be needed 
which develops and maintains European standards, organizes training for the use of the 
standards, conducts external quality control, and evaluates the success of the standardization 
in each country. Currently, the most recent internationally widely comparable HES data come 
from the WHO MONICA Project, which collected data on the classic risk factors for 
cardiovascular disease (weight, height, blood pressure and blood cholesterol). These data are 
now over 10 years old; no internationally comparable population level data even on these 
measurements are available in Europe from the past ten years. 
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12.5  ETHICAL AND LEGAL ISSUES 
Ethical and legal issues in HESs concern the rights and the protection of the survey 
participants, but there may also be legislation and ethical obligations for those responsible of 
health policies to monitor the public health. There are both similarities and differences 
between countries in the requirements for safeguarding privacy and obtaining informed 
consent. It is important that the national requirements are met, but also that sufficient 
internationally agreed measures are taken in all countries. Therefore, it is advised that 
international advice be made available for those planning and conducting national HESs, and 
that the measures taken nationally will be subject to international quality control. 
12.6  COST OF A HES 
We attempted to collect comparable estimates of the cost of recent HESs in Finland, 
Germany, the Netherlands, Norway and England (see Chapter 11). The attempt was not very 
successful because the components of the costs were not comparable between the countries. 
For example, there were differences in the way the salaries of contributing public officials, 
laboratory costs and piloting were reported. Nevertheless, it was obvious that the cost per 
participant of the most expensive surveys was many times higher than in the cheapest survey. 
Of course, costs were directly affected by the contents of the survey and the number of 
persons examined. Face-to-face interviews compared with self-administered questionnaires 
also increased the cost. In all cases, personnel costs were more than half of the total budget, 
and the laboratory analyses constituted the second biggest component. In some surveys, all of 
the funding came from the Ministry of Health (or equivalent), but often also from other 
governmental bodies, which were stakeholders of the HESs. In the Health 2000 survey in 
Finland, which was the most comprehensive of those conducted in Europe, nine governmental 
or non-governmental organizations were involved. 
The total benefit from a HES is impossible to quantify, and therefore it would be very 
difficult to do a reliable cost-benefit analysis. However, countries that have established HES 
systems, such as England, Finland and the United States, consider HESs an integral part of 
their health system, and to our knowledge have not considered giving up the regular HESs. In 
addition to the planning and evaluation of health policies and health care, HES data are 
widely used also for other research in these countries. 
12.7  CONCLUSIONS 
We conclude that it is feasible to carry out some form of a HES, including at least some 
core measurements, in a nationally representative sample in nearly all European countries. A 
key prerequisite for this is that sufficient funding will be available for conducting the surveys, 
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including also proper planning of the survey and the analysis, interpretation and reporting of 
the results. Another key prerequisite for comparability between countries is that 
standardization and advice in planning the surveys is organized internationally. We think that 
this should be organized by knowledgeable Public Health Institutes and financed by EU/DG 
Sanco. If the two above conditions are met, we believe that most countries have the local 
expertise and other capacities to organize a national HES. 
We also believe that whenever possible, the responsibility of planning and conducting 
the HES should be at the national level. This increases the local motivation for high quality of 
the HES, and is important for the selection of the nationally most important measurements. 
The national infrastructure and other national aspects such as habits, public and professional 
attitudes and health information needs can be taken into account. This approach also 
facilitates the training of national experts for the proper analysis and interpretation of the 
survey results. 
The motivation for carrying out a collaborative HES is high in Europe. There are active 
plans for a national HES in the next five years in 17 countries (see Chapter 4). This finding 
gives a unique opportunity for creating a European HES. The other side of this coin is that 
many countries seem to be taking steps toward national HESs now so it is possible that the 
opportunity for European standardization will be missed. Therefore, the European 
infrastructure for a joint standardized HES should be established as soon as possible. The first 
task is to facilitate the planning and the standardization of national HESs in the countries that 
plan to start their HESs in the next few years. The full-size HESs in these countries would 
constitute a set of pilots for the European HES. 
It would be wise to include in the first round both countries with little recent experience 
on HESs and countries with an existing HES system. In countries with little experience, the 
focus would be on setting up the HES. In countries with earlier experience, the focus could be 
on harmonizing older and newer procedures and also supporting the new countries. 
Our experience suggests that one to two years are needed to set up a HES. To 
achieve international standardization, two years is probably a better estimate. After running 
the field work of the HES, one needs to reserve at least two to three years for data editing and 
basic reporting. Again, European aspects may cause some additional time demands. 
The FEHES Project is preparing a separate report on specific recommendations for the 
European HES in adults.  The feasibility of a European HES in children and adolescents 
should be assessed separately, probably when there is more experience on such surveys. 
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ANNEX 2. QUESTIONNAIRE ON HES IN EUROPE 
Previous and planned HES in your country 
By  “Health Examination Survey “ (HES), we mean a sample survey of the general 
population at the national or major regional level for the purpose of health monitoring and 
possibly epidemiological research. A HES includes at least some clinical measurements or 
procedures, such as anthropometric measurements, blood pressure measurements and/or 
blood samples. Usually, a HES also includes an interview and/or a self-administered 
questionnaire. 
We have already carried out a review of previous and planned HESs, with the aim of 
evaluating the level of previous experience and expertise in each country. The draft review is 
available at http://www.ktl.fi/fehes/internal/WP4/review_draft1.htm. If you have forgotten the 
name and/or password for the FEHES internal website, please contact us. 
You may wish to look at the draft review before filling in this questionnaire. 
In the review we have identified the following HES(s) in (country name): 
Name of the survey Year Type of survey: National/regional  Reference 
                            
                            
                            
 
1. Are you aware of other HESs in your country in the past 10 years?  
Name of the 
survey 
Year 
Institute 
responsible for 
this survey 
Name of contact 
person(s) 
E-mail address 
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2. Please provide the name(s) of all of the organisations/institutions that in your opinion 
have the necessary expertise to conduct national HESs in your country (e.g. national or 
regional public health institutes, universities and other research organizations): 
      
      
      
3. Are there currently plans for a national or major regional HES(s) in (country name)? 
 No plans at all (go to question 5) 
 Yes there are some preliminary plans, but no decisions yet  
 Yes, a decision has been made to carry out a survey(s)  
 
4. For each planned survey, please specify the following aspects, if available: 
A. Survey name                 , year(s)      
Organisation(s) responsible for the planning and coordination of this survey: 
      
      
      
Name(s) and address(es) of contact person(s), including e-mail addresses: 
      
      
      
Geographic area:  
 Entire country  
 Region(s), specify      
Age range: from       years to       years 
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Sample size:       persons       households 
Will the survey be targeted to cover:  
 The general population  
 Specific population groups, please specify        
  
B. Survey name         , year(s)       
Organisation(s) responsible for the planning and coordination of this survey: 
      
      
      
      
Name(s) and address(es) of contact person(s), including e-mail addresses: 
      
       
      
Geographic area:  
 Entire country  
 Region(s), specify      
Age range: from min       years to       years 
Sample size:       persons,       households 
Will the survey be targeted to cover:  
 The general population  
 Specific population groups, please specify       
 
C. Please copy the above template if needed for additional surveys 
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Additional comments to previous and planned HES in your country:  
      
      
      
Availability of sampling frames 
 5. What sampling frames of the general population are available in your country? (By 
“sampling frame” we mean a list of people from which the sample is selected.) 
  
Yes, 
national 
Yes, regional or 
local 
Not 
available 
Population register    
Census data    
Health or social insurance register    
Electoral rolls    
Other sampling frame, please specify: 
         
6. If more than one sampling frame is available, which of them would be the most 
suitable for a HES?  
      
 7. Specify the coverage of the sampling frame in Question 6? 
  Yes No 
All ages   
All persons, regardless of employment status   
Institutionalised persons   
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All residents, including non-citizens   
 
8. How frequently is this sampling frame updated for e.g., deaths, births, migration and 
address information? 
 Continually 
 Periodically, at least once a year 
 Less frequently, specify       
Additional comments on the availability of sampling frames: 
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General aspects affecting the feasibility of conducting a HES in 
your country 
 9. How would you assess the level of difficulty in addressing the following issues before 
a national HES could be conducted in your country? 
  
Not difficult 
at all 
Somewhat 
difficult 
Very 
difficult 
Availability of national funding    
Recognising the need to improve health 
information 
   
Accepting the value of health information 
obtainable only by HES 
   
Availability of expertise in national research and 
public health organizations 
   
Raising interest of these organisations to carry 
out HES 
   
Raising interest in HES among the general 
population (e.g., willingness to participate) 
   
Additional comments on general aspects affecting the feasibility of HES in your country:  
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10. How important do you consider HES as a source of information for the following 
topics in your country (at present or potentially in the future)? 
  
Not important 
at all 
Somewhat 
important 
Very 
important 
Risk factors for major chronic diseases: 
  Blood pressure    
  Blood lipids    
  Body weight and height    
Functional capacity: 
  Hearing    
  Vision    
  Mobility    
  Cognitive capacity    
  Activities of daily living    
Prevalence of specific diseases and public health problems: 
  Diabetes    
  Cardiovascular diseases    
  Respiratory diseases    
  Musculoskeletal problems    
  Mental health problems (e.g., depression)    
Other topics, specify 
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Ethical and legal aspects of HESs 
11. An important aspect of HESs is the protection of personal data, and the rights of the 
survey participants. In your country, which laws, decrees and guidelines have to be 
taken into account when conducting a HES? 
  Relevance for HES in your country 
  No
Yes, specify the name(s) and the year(s) that 
the law(s)/guideline(s) were created  
Data protection act         
Medical research act         
Act regulating the status and/or rights 
of patients 
        
National ethical principles of research 
involving human subjects 
        
International biomedical research 
guidelines  
        
Other, specify              
12. In your country is there a commonly accepted or recommended informed consent 
form that should be used in HESs, or specifications regarding issues that should be 
covered in the consent form for HESs? 
 Yes 
 No 
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13. When conducting a HES in your country, does the study protocol have to be 
approved by:  
  Yes No
A national ethics committee   
Regional or local ethics committees   
Other committees or bodies, specify        
Additional comments on ethical and legal issues in your country: 
      
      
      
  
Practical aspects of HESs 
14. How feasible would it be to conduct the fieldwork for a HES in your country in the 
following environments? 
  
Not 
feasible at 
all 
Fairly/somewhat 
feasible 
Very 
feasible 
Home visits    
Mobile units (e.g., buses or trailers)    
Normal health care facilities/offices (e.g., 
health centres, GP surgeries, hospital clinics) 
   
Rented premises for temporary clinics    
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15. In many countries, the following measurements are carried out by specially trained 
nurses or laboratory technicians, whereas in others a physician is needed to carry out 
the measurements. What is the situation in your country? 
  
Needs to be carried 
out by a physician 
Needs to be carried out in 
the presence of  
a physician or a physician 
needs to be available  
during the examinations 
No 
physician  
is needed  
 
Blood pressure 
measurement 
   
Drawing blood samples    
Measurement of lung 
function by spirometry 
   
Electrocardiogram (ECG)    
Additional comments on practical aspects: 
      
      
      
  
International aspects of HESs 
16. International standards and protocols are developed to increase the comparability of 
data. This also enhances implementation in countries with less experience in national 
HESs. However, a possible drawback in countries that already have a tradition of 
national surveys is that the application of international standards and protocols could 
impede the assessment of time trends. How would you rate the importance of the 
following for a national HES in your country? 
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Not important 
at all 
Important 
Very 
important 
Adoption of international standards    
Continued use of national standards to follow 
national time trends 
   
International collaboration for quality control    
17. Assuming that there would be two alternatives for a European HES, i.e., conducted 
as a part of a national survey or a totally separate survey, how do you consider these 
approaches for your country?  
  
Not at all 
likely 
Somewhat 
likely 
Very 
likely 
A national survey incorporating some topics/modules 
to meet the international needs 
   
Participation in a separate internationally 
standardised survey 
   
18. Assuming that the international co-ordination and much of the international 
standardisation would be funded by an outside source (e.g., by the European 
Commission or research funds), do you think that national funding could be found for 
the local fieldwork in your country? 
 No, not at all likely 
 Yes, somewhat likely 
 Yes, very likely  
19. How important would you consider receiving international expert consultation for a 
HES in your country? 
 Not important at all 
 Somewhat important 
 Very important 
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Additional comments on international aspects: 
      
      
      
 
Any other additional comments 
Please provide any other comments concerning the feasibility of a HES in your country. 
      
      
      
      
 Thank you very much for your collaboration! 
Return to: 
Päivikki Koponen 
paivikki.koponen@ktl.fi 
 
National Public Health Institute 
Department of Health and Functional Capacity 
Mannerheimintie 166 
00300 Helsinki 
FINLAND 
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ANNEX 3. SOME QUESTIONS ON RECRUITMENT AND 
PARTICIPATION  
 
If Health Examination Surveys (HES) have been conducted in your country, please answer 
for the most recent HES (national or regional):  
 
Survey name: 
Year: 
 
If no HES, but Health Interview Surveys (HIS) have been conducted, please answer for 
the most recent HIS (national or regional):  
 
Survey name:  
Year:  
 
IT IS POSSIBLE TO CHECK MORE THAN ONE ANSWER FOR MOST QUESTIONS: 
1.         How was the general public informed? 
□         newspapers  
□         radio  
□         television  
□         internet (survey websites)  
□      other means, please specify     
2.         How were the selected persons/households contacted? 
□         mailed invitation letter  
□         Visit 
□         Phone     
□         other means, please specify __________        
 
(Which of these was the first contact: First contact by letter, phone, or visit? If the first contact 
was by mail, did it contain a survey questionnaire in addition to the invitation letter?) 
  
325
 
 
3.       Did participants receive any compensation, reimbursement or gift? 
□        No 
□         reimbursement of travel expenses to all participants 
       □        reimbursement of travel expenses to participants with certain criteria            
     (please specify the criteria) 
□         a small gift (pen with logo, lottery ticket, telephone card etc) sent with the  
           invitation  
□         other (specify) __________       
  
4.         Did you make particular efforts to recruit certain minorities (e.g. ethnic, 
people with intellectual disability, or other disabled or illiterate persons)? 
□         no 
□         “user-friendly” lay-out of written materials  
□         personal assistance (by telephone__? on site?___) 
□         written materials in ___ languages  
□         culturally adapted written materials  
□         staff trained or selected for examination of minorities   
□         interpreter on site   
□         collaboration with authorities or representatives for relevant groups  
□         other efforts, please specify ___________ 
              
Please specify which groups were addressed by the above specific means 
 
            _________________________ 
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5.         In case of non-response (to the first invitation): were the subjects re-
contacted? 
□         No  
□         mailed letter, only 
□         mailed letter with the full survey questionnaire 
□         mailed letter with a shortened questionnaire     
□        Telephone_call 
□        Home visit(s) 
□         other means, please specify __________        
Could you please briefly describe the process of attempting to contact the person 
before he/she was considered to be a definite non-respondent? (eg. first an invitation 
letter, then phone call, and finally a visit to address etc.) 
What was the maximum number of attempts after the first invitation?  
 
6.         Which were, in your opinion, the most effective strategies to increase the 
response rate? 
  
7.         Did you collect any health information from the non-respondents?  
□        no 
□         a shortened examination protocol (e.g. home visit if not attending the 
clinic visit)   
□         a short mailed questionnaire 
□         a short telephone interview 
 
8.         Did you ask why people refused to participate?  
□         no 
□        yes, please list the main reasons 
Do you have other information on reasons for non-response?  
 
             Please specify   __________ 
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9.         Was any basic information (e.g. sex, age, marital status…) collected from the 
definite non-respondents?  
□        No.  
       □         information available in the sampling frame 
□         information from other registers. Please specify __________ 
 
If the response or recruitment issues have been documented, could you please give 
the reference(s) or attach a copy?   
 
Thank you for spending your time on sharing this important information with us! 
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ANNEX 4. QUESTIONNAIRE OF SURVEY QUALITY ASSURANCE 
 
 
 
 
Questionnaire of Survey Quality Assurance Procedures 
Instructions 
Please, fill in the questionnaire for the survey indicated in the first page of the 
questionnaire. We have already filled in all the information we were able to obtain from the 
data sources we had. Please, check the correctness of this information. 
In case the measurement in question is not done in the survey in question, please mark 
that information to the questionnaire. 
You can find the filled questionnaire for Finnish Finrisk 2007 survey from the FEHES 
internal web site at http://www.ktl.fi/fehes/internal/WP6/quality_questionnaire_Finrisk07.pdf 
if you want to see the level of details we would like to get from you.
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Survey information 
Country:       
Survey name:       
Year(s) of the survey:       
Months when the survey was conducted:  
 January 
 February 
 March 
 April  
 May  
 June  
 July 
 August 
 September 
 October 
 November 
 December 
 
Days of the week when the survey was conducted: 
  Monday 
 Tuesday 
 Wednesday 
 Thursday 
 Friday 
 Saturday 
 Sunday 
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Hours of day when the examinations were conducted:       -        
 
Selection and training of the fieldwork personnel 
 
Was there a special selection criterion for the fieldwork personnel? 
 Yes 
 No 
If yes, please specify:      
 
Type and number of fieldwork personnel:  
Profession Number 
Doctor/ physician      
Nurse     
Laboratory technician      
Physiotherapist      
Dentist      
Dental hygienist      
Psychologist      
Interviewer      
Nutritionist      
Medical receptionist      
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Training: 
 Duration:       days 
 Trained by:      
Which topics did the training cover:       
Was the specific certification of personnel required (for example for blood 
pressure measurement)? 
  Yes 
  No 
If yes, please specify:      
 
Written manual and protocols 
Did the survey have a written description (document including background of the 
survey, measurements included, information about the parties involved, ect.)?  
  Yes 
  No 
 If yes, has the description been published? 
   Yes, where:       and on which language:       
   No 
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Did the survey have a written manual (a detailed, step by step instructions for 
each measurement)? 
  Yes 
  No  
 If yes, has the manual been published? 
   Yes, where:       and on which language:       
   No 
Quality assurance protocols and results 
Has the used quality assurance protocols been documented? 
  Yes 
  No 
If yes, how:       and on which language:       
 
Has the results of the quality assurance been documented? 
  Yes 
  No 
If yes, how:    and on which language:    
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Quality assurance of the measurements 
Height 
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
Device:  
Type:      
Model:       
 Calibration 
Calibration before the survey:  
How:     
By whom:       
Calibration during the survey: 
How:     
By whom:      
Frequency:       
Calibration after the survey:  
How:     
By whom:       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):      
How frequently quality of the measurements was checked:      
By whom the quality of the measurements was checked:     
What was done if it was observed that there was some problems with 
measurements:      
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 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:     
Weight 
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
Device:  
Type:      
Model:       
 Calibration 
Calibration before the survey:  
How:       
By whom:       
Calibration during the survey:  
How:      
By whom:     
Frequency:       
Calibration after the survey:  
How:     
By whom:       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):     
How frequently quality of the measurements was checked:     
By whom the quality of the measurements was checked:       
What was done if it was observed that there was some problems with 
measurements:      
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 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:     
Waist and hip circumference 
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
Device:  
Type:       
Model:       
 Calibration 
Calibration before the survey:  
How:     
By whom:       
Calibration during the survey:  
How:     
By whom:       
Frequency:       
Calibration after the survey:  
How:    
By whom:       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):      
How frequently quality of the measurements was checked:      
By whom the quality of the measurements was checked:     
What was done if it was observed that there was some problems with 
measurements:       
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 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:     
Blood pressure 
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
Device:  
Type:       
Model:       
 Calibration 
Calibration before the survey:  
How:     
By whom:       
Calibration during the survey:  
How:     
By whom:     
Frequency:      
Calibration after the survey:  
How:      
By whom:       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):    
How frequently quality of the measurements was checked:      
By whom the quality of the measurements was checked: )    
What was done if it was observed that there was some problems with 
measurements:     
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 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:      
Blood samples (for lipids and glucose) 
 Was the blood sample(s) collected? 
   Yes, proceed to next question 
   No, proceed to next measurement 
Sample collection 
Was blood sample collected after fasting? 
  Yes 
  No 
 If yes, length of the fasting period     
Position of the subject during the sample collection: 
  Sitting 
 Supine   
Was the blood sample collected before blood pressure measurement? 
  Yes 
 No 
Was the tourniquet used during the blood sample collection? 
  Yes 
  No 
 If yes, for how long period:      
Sample handling on the field 
Were samples centrifuged on the field? 
  Yes 
  No 
 If yes, please describe the procedure:     
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How samples were stored on the field? 
Temperature:     
Duration:     
Quality control on the field 
Describe the fieldwork quality control procedures during the survey (for example 
audits, ect.):    
How frequently the fieldwork quality of the measurements was checked:   
By whom the fieldwork quality of the measurements was checked:     
What was done if it was observed that there was some problems with 
measurements:    
Laboratory analysis 
 Lipids 
 Was the total cholesterol determined? 
   Yes 
   No 
 Was the HDL cholesterol determined? 
   Yes 
   No 
Laboratory doing cholesterol analysis:     
Did the analysing laboratories have internal quality assessment scheme?  
 Yes  
 No 
If yes, please describe:    
Did the analysing laboratories participate to the external quality assessment 
schemes? 
  Yes  
 No 
If yes, please describe:      
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Cholesterol determined from  
  Plasma 
  Serum 
 If plasma, used anticoagulant:       
Methods used for total cholesterol determination:      
Method used for HDL cholesterol determination:      
Glucose 
Was the glucose determined? 
  Yes 
 No 
Laboratory doing glucose analysis:     
Did the analysing laboratories have internal quality assessment scheme?  
 Yes  
 No 
If yes, please describe:     
Did the analysing laboratories participate to the external quality assessment 
schemes? 
  Yes  
 No 
If yes, please describe:    
Glucose determined from  
  Plasma 
  Serum 
 If plasma, used preservative:      
Method used for glucose determination:      
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Physical performance tests  
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
 What measurements tests included:       
Device:  
Type:       
Model:       
 Calibration 
Calibration before the survey (how and by whom):       
Calibration during the survey (how, by whom and frequency):       
Calibration after the survey (how and by whom):       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):       
How frequently quality of the measurements was checked:       
By whom the quality of the measurements was checked:       
What was done if it was observed that there was some problems with 
measurements:       
 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:       
 
Physical fitness tests 
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
 What measurements tests included:       
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Device:  
Type:       
Model:       
 Calibration 
Calibration before the survey (how and by whom):       
Calibration during the survey (how, by whom and frequency):       
Calibration after the survey (how and by whom):       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):       
How frequently quality of the measurements was checked:       
By whom the quality of the measurements was checked:       
What was done if it was observed that there was some problems with 
measurements:       
 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:       
Lung function   
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
 What measurements tests included:       
Device:  
Type:       
Model:       
 Calibration 
Calibration before the survey (how and by whom):       
Calibration during the survey (how, by whom and frequency):       
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Calibration after the survey (how and by whom):       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):       
How frequently quality of the measurements was checked:       
By whom the quality of the measurements was checked:       
What was done if it was observed that there was some problems with 
measurements:       
 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:       
Hearing 
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
Device:  
Type:       
Model:       
 Calibration 
Calibration before the survey (how and by whom):       
Calibration during the survey (how, by whom and frequency):       
Calibration after the survey (how and by whom):       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):       
How frequently quality of the measurements was checked:       
By whom the quality of the measurements was checked:       
What was done if it was observed that there was some problems with 
measurements:       
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 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:       
Vision 
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
Device:  
Type:       
Model:       
 Calibration 
Calibration before the survey (how and by whom):       
Calibration during the survey (how, by whom and frequency):       
Calibration after the survey (how and by whom):       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):       
How frequently quality of the measurements was checked:       
By whom the quality of the measurements was checked:       
What was done if it was observed that there was some problems with 
measurements:       
 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:       
ECG 
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
Device:  
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Type:       
Model:       
 Calibration 
Calibration before the survey (how and by whom):       
Calibration during the survey (how, by whom and frequency):       
Calibration after the survey (how and by whom):       
 Quality control during the survey 
Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):       
How frequently quality of the measurements was checked:       
By whom the quality of the measurements was checked:       
What was done if it was observed that there was some problems with 
measurements:       
 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:       
Bone density 
 Was the measurement done in the survey? 
   Yes, proceed to the next question 
   No, proceed to the next measurement 
Device:  
Type:       
Model:       
 Calibration 
Calibration before the survey (how and by whom):       
Calibration during the survey (how, by whom and frequency):       
Calibration after the survey (how and by whom):       
 Quality control during the survey 
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Describe the quality control procedures during the survey (for example 
audits, double measurements, checking of the data distributions, ect.):       
How frequently quality of the measurements was checked:       
By whom the quality of the measurements was checked:       
What was done if it was observed that there was some problems with 
measurements:       
 Quality assessment after the survey 
Describe the quality assessment protocols (for example how data was 
checked or correct values) after the survey:       
  
Urine samples 
 Was the urine sample(s) collected? 
   Yes, proceed to next question 
   No, proceed to next measurement  
 Sample collection 
  How the sample was collected:       
 Sample handling on the field 
  How samples were handles and stored on the field:       
 Quality control on the field 
Describe the fieldwork quality control procedures during the survey (for 
example audits, double measurements, checking of the data distributions, ect.): 
      
How frequently fieldwork quality of the measurements was checked: 
      
By whom the fieldwork quality of the measurements was checked: 
      
What was done if it was observed that there was some problems with 
measurements:       
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 Laboratory quality control 
What was analysed from the urine samples:       
Laboratory doing the analysis:       
Did the analysing laboratory have internal quality assessment scheme? 
      Yes 
 No 
If yes, please describe: 
Did the analysing laboratory participate to the external quality assessment 
scheme? 
  Yes 
  No 
 If yes, please describe:       
Saliva samples 
 Was the saliva sample(s) collected? 
   Yes, proceed to next question 
   No, proceed to next measurement  
 Sample collection 
  How the sample was collected:     
 Sample handling on the field 
  How samples were handles and stored on the field:    
 Quality control on the field 
Describe the fieldwork quality control procedures during the survey (for 
example audits, double measurements, checking of the data distributions, ect.): 
  
How frequently fieldwork quality of the measurements was checked: 
      
By whom the fieldwork quality of the measurements was checked: 
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What was done if it was observed that there was some problems with 
measurements:       
 Laboratory quality control  
What was analysed from the saliva samples:       
Laboratory doing the analysis:       
Did the analysing laboratory have internal quality assessment scheme? 
     Yes 
 No 
If yes, please describe: 
Did the analysing laboratory participate to the external quality assessment 
scheme? 
  Yes 
  No 
 If yes, please describe:       
  
Comments 
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Thank you for your help! 
 
Please,  
return this questionnaire to  
Hanna Tolonen (hanna.tolonen@ktl.fi)  
by 8 February 2008 
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ANNEX 5. EVALUATION OF THE COST OF THE PREVIOUS HESS IN 
THE EU MEMBER STATES 
Basic information about the survey 
 
Country: 
Year of the survey:  
Name of the survey:  
Responsible organization(s):  
Geographical area covered: 
Sample size: 
Brief description of the sampling procedures: 
Sample age range: 
Included institutionalized persons: YES / NO 
Questionnaire items were filled in 
1. During the home interview 
1. During the interview at the examination site 
2. Self-administered questionnaire, mailed to sampled persons 
3. Self-administered during the  home visit 
4. Self-administered at the examination site 
5. Other, specify 
 
How the sampled persons were invited to the survey (examination) 
1. By mail 
2. By telephone 
3. During the home visit 
4. Other, specify 
Physical measurements were conducted  
 
1. At HOME during the same visit as interview  
2. At HOME during different visit than interview  
3. In non-mobile EXAMINATION SITE 
4. In mobile EXAMINATION unit 
5. Other, specify 
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Main sources of funding (if possible give the proportion of total costs funded by the 
organization) 
 
Cost categories 
(All person years should be reported using EU calculations bases 1 year = 200 days) 
General planning and fund-raising 
Actual survey Pilot study Personnel costs 
(if possible specify the 
type of personnel) 
Total cost 
(€) 
Person 
years 
Total cost 
(€) 
Person 
years 
     
     
 
Actual survey Pilot study Other costs 
(specify the type of cost) Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
 
Planning of the operations and logistics 
Actual survey Pilot study Personnel costs 
(if possible specify the 
type of personnel) 
Total cost 
(€) 
Person 
years 
Total cost 
(€) 
Person 
years 
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Actual survey Pilot study Other costs 
(specify the type of costs) Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
 
Actual survey Pilot study Design and construction of 
computer programs (for 
example appointment 
system, data entry during 
the interview, database, 
ect.) 
specify the type of costs 
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
Sampling 
Actual survey Pilot study Specify possible 
subcomponents if relevant 
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
Personnel recruitment 
Actual survey Pilot study Specify possible 
subcomponents if relevant 
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
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Training of the personnel 
Actual survey Pilot study Personnel costs 
(if possible specify the 
type of personnel) 
Total cost 
(€) 
Person 
years 
Total cost 
(€) 
Person 
years 
     
     
 
Actual survey Pilot study Other costs 
(specify the type of cost) Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
Equipment (for field work, for example blood pressure device, ect.) 
Actual survey Pilot study Specify  
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
Printing costs 
Invitation 
letters 
Total cost (€) Number of 
letters 
Pages per letter Black&white / 
Color printing 
Actual survey     
Pilot study     
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Questionnaires Total cost (€) Number of 
letters 
Pages per letter Black&white / 
Color printing 
Actual survey     
Pilot study     
 
Other 
material 
Total cost (€) Number of 
letters 
Pages per letter Black&white / 
Color printing 
Actual survey     
Pilot study     
Mailing costs 
Actual survey Pilot study  
Total cost 
(€) 
Number of 
letters 
Total cost 
(€) 
Number of 
letters 
Invitations     
Questionnaires     
Feedback letters     
Other material     
Field work costs 
Actual survey Pilot study Personnel costs  
(if possible specify the 
type of personnel) 
Total cost 
(€) 
Person 
years 
Total cost 
(€) 
Person 
years 
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Actual survey Pilot study Accommodation and daily 
allowances 
Total cost 
(€) 
Number of 
person 
nights/days 
Total cost 
(€) 
Number of 
person 
nights/days 
Accommodation     
Daily allowances     
Actual survey Pilot study Transportation costs 
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
Field work personnel     
Equipment and materials     
Collected samples     
 
Actual survey Pilot study Incentives or other 
compensations paid for the 
participants (specify)  
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
 
Actual survey Pilot study Other costs (specify, for 
example sample storage)  
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
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Rents for examination sites 
Actual survey Pilot study Specify  
Total cost 
(€) 
Number of 
days 
Total cost 
(€) 
Number of 
days 
     
     
Central coordination during the survey 
Actual survey Pilot study Personnel costs 
(if possible specify the 
type of personnel)  
Total cost 
(€) 
Person 
years 
Total cost 
(€) 
Person 
years 
     
     
 
 
Actual survey Pilot study Other costs (for example 
computer facilities, office 
space, ect.) 
Specify 
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
Data management 
Actual survey Pilot study Personnel costs  
(if possible specity the 
type of personnel) 
Total cost 
(€) 
Person 
years 
Total cost 
(€) 
Person 
years 
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Actual survey Pilot study Equipment (specify) 
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
 
Actual survey Pilot study Other costs (specify) 
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
External quality control (during the survey) 
Actual survey Pilot study Specify relevant 
subcategories is possible 
Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
     
     
Laboratory analysis 
Actual survey Pilot study Specify  
Total cost 
(€) 
Number of 
analyzed 
samples 
Total cost 
(€) 
Number of 
analyzed 
samples 
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Basic report (analysis and reporting) 
Actual survey Pilot study Personnel costs  
(if possible specify the 
type of personnel) 
Total cost 
(€) 
Person 
years 
Total cost 
(€) 
Person 
years 
     
     
 
Printing costs Total cost (€) Number of 
letters 
Pages per letter Black&white / 
Color printing 
Actual survey     
Pilot study     
 
Actual survey Pilot study Other costs  
(specify) Total cost 
(€) 
Number of 
units 
Total cost 
(€) 
Number of 
units 
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